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Figure 1.
Superficial spreading malignant melanoma
Legend : the superficial radial component is seen surrounding the invasive
nodule.
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ABSTRACT
Epidemiology, clinical presentation, natural history, pathological
features and treatment of cutaneous malignant melanoma have been
studied in the British Columbia Cancer Agency [BCCA], A retrospective
review of 891 patients registered between 1972 and 1981 is presented.
Age standardised incidence rates have increased significantly.
Incidence rates in males and females in 1988 were 11.5 and 12.8 per
100,000 respectively. Sex ratio was 1.13 : 1 in favor of females and
median age was 47 years. Change in size of a mole was the commonest
presenting symptom and median symptom duration before primary
treatment was 5.9 months. Predominant primary sites were trunk for males
and lower limb for females.
Dominant growth patterns were superficial spreading melanoma
[65%], nodular melanoma [25%], lentigo maligna melanoma [5%] and
acral-lentiginous melanoma [2%]. Staging of the primary tumor was local
[90%], regional [9%] and distant [1 %] at presentation. Median primary
tumor depths at presentation were 1.45mm for males and 1.10mm for
females. No T1 tumors were staged beyond the local area.
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Disease recurred in 44% of males and 32% of females. Fifteen year
survival was 55.5% for males and 70.3% for females. These findings
compare favorably with other recent world experience.
Of the whole series, 753 patients with clinical stage 1 disease were
identified and 28 clinical and pathological variables were subjected to
prognostic factor analysis. Univariate analysis showed the following factors
to be significant in descending order : Clark level, depth, clinical and
pathological ulceration, growth pattern, tumor volume, sex, date of
diagnosis, surface description, lymphatic invasion and primary site [all
p=<0.0001], inflammatory reaction, BANS sites, pigmentation, mitotic rate,
polypoid configuration, invasion to stratum corneum, tumor diameter [all
p=<0.0052], and type of surgery [p=0.0472]. Primary color was marginally
significant, but cell type, type of inflammatory infiltrate, age, clinical and
pathological regression, type of regression, and history of previous nevi
were insignificant.
Multivariate analyses of prognostic factors in 556 patients showed
that micrometer depth, pathological ulceration, primary site and type of
initial surgery were the principal prognostic factors. An alternate model
coding primary sites differently showed BANS [upper back, posterior upper
arm, neck and scalp] sites and sex to be significant while other primary
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sites ceased to be significant : adjusting this model for Clark level made
BANS sites and sex again significant along with lymphatic invasion. Using
linear coding for categorical variables, the following covariates were
significant : depth, primary site, pathological ulceration, type of surgery,
growth pattern, Clark level, BANS sites and lymphatic invasion [in
descending order]. Significant factors after depth adjustment was made
were [in descending order] Clark level, ulceration, BANS sites, type of
surgery, sex and lymphatic invasion. The significant factors in multivariate
analysis have been compared with the results of 60 other reports
worldwide. The present report confirms primary site, depth and
pathological ulceration as key prognostic factors. Inter-relations between
several prognostic factors, notably depth, diameter, age, sex, primary site,
growth pattern, ulceration and mitotic rate contribute to the reported
variation in prognostic significance attached to these covariates.
Elective lymph node dissections were undertaken in 232 patients,
208 of whom had primary depth measured. Nodes examined after elective
lymph node dissection were positive pathologically in 36 [16%] patients, 18
with 1, 7 with 2, 8 with 3+ and 3 with unspecified number of nodes positive.
Ranges and median depths of primary in patients with positive and
negative elective dissections were 0.85 - 8.00mm and 3.00mm, and 0.45
- 7.00mm and 1.6mm respectively.
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Positive/negative elective dissection ratios were : 20/86 and 16/102
in males and females : 3/42 [upper limb], 16/76 [lower limb], 12/45 [trunk],
5/24 [head and neck] : 16/103 [superficial spreading melanoma], 15/57
[nodular melanoma], 0/3 [acral-lentiginous melanoma] : 5/68 T2 primary,
12/66 T3, 14/20 T4 : 3/64 Clark level III, 25/106 level IV and 6/8 level V.
Disease recurred in 23 [64%] elective node dissection positive and 47
[25%] negative patients with corresponding median survivals of 4.2 and 9.1
years.
In spite of having thicker primary tumors [median depth 1.7mm]
ELND patients had superior survival compared with Control patients
[median depth 1.00mm]. The survival differences were principally in T2 and
Clark level IV primaries. However, the Control group had more unfavorable
primary sites.
Ten year disease-specific survival for all patients undergoing wide
primary excision [>5cm total width of specimen] and ELND for clinical stage
1 melanoma was 67%. Over the same period, 10 year survival for clinical
stage 1 patients having only wide excision was 67%. Multivariate analysis
of potential prognostic factors did not show ELND to be of independent
significance in clinical stage 1 patients.
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Survival comparisons were also made with extremity primary
patients treated with ELND in the World Health Organisation prospectively
randomised study. BCCA ELND patients had better survival in all groups
examined, likely due to more favorable primary depths. Further
comparisons were made in the subgroups of T3 primary patients : male,
trunk : male, extremity : female, extremity. Survival of BCCA ELND and
Control patients was compared with results from the University of Sydney
in these subgroups. BCCA survival results were intermediate between the
Sydney control and ELND groups and did not show any advantage for
ELND.
Therapeutic node dissections were performed in 50 patients and 36
[72%] were positive. Range and median depths of primaries in patients with
positive therapeutic node dissections were 1.67-8.00mm and 2.00mm
respectively. Disease recurred in 24 [67%] positive therapeutic node
dissection patients with median survival 2.7 years.
Therapeutic lymph node dissections were also performed in 90
patients with regional node metastases from previous primary melanoma.
Range and median depth of responsible primaries were 1.0 - 7.0mm and
2.0mm respectively. Median time to regional lymph node recurrence from
primary treatment was 1.5 years. Median survival was 1.8 years from the
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date of regional node recurrence, and 4.4 years from primary diagnosis.
Median survivals of ELND negative, positive and TLND patients compare
favorably with reports from New York, Chicago and Buffalo.
Survival comparisons were also made between all 3 groups of
BCCA lymph node dissection positive patients ie ELND +ve, TLND +ve and
RTLND. Survival was defined from the date of LND positive surgery. No
statistically significant difference in survival was demonstrated.
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1. Incidence of malignant melanoma.
Malignant melanoma represented 3.1% and 3.7% of cancers in
males and females in British Columbia in 1987 [Gallagher and McBride,
1987], The present incidence of 11.5 and 12.8 per 100,000 for males and
females has more than doubled since the 1970's. However, translated into
the likelihood of individual general physicians encountering melanoma, the
probability of a physician caring for 1000 patients annually seeing a new
melanoma patient is remote. In 40 years of general practice one would
expect to see about 4 or 5 new melanoma patients, or one every 8 years
on average. Many patients have excision biopsies before they are seen by
consultants in North America. Practical experience among junior physicians
and medical students of seeing primary melanoma or indeed patients with
relapse is limited. Individual physicians and their patients, on whom early
diagnosis depends, must be alert to the possibility of melanoma [Kopf,
1988 : Mackie 1990],
2. Historical Perspective
The history of malignant melanoma has been divided into three
periods [Veronesi, 1985], The original description of partly black metastatic
tumor in cervical lymph nodes by Dr John Hunter in 1787 was later
confirmed histologically as melanoma [Bodenham, 1968], Malignant
melanoma has however existed for centuries. Gross and histological
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evidence of melanoma has been found in nine mummies of pre-Columbian
Incas from Peru [Urteaga and Pack, 1966], These bodies are estimated to
have lived over 2400 years ago. The term "melanosis" was applied to black
tumor deposits in visceral organs [Laennec, 1812], The first English
language report of cutaneous malignant melanoma was an anterior
abdominal wall primary in a middle-aged male who developed local,
regional and distant metastases [Norris, 1820]. Interestingly, the patient's
father had died from metastatic melanoma. The associations of melanoma
arising in a pre-existing mole and in individuals with fair hair and
complexion were also established. The now-familiar patterns of metastatic
disease were described and wide excision was advocated to prevent local
recurrence.
Observations of growth in diameter followed by growth in height in
a primary melanoma [Williams, 1834 reported by Silvers, 1982] may have
been the first description of what are now described as the radial and
vertical growth phases. Primary sites in the nail bed [sub-ungual] and face
were recognised later [Hutchinson, 1857 & 1892].
Therapeutic lymphadenectomy for recurrence was first reported in
1851 [Case Report, 1851]. Recommendation for elective lymph node
dissection [Snow, 1892] marks the beginning of the second period of
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melanoma history. This concept, along with wide excision of the primary
site, was affirmed following the demonstration at autopsy of lymphatic
permeation in a patient dying from melanoma [Handley, 1907], Wide
primary excisions and regional lymph node dissections were widely
practiced thereafter until the 1970's.
The third and contemporary period started with the constitution of
the World Health Organisation [WHO] International Melanoma Group, the
establishment of a geographic multi-disciplinary study in Queensland,
Australia [Davis, Mcleod, Beardmore et al., 1976], and new definitions of
histopathology of melanoma, describing growth patterns and depth of
invasion. To these developments in the past 25 years, the most recent
areas of progress should be added. These include the recognition of the
dysplastic nevus syndrome and its relation to familial and sporadic
melanoma, contemporary knowledge of the complexities of the immune
system, advances in bio-technology including genetic engineering and
monoclonal antibodies, chromosome abnormalities and oncogene
expression in dysplastic nevi and melanoma, and the availability of new
cytokines in the treatment of malignant melanoma [Yarbro, 1988],
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3. Contemporary philosophy of melanoma etiology, pathology and
treatment.
Prior to 1969 there was a widespread assumption that malignant
melanoma invariably arose in melanocytic nevi [Clark, From, Bernardino
et al., 1969]. Nevi are classified [Roses, Harris, Ackerman, 1983] as
congenital or acquired, according to location of the nevus cells
[epidermis/junctional; dermis/intradermal; epidermis + dermis/compound],
and according to the cell type [eg Spitz nevus/large spindle +/- balloon
cells ; blue nevus/ melanocytes dendritic or spindle-shaped or both]. The
description of intradermal portions of malignant melanoma discrete from
the invasive component was in contrast with previous interpretations of
co-existing "junctional activity" ie benign nevus [Clark, Ainsworth,
Bernardino et al., 1969], Evidence of a pre-existing benign nevus was
considered present in only 8.3% of melanomas.
4. Growth Patterns.
Three types of melanoma according to histologic criteria have been
described. The invasive component was defined in terms of anatomic
depth and the latter related to risk of recurrence and death from
melanoma. Classification was based on the appearance of the non-invasive
component since the invasive parts are indistinguishable [Clark, Ainsworth,
Bernardino et al., 1969 ].
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Superficial spreading melanoma [SSM] and lentigo maligna
melanoma [LMM] by definition have a radial growth component beyond the
width of at least 3 rete ridges beside the invasive nodule in any section,
while the invasive component of nodular melanoma [NM] has a negligible
adjacent component. The superficial spreading part of SSM is described
as the radial growth phase. SSM and LMM are distinguished on
morphologic grounds, SSM for example usually having epithelioid cells of
uniform appearance. LMM occurs mainly on the head and neck, has an
irregular outline, mainly flat surface, and primarily shades of brown in color.
SSM has haphazard colors, sharp demarcation of outline, and irregularly
elevated surface. NM is uniformly invasive, raised to variable degree,
sometimes exophytic and ulcerated. Complete clinical and pathological
descriptions of primary melanoma are widely available [Davis, McLeod,
Beardmore etal., 1976], Representative clinical photographs of SSM, LMM
and NM are shown in Figures 1, 2 and 3.
A fourth histogenic or growth pattern of primary melanoma arising
on the palms, soles or nail-beds was named acrai-lentiginous melanoma
[ALM, Figure 4] [Reed, 1976], This is the same clinico-pathological entity
as the original "melanotic whitlow" [Hutchinson, 1886]. This type of
melanoma is also characterised by a radial growth phase, in which there
is acanthosis, elongation of rete ridges and lentiginous proliferation of
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atypical melanocytes in the epidermis. Similarities between the radial
phases of ALM and mucosal membrane melanomas have led to a
recommendation that they be classed together [Clark, Bernardino, Reed et
al„ 1979],
5. Depth Assessment.
Depth of invasion is classified in 5 anatomic levels, shown
diagramatically in Figure 5. In level I, all tumor cells are superficial to the
basement membrane ie in situ. In level II, tumor cells penetrate the
basement membrane into the upper part of the papillary dermis. In level III,
tumor cells extend to the interface of papillary and reticular dermis. In level
IV, tumor cells extend into the reticular dermis. In level V, tumor cells
invade subcutaneous tissue.
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Figure 1.
Superficial spreading malignant melanoma
Legend : the superficial radial component is seen surrounding the invasive
nodule.
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Figure 2.
Nodular malignant melanoma
Legend : no radial component adjacent to the invasive nodule is noted.
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Figure 3.
Lentigo maligna melanoma
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Figure 4.
Acral lentiginous malignant melanoma
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Figure 5.
Clark levels of invasion
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In addition to anatomic depth, tumor thickness has also been
measured by micrometer [Breslow, 1970]. Vertical measurement of tumor
thickness from the upper level of the granular layer of the epidermis to the
deepest part of the tumor has been found to be the best single indicator
of prognosis [Breslow, 1970 : Balch, Murad, Soong et al., 1978 :
McGovern, Shaw, Milton, 1979], Many groups and institutions have since
reviewed their experience of malignant melanoma using the above criteria
for growth pattern and depth of invasion. These are discussed along with
British Columbia Cancer Agency [BCCA] experience in Chapter 2.
6. World Health Organisation contributions.
The World Health Organisation [WHO] Melanoma Group has made
significant contributions in the assessment of treatments for melanoma.
The importance of prospective randomised trials for new and indeed some
time-honored treatments has been realised. The WHO Group has
conducted a study in patients with melanomas less than 2 mm thick and
found no advantage to a 3 cm width of excision compared with 1 cm
[Veronesi, Cascinelli, Adamus et al., 1988]. The trend towards narrower
excision margins for melanoma is supported by this study. A representative
example of a wide excision around a primary melanoma of the posterior
trunk is shown in Figure 6 ; fewer procedures of this type are being
performed as a result of clinical trials of surgical margins. The WHO
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Melanoma Group has also conducted a prospective randomised study of
elective lymph node dissection [ELND] in extremity melanoma [Veronesi,
Adamus, Bandiera et al., 1982] which did not confirm the beneficial
expectations from non-randomised studies and has led to a further
on-going study of ELND in patients with trunk primaries over 2 mm thick.
They also conducted a study of adjuvant chemotherapy and
immunotherapy which showed no benefit from either [Veronesi, Adamus,
Aubert et al., 1982],
7. Genetics and Family Studies including Dysplastic Nevus
Syndrome.
Genetic studies of malignant melanoma have attempted to identify
genes involved in the transformation of melanocytes and in melanoma
tumor progression [Drapacoli and Bale, 1988], Methodologies include :
screening melanoma cells for dominant acting oncogenes, screening for
recessive tumor genes by loss of heterozygosity analysis of matched sets
of DNAs from melanoma and normal lymphocyte samples, genetic linkage
studies of familial melanoma and dysplastic nevus syndrome.
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Figure 6.
Wide Excision : Primary Melanoma of Posterior Trunk
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No consistent oncogene activation has yet been observed.
Cytogenetic abnormalities of chromosomes 1, 6 and 7 have been reported
[Balaban, Herlyn, Clark et al., 1988] but without associated oncogene
changes. There is presently no strong evidence implicating loss of
heterozygosity in the transformation of human melanocytes.
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Studies of patients with positive family histories of malignant
melanoma led to the identification of a precursor to melanoma, the
"dysplastic nevus" [Clark, Reimer, Greene et al., 1978 ; Figure 7]. Such
nevi have characteristics which are different from normal acquired nevi
[Greene, Clark, Tucker et al., 1985], They are often larger than 5mm
diameter and usually have a macular component. A central papular area
may give a "fried egg appearence". Borders are irregular and indistinct.
Colors therein are variable from pink to dark brown. They are most
frequent on sun-exposed areas but also occur on less sun-exposed areas.
The number of dysplastic nevi is directly related to the amount of sun
exposure [Kopf, Lindsay, Rogers et al., 1985], They are usually absent at
birth and may be associated with a normal nevus distribution or an excess
of morphologically normal nevi. They are often not apparent until puberty
and continue to appear throughout adult life. Histologically, they are
distinctive with melanocytic hyperplasia of large epithelioid melanocytes
with variable nuclear atypia in the basal layers, a patchy lymphocytic
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infiltrate, concentric eosinophilic fibroplasia and lamellar fibroplasia. In
dysplastic nevi positive family members of patients with melanoma, the
relative risk of melanoma is 150-fold increased above normal [Greene,
Clark, Tucker et al., 1985], those with the largest number of nevi being at
the greatest risk [Kraemer, Greene, 1985]. Familial melanoma is
transmitted as an autosomal dominant and this has implications for
surveillance of first degree relatives [Drapacoli and Bale, 1988],
Dysplastic nevi also occur in the general population, with an
estimated prevalence between 5-8% [Rhodes, Sober, Mihm et al., 1980 :
Crutcher and Sagabiel, 1984 : Holly, Kelly, Shpall et al., 1987], Recent
studies associating melanoma incidence and presence of nevi have
distinguished normal from dysplastic nevi. Increased melanoma risk has
been attributed to both the presence of dysplastic nevi [Holly, Kelly, Schpall
et al., 1987 : Roush, McKay, Forget et al., 1986] and benign melanocytic
nevi [Swerdlow, English, Mackie et al., 1986] The risk of melanoma in
sporadic dysplastic nevus syndrome patients has been estimated at 10
times normal [Kraemer, Tucker, Tarone et al., 1986], Fibroblasts and
lymphoblastoid cells from familial melanoma and dysplastic nevi patients
exhibit increased sensitivity to ultraviolet radiation and increased
mutagenesis respectively [Smith, Greene, Devlin et al., 1982 : Perera, Urn,
Greene et al., 1986].
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8. Other Risk Factors for Melanoma.
Other risk factors for the development of malignant melanoma have
been investigated mostly by retrospective analysis or case - control
studies. Sun exposure has been implicated in the pathogenesis of
malignant melanoma for several reasons ; there is an inverse relationship
between melanoma incidence and latitude : there is a difference in
melanoma incidence according to skin type, being lowest in blacks and
highest in whites : there is a higher incidence of melanoma on the trunk in
men and lower extremity in females, suggesting that clothing may be
protective [Loggie and Eddy, 1988],
Relative risks of developing malignant melanoma have been
calculated for 10 factors [Rhodes, Weinstock, Fitzpatrick et al., 1987],
These are summarised, along with relative risk factors, overleaf. However,
all these factors except change in mole size or color collectively can
account for only about half the cases of malignant melanoma. The
observations that the incidence of melanomas of the head and neck in
older patients is increasing slowly while the incidence of those on the trunk
is increasing rapidly and occurring in younger patients suggest that as yet
unknown events of youth are implicated in the pathogenesis of melanoma
[Lee, 1990], For the present, physicians and patients must focus on
primary prevention against the known risk factors, and secondary
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prevention ie early detection and treatment [Rhodes, Sober, Mihm et al.,
1987 : Mackie, Freudenberger, Aitchison, 1989],
Relative risks of developing malignant melanoma
Relative Risk
Persistently changed or changing mole >400
Age >15 years vs < 15 88
1 + large or irregularly pigmented lesions:
Dysplastic mole and familial melanoma 148
Dysplastic mole without " " 27
Lentigo maligna 10
Congenital mole 21
Caucasian race 12
Previous melanoma 9
Family history of melanoma 8
Immunosuppression 4
Sun sensitivity 3
Excessive sun exposure 3
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9. Adjuvant Therapy.
Surgery and radical radiation therapy have significant failure rates
in the common solid tumors. The concept of adjuvant therapy, treatment
aimed at eradicating microscopic metastases in patients in whom all visible
disease has been removed, has been investigated in many solid tumors
and has become standard practice in several eg stage 2 breast cancer
[Bonnadonna, 1989],
Treatment selected for investigation as adjuvant therapy should be
able to produce some complete remissions in advanced metastatic disease
in humans or prevent recurrence in animal tumor systems after primary
surgery. Even if partial responses are the best response category seen in
advanced disease, there are kinetic reasons to expect that the same
treatment may still be able to prevent recurrence.
After a potential adjuvant therapy has been developed, the
appropriate patient population to whom it may be offered is identified. The
expected prognosis of patients who have had initial definitive therapy is
assessed. Usually patients with at least a 25% chance of recurrence are
considered for adjuvant therapy studies. The risks/toxicities of the proposed
adjuvant therapy must also be considered [Salmon, 1986]. In melanoma,
many trials of immunotherapy and chemotherapy or both combined have
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been undertaken [Balch and Hersey, 1985].
Patients with malignant melanoma who are at significant risk of
recurrence can now be identified. The principal risk factor in the primary is
depth, and any patient who has had a recurrence is at extreme risk of
further recurrence and death.
Chemotherapy for advanced melanoma rarely produces complete
remissions. Partial remissions are the rule and the response rate is only
20-25% [Balch, Milton, 1985], Adjuvant chemotherapy studies have not
shown any reduction in mortality in either stage 1 high risk or lymph node
positive melanoma [ Balch, Hersey, 1985],
The relation between host [patient] and tumor [melanoma] has
fascinated physicians for decades. Observations of spontaneous regression
in primary and metastatic melanoma, and the phenomenon of late
recurrence many years after primary treatment pointed to a relationship
which might be exploited to the patient's advantage. This is the basis of
adjuvant immunotherapy, administration of drugs or biological materials to
restore or enhance the ability of the patient's immune system to recognise
and destroy micrometastases.
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The selection of agents for development as immunotherapy does not
follow the same guidelines as for chemotherapy. Immunotherapy agents
are not expected to be able to eradicate large tumor masses. Ideally
certain host defence mechanisms can be quantitated and the
immunomodulatory effect of drugs or biological materials assessed
thereafter. In the 1970's, few tests of immune function were available.
Tuberculin testing was the only routine test for cellular immunity. Even in
the late 1980's, while T lymphocyte function tests and immunomodulatory
doses of interferon could be selected in the laboratory [Maluish, Walter,
Urba et al., 1988], their effects in vivo in clinical trial in melanoma have not
shown any benefit [Meyskens, Kopecky, Samson et al., 1991], In the
1970's, several approaches to boost host defences were taken including
Bacillus Calmette-Guerin [BCG], Corynebacterium parvum and levamisole.
BCG was introduced as a non-specific immune system stimulant
[Bast, Zbar, Borsos et al., 1974 : Lamoreux and Turcotte, 1976]. BCG acts
as a potent non-specific stimulator of macrophages and the
reticulo-endothelial system. In animal tumor systems, prophylactic BCG
immunisation will suppress the development of some transplanted antigenic
tumors and can cause the regression of established cancers in
experimental tumor models. Established skin tumors regress after
intralesional BCG. Survival is enhanced if BCG is given after surgery for
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spontaneous mammary cancer in rats.
Levamisole, initially introduced as an antihelminthic in 1968, was
found to increase immunity to Brucella infection in mice [Renoux and
Renoux, 1971] and subsequently shown to restore several T cell functions
and phagocytic functions in polymorphonuclear cells, monocytes and
macrophages. It did not, however, enhance normal immune functions
[Amery and Horig, 1984], Dinitrochlorobenzene [DNCB] reactivity in anergic
cancer patients was restored after levamisole administration [Tripodi,
Parks, Brugmans, 1973], Levamisole was investigated in a randomised trial
[Spitler and Sagabiel, 1980] in the 1970's in melanoma and there was a
trend towards improved survival [p = 0.07] in levamisole-treated patients.
From 1979-82, the National Cancer Institute of Canada Clinical
Trials Group Melanoma Committee undertook an adjuvant trial of BCG and
levamisole [Quirt, Shelley, Bodurtha et al, 1986], Prior to the activation of
this trial, BCG was recommended routinely to high risk melanoma patients
in British Columbia although at that time there was conflicting evidence of
benefit [Silver, Ibrahim, Evers et al., 1983], A prospective randomised trial
including BCG was thought appropriate and duly commenced as a
multi-centre study. Results of this study showed a reduction in melanoma
mortality by 30% in patients receiving levamisole, but no benefits from
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BCG [Quirt, Shelley, Pater et al., 1991], I entered and treated 41 patients
in this co-operative study.
A second NCIC adjuvant trial comparing levamisole with gamma
interferon was commenced in 1988 but accrual was terminated in 1990
because a study from the South West Oncology Group failed to show any
suggestion of the anticipated benefit from gamma interferon [Meyskens,
Kopecky, Samson et al., 1991]. This latter study compared gamma
interferon with observation as adjuvant therapy in completely resected
stage 1 melanoma > 1.5 mm thick.
10. Chemotherapy.
From a chemotherapy viewpoint, malignant melanoma presents
many problems, being one of the least sensitive tumor types to
conventional anti-cancer drugs [Balch, Houghton, Peters, 1989]. This has
led to a focus on new drug development in the laboratory and clinic. There
has, however, been little progress in this direction over the past 20 years
since the introduction of imidazole carboxamide [DTIC], Virtually every new
potential anti-cancer drug is evaluated first in refractory tumors such as
metastatic melanoma, non- small cell lung cancer and renal cell carcinoma
[de Vita, 1989], Medical oncology literature abounds with negative reports
of activity of new drugs in malignant melanoma [Rumke, 1986 ; Rumke,
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1988 ; Smyth, 1990], Drugs which have produced "responses" in metastatic
melanoma rarely cause complete tumor regression and improvements
which do occur are usually short-lived. The same principles which led to
the development of successful chemotherapy in malignant lymphomas
have been adopted in melanoma, but simultaneous use of drugs with
different mechanisms of action and non-overlapping toxicities have failed
to provide the desired quantum leap forward.
The Melanoma Group of the National Cancer Institute of Canada
has participated in this search with drug combinations of cis-platinum,
vinblastine and bleomycin [NCIC Melanoma Group, 1984], and vincristine,
procarbazine and CCNU [Shelley, Quirt, Bodurtha et al., 1985], The
Melanoma Tumor Group of the BCCA has also undertaken a phase 2 study
in melanoma with dibromodulcitol [Murray, Silver, Shah et al., 1985], I was
involved as a local investigator treating patients with these regimens.
Publications on these subjects are attached in the Appendix.
Regional administration of chemotherapeutic agents has been
investigated in patients with local-regional recurrence or who are at at high
risk thereof. This technique has been combined with regional hyperthermia
to try to increase the therapeutic index [Krementz, Ryan, Carter, 1985], A
recent randomised trial of hyperthermic perfusion with L-phenyl alanine
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mustard [melphalan] showed a reduction in recurrence rate among
resected high risk stage 1-3 patients [Ghussen, Kruger, Groth et al., 1987],
This technology is not however widely available. No hyperthermia facilities
are available in British Columbia and regional chemotherapy perfusion is
rarely undertaken.
11. Biological Therapy.
Biological treatments as potential adjuvant therapy and for advanced
disease have been under intensive investigation in the 1980's. Expanding
knowledge of the complexities of the immune system and genetic
engineering technology have combined to permit study of newly discovered
cytokines, monoclonal antibodies and hemopoietic growth factors [de Vita
and Roper, 1987], Vaccines with melanoma-associated antigens have been
developed and tested in advanced disease and as adjuvant therapy
[Rumke, 1988], Vaccines combining tumor cells and viruses [eg vaccinia,
Newcastle disease virus] to enhance immunogenicity of the tumor cells
have been tested in phase 1 and 2 adjuvant studies [Wallack, Bash,
Bartolucci, 1989],
Interferon was discovered [Isaacs and Lindemann, 1957] while
studying the phenomenon of viral interference [cellular resistance induced
by a virus to superinfection by another virus]. The inhibition of growth of
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uninfected mouse cells in culture was the first demonstration of the
antiproliferative of interferon [Paucker, Cantell, Henle, 1962],
Subsequently, several species of interferon have been recognised. The
original interferon was beta interferon. Alpha interferon derived from
Burkitt's lymphoma [lymphoblastoid] or prepared by recombinant DNA
technology [alpha-2a, 2b and 2c] has been tested extensively in metastatic
melanoma. Alpha interferons share the same receptor and clinical
anti-cancer activities. Anti-tumor activity may be expressed by direct effects
on tumor cells and also by indirect immune stimulation. Gamma interferon,
or immune interferon, has some unique properties, increasing expression
of Class II histocompatibility antigens and producing greater macrophage
stimulation [Silver, 1986], Although much is known about the biological
effects of interferon, the explanation for the exquisite sensitivity of hairy cell
leukemia cells to "minimal" doses of alpha interferon remains a mystery.
Similarly, the relative resistance of many tumor types, including melanoma,
to massive doses of interferon is poorly understood.
Interferon [alpha and gamma] has been tested in patients with
metastatic melanoma using several different doses, schedules and routes
of administration [Silver, 1986], From these studies, it can be concluded
that some patients exhibit tumor shrinkage, that best responses may take
several months, that stabilisation may be a more worthwhile response
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category with biological agents as opposed to chemotherapy, that dose /
response relationships may be more complex than with chemotherapy
agents, and that in vitro correlates of activity are required for further
clarification of optimal dose and schedule. Interferon has also been
administered directly into metastases of melanoma with local tumor
regression in 24 of 26 patients ; 9 patients also had responses in distant
sites [von Wussow, Block, Hartmann et al., 1988], Combination therapies
eg interferon alpha and gamma, interferon and interleukin, interferon and
tumor necrosis factor, interferon and chemotherapy are also being
investigated in metastatic melanoma. Although the mechanisms of action
may be different and theoretically additive therapeutic effects might be
expected, there is certainly potential for additive toxicities, notably
hematologic and constitutional. Such combination therapies are presently
in phase 1 and 2 development stages [Hirsh, Lipton, Harvey et al., 1990
: McLeod, Thompson, Hersey, 1987],
Initial dramatic results of interleukin 2 and lymphokine-activated
killer [LAK] cell therapy for metastatic melanoma at the United States
National Cancer Institute [Rosenberg, Lotze, Muul et al., 1985] have
unfortunately not been confirmed by subsequent extramural studies of the
same agents given in the same manner [Dutcher, Creekmore, Weiss et al.,
1989]. In any event, the toxicities of interleukin 2 were so severe that many
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patients required intensive care unit support. Clearly, the practicalities of
its administration would have been prohibitive for most hospitals. The
necessity for LAK cells in producing responses with interleukin has been
questioned since interleukin alone has been shown to produce a similar
response rate in metastatic melanoma [Parkinson, Abrams, Wiernik et al.,
1990]. Modification of the toxicity of interleukin 2 has been attempted in a
BCCA study of administration of interleukin directly into the splenic artery.
Preliminary analysis of results indicates that the toxicity is reduced but
response rates have been disappointing [Silver and Klasa, 1990 : personal
communication].
Monoclonal antibodies directed against malignant cells are under
investigation for tumor localisation and treatment. The first patient with
malignant lymphoma treated with anti-idiotypic antibodies enjoyed a
complete remission lasting 42 months [Meeker, Lowder, Maloney et al.,
1985], Unfortunately, this gratifying result was the exception rather than the
rule. Furthermore, potential therapeutic antibodies had to be
"custom-made" for the patient since tumor antigenicity, based on surface
immunoglobulin expression, is so variable. Monoclonal antibody technology
has utilised attached toxins, chemotherapeutic drugs and radio-active
isotopes in attempts to kill the targeted cells [Baldwin and Byers, 1985], In
melanoma, therapeutic monoclonal antibodies have been directed against
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different melanoma antigens including p97, a proteoglycan, 250kD
chondroitan sulfate proteoglycan, GD2 and GD3 gangliosides but clinical
results have been disappointing [Rumke, 1986 ; Mastrangelo, Schultz,
Kane et al., 1988 ; Dimaggio, Scheinberg, Houghton, 1990], A phase 1
study of an IgG antibody specific for distinct determinants of the high
molecular weight antigen associated with malignant transformation of
human melanocytes has been reported [Cascinelli, Attili, Belli et al., 1988].
A phase 2 study of IgG 2a monoclonal [directed against a
melanoma-associated antigen] attached to ricin A chain, one of the most
poisonous molecules available, failed to produce any tumor regressions
[von Wussow, Spitler, Block et al., 1988], For diagnostic purposes, a
monoclonal antibody NKI/beteb detects an antigen on the inside of
melanosome membranes and appears specific and sensitive in detecting
cells of melanocytic derivation [Vennegoor, Hageman, van Houhuijs et al.,
1988],
12. Systemic Treatments and Survival.
The impact of treatments for advanced melanoma has not been
impressive. This is important as far as the present study is concerned.
Survival is the most important end-point. Evidence that treatments for
advanced disease prolong survival in cohorts of patients receiving such
treatments is lacking. Difficulties of attributing survival benefits to drug
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therapy in responding patients are well known [Simon and Wittes, 1985],
It is therefore acceptable to assume that there is no survival advantage
from systemic treatments for relapse in this study. Previous reports of
world experience of melanoma discussed in Chapter 2 do not make
reference to systemic treatments for recurrent disease suggesting by
inference that they confer no significant survival benefit.
13. Melanoma Practice in the British Columbia Cancer Agency.
Malignant melanoma is truly a multi-disciplinary problem involving
epidemiology, general practice, dermatology, pathology, surgery,
immunology, medical and radiation oncology. In medical oncology at the
BCCA, patients with malignant melanoma are assessed shortly after
diagnosis, and usually after definitive surgery for consideration of
appropriate adjuvant studies and subsequent surveillance. Patients with
recurrent disease not amenable to surgery are assessed for palliative
therapy with chemotherapy, radiation therapy or symptomatic care.
14. Origins and Objectives of Present Research.
It became apparent that patterns of management of melanoma in
the 1970's and 80's were variable between provinces in Canada and
between countries. Specifically, recommendations for lymph node
dissection and adjuvant therapy differed between Saskatchewan and British
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Columbia where I had clinical appointments. Clinical observations of
recurrence of relatively thin melanomas, cure in some thick melanomas,
hepatic metastases in one patient 37 years after enucleation for choroidal
melanoma, sequential single site distant metastases in some patients, the
formation of the National Cancer Institute of Canada Melanoma Group, the
initiation of a Western Canada Melanoma Study of risk factors and natural
history of melanoma all further stimulated my interest.
Finally, the 1980's mark the emergence of "Quality Assurance" in
patient care. The importance of outcome analysis has long been
recognised but heretofore had been relegated in the list of priorities for
many clinicians. Hence, a retrospective review of the British Columbia
Cancer Agency experience was commenced. A defined period after the
acceptance of histogenic grouping and depth assessment of primary
melanomas was chosen and initially a minimum follow-up time of 2 years
was proposed. This was later lengthened because of time required for
data retrieval.
Although there existed both a Provincial Cancer Registry [where all
new cases of cancer are recorded] and a large provincial cancer treatment
organisation [the British Columbia Cancer Agency], it would have been
extremely difficult to capture all patients' records in a defined period, even
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retrospectively. This is in contrast to regions where there are dedicated
units providing treatment services, prospective data collection and
monitoring of all aspects of the disease with consulting epidemiologists and
statisticians. The present review of all patient records at the BCCA was
initiated accepting certain limitations. It was known that there would be
patients with the disease during the specified time who were not registered
and on whom no data would be available. The broader limitations of the
retrospective nature of the study were also appreciated. Practically,
individual chart review was required since the only computerised patient
information available was basic demography, primary site, stage and
survival status [alive or dead]. Relative to the sample size, the amount of
missing data is acceptable and unlikely to influence conclusions.
The 3 principal original aspects of the thesis are :
1. the study reported in Chapter 2 is the largest outcome analysis of any
disease yet undertaken in the BCCA, and is one of the most mature series
of melanoma patients in the world literature..
2. Chapter 3 contains one of the largest single institution analyses of
prognostic factors for clinical stage 1 patients.
3. the analysis of elective lymph node dissection [Chapter 4] is one of the
largest single institution reports in the world literature.
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15. Future Prospects.
Progress in the understanding and management of malignant
melanoma is continuing, more rapidly in some areas than others.
Awareness of the disease and its precursor lesions is increasing. The
importance of complete pathological description of the primary has been
emphasised. The desirability of inter-disciplinary consultation is exemplified
by the evolution of tumor groups and conferences. The necessity for
radical excision of primary melanoma has been questioned and the results
of lesser surgical procedures are now being examined. The role of elective
lymph node dissection will become clearer with two major surgical trial
results. High risk groups of patients can now be identified and offered
participation in appropriate adjuvant trials. Biological treatments may
shortly have an established place in adjuvant therapy. Surveillance after
definitive primary treatment is particularly important in detecting
local-regional recurrence and monitoring nevi, dysplastic or otherwise. The
search for new active drugs in the treatment of metastatic melanoma
continues. For the present, however, it appears that the largest reduction
in melanoma mortality will come from earlier diagnosis. Information
campaigns in areas of even moderate incidence have yielded success
[O'Doherty and Mackie, 1988] and more education of the public and their
physicians is recommended.
CHAPTER 2
52
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1. INTRODUCTION
The incidence of malignant melanoma is increasing worldwide with
an estimated doubling of incidence rates every 10-17 years [Lee and
Canter, 1970 : Schreiber, Bozzo, Moon, 1981 : Thorn, Adami, Bergstrom
et al, 1989] and has reached epidemic proportions [Lee, 1990], However,
malignant melanoma presently accounts for only a small proportion of all
cancers. In British Columbia, melanoma represented 1.41% of all cancers
in 1974, but in 1987 this increased to 3.11% for males and 3.7% for
females [Gallagher and McBride, 1987], In British Columbia and in Nordic
countries [Thorn, Adami, Bergstrom et al., 1989], the age adjusted
standardised rates have increased 3-5 fold in the last 20 years. Melanoma
incidence rates have been monitored in Scandinavia and Australia for
many years and there appears to be little if any tendency of increasing
incidence to level off [Mackie, 1989].
The rise in melanoma incidence has prompted many studies
examining risk and prognostic factors. These suggest that the increase in
incidence is real and not due to improved data collection [Hiatt and
Fireman, 1986], artifacts of diagnosis or notification, or changes in
"cosmetic factors" [McCarthy, Black, Milton, 1980 Kopf, Bart,
Rodriguez-Sains, 1977 : Magnus, 1975], Established risk factors include
the presence of freckles [Osterlind, Tucker, Hou-Jensen et al., 1988],
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multiple melanocytic nevi [Swerdlow, English, Mackie et al., 1986 : Green,
MacLennan, Suskind, 1985], history of severe sunburn resulting in peeling
[Mackie and Aitchison, 1982 : Green, Suskind, Bain, 1985], exposure to
ultraviolet light [Gallagher, Elwood, Hill, 1986 : Holman, Armstrong, Hennan
et al., 1986 : Retsas, 1983], occupation and socio-economic status [Lee,
1982: Graham, Marshall, Haughey etal., 1985, Gallagher, Elwood, Threfall
et al., 1987 : Cooke, Skegg, Fraser, 1984],
Many biological factors influence the course and outcome of
malignant melanoma [Balch, Soong, Shaw et al., 1978] including stage,
growth pattern, anatomical site, age and sex. This study is a retrospective
descriptive review of these and other factors in melanoma patients
registered with the British Columbia Cancer Agency [BCCA] from 1972-81.
2. MATERIALS AND METHODS
2A. Geographic considerations.
British Columbia is located on the west coast of Canada and
extends from the 49th to the 60th parallel north. The climate ranges from
temperate coastal to one of wide extremes in the interior of the province.
Figure 1 illustrates the area of the province relative to Europe. From
1971-81 the proportion of persons of British origin decreased from 58 to
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51%. Those of European ancestry increased from 18 to 27%, and the
proportion of Asians increased from 2.6 to 4.5% [Gallagher and McBride,
1987], The higher proportion of those of British origin is significant in that
persons of Caledonian origin appear to have a higher incidence of
malignant melanoma [Mackie, 1989].
2B. British Columbia Cancer Agency and Cancer Registry.
The British Columbia Cancer Foundation was incorporated in 1935
and the Institute was opened in 1938 in Vancouver, British Columbia. Since
then, expansion has included a second full service cancer treatment facility
in Victoria and 16 consultative clinics throughout the province attended by
visiting specialists in Radiation and Medical Oncology. As part of its
mandate "to establish, maintain and operate a co-ordinated province-wide
programme of cancer care, control and research" the recently renamed
British Columbia Cancer Agency [BCCA] maintains a provincial Cancer
Registry. The responsibility for the development and maintenance of the
provincial Cancer Registry was transferred from the Health Surveillance
Registry to the BCCA in 1980. The Registry monitors the incidence of
cancer in the community and provides a central cancer data bank for
research and education. Starting in 1969, pathologists were required to
submit duplicate copies of all pathology reports of malignant disease
including in situ and borderline malignancy to the Registry. Referral of new
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cancer patients to the BCCA for consultation and treatment can be made
by any physician but, in contrast to Registry notification, is voluntary.
Patients in this study were seen by Agency oncologists in Vancouver,
Victoria and clinics throughout the province.
In 1980 and 1981, the proportion of new patient examinations to
total new primary cancers by site was 45% [Cancer Control Agency of BC
Annual Report 1981], Historically this percentage ranges from 40 to 50%.
The reasons for this lower consultation rate are varied. For example,
treatment may be undertaken at a community level, patients may be in a
terminal condition, the diagnosis may be made post mortem, patients may
refuse consultation due to age or personal beliefs. Interpretation of the
findings in this study assumes that the referred population does not differ
significantly from the whole population in terms of epidemiologic, clinical,
pathological or natural history factors. If bias exists, it is probably against
the referred group, since non-surgical treatment of recurrent melanoma is
available almost exclusively through the BCCA.
2C. Review of Malignant Melanoma from 1972 - 1981.
This retrospective study included all new cases of cutaneous
malignant melanoma [CMM] diagnosed between June 1, 1972 and May 31,
1981 and registered with BCCA. Follow-up extended to April 30, 1990. In
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the defined period of the study there were 1944 patients in BC registered
with melanoma in the provincial Cancer Registry. Of these, 1245 were
referred to and registered with the BCCA [64% of total population].
Increased awareness and incidence of CMM may account for the high
percentage of patients with melanoma entering the Agency for consultation.
2D. Excluded Patients.
Reasons for exclusion from this study of patients registered with the
BCCA and diagnosed in the study period are shown in Table 1. Ocular
category includes eyeball [33], retina [3], choroid [17], not otherwise
specified NOS [32], conjunctiva [3] and cornea [1], Nasal cavity includes
ethmoid sinus [1], maxillary sinus [1] and nasal cavity [5], Genital organ
category includes vulva-NOS [6], scrotum-NOS [1], labium majus [3] and
vagina-NOS [3], Lymph nodes were located on the leg [5], arm [1], and
head and neck [2], The other category includes lesions located in gall
bladder, lung, brain, cervix uteri and rectum.
Patients who were registered but not included in the original list in
1983 were excluded [designated "Arbitrary" exclusions in Table 1]. The
complete list of patients registered was computer-generated in 1990 as
opposed to the manually-created list compiled in 1983. "Registration"
exclusions were patients whose diagnosis of primary melanoma occurred
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outwith the study period (referral usually being precipitated by recurrence).
The 1983 list had 908 patients and the first descriptive analysis was
undertaken on these patients. This will be designated "First Analysis".
When the data base was updated for recurrence and survival in 1990,
there were 17 further excluded patients, The 1990 analysis will be
designated "Final Analysis". All Tables with statistical analyses refer to the
Final Analysis.
2E. Multiple Primary Melanoma.
Primary malignant melanoma in multiple sites occurred in 27 [3%]
patients at diagnosis, while 25 [2.8%] patients had a subsequent
melanoma. These patients were counted only once in the incidence
analysis.
2F. Data Collection.
Data on 147 demographic, histopathologic, treatment and outcome
variables was extracted from the medical records of the study population.
Data was transcribed on to an abstract form [Table 2] and later
computerised into a data-base [dBase IV] to facilitate follow-up and
statistical analysis. An update of the data base was completed in April
1990.
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Table 1.
Reasons for exclusion from present study
REASONS # CASES % BCCA
SERIES
% BC
POPULN.
Eye 89 7.1 4.6
Nasal Cavity 7 0.6 0.4
Genital Organs 15 1.2 0.8
Lymph Nodes 8 0.6 0.4
Other 11 0.9 0.6
Unknown Primary 26 2.1 1.3
Registration 90 7.2 4.6
Arbitrary 108 8.7 5.6
TOTAL 354 33.8 18.3
Footnote : definitions of Registration and Arbitrary exclusions are in the
preceding text.
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2G. Histopathology.
Histopathology was performed at hospitals throughout the province.
The majority of the biopsies were reviewed by 2 BCCA pathologists in
Vancouver. Primary growth patterns were described using a standard
classification [Clark, Ainsworth, Bernardino et al., 1969], The four principal
growth patterns described in this study were lentigo malignant melanoma
[LMM], superficial spreading melanoma [SSM], nodular melanoma[NM] and
acral-lentiginous melanoma [ALM], Differentiation was assessed as a
composite of histologic grade, nuclear grade and mitotic rate (Doussal,
Tubiana-Hulin, Friedman et al, 1989), as opposed to the presence or
absence of various differentiation antigens (Si and Hersey, 1993).
Tumor depth was assessed by Clark's histopathological method
[Clark, 1967] and Breslow's micrometer measurement [Breslow, 1970]. The
study antedated the universal usage of these methods. Depth
measurements were not available on 223 [25%] of the final analysis
patients. Depth categorisation was determined from the "T" category of the
TNM classification system [American Cancer Society, 1983] : T1 =
0.01-0.75mm, T2 = 0.76-1.50mm, T3 = 1.51-3.0mm and T4 = 3.01+mm.
Tumor volume was calculated from diameter and depth [Vol =IIX{Diam/2}2
X depth ].
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Table 2.
Chart Abstract Form
Study Number XXXXXXX
Date of Birth XX XX XX
Sex X
Code 1 = M, 2 = F, 9 = unspec.
Previous melanoma history
Yr of Diagnosis Site
XX XX XX xxxxx
XX XX XX xxxxx
# Biopsied benign nevi X
Yr biopsied XX
Basal cell carcinoma [ Year of diagnosis ] XX
Squamous cell carcinoma " " " XX
Other cancer X
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Yr of diagnosis site morphology
XX xxxx xxxxx
[ ICDO site and morphology codes ]
Current Melanoma ;
Presenting Symptom
[ code in Table 9 ]
Date of first symptom XX XX XX
Date of diagnosis XX XX XX
Primary site XXXXX
Site at diagnosis
if different from primary
Location ; body site ; R / L
XXXXX
X
Ant / post X
Med / Lat
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X
Clinical appearance at time of diagnosis ;
Max. diameter in mms XX
Surface XX
Code 0, 1 = flat ; 2 = raised ; 3 = both ; 9 = unspec.
Color ; Dominant X
Code 0 = none, 1 = black, 2 = blue, 3 = red, 4 = brown, 5 = grey, 6 =
white, 8 = other, 9 = unspec.
Clinical evidence of regression XX
Pathology [as recorded at primary treatment centre] ;
Type of biopsy X
Code 1 = shave, 2 = punch, 3 = excision, 8 = none, 9 = unspec.
Diagnosis X
Code 1 = benign, 2 = in situ, 3 = invasive, 4 = benign, reviewed malignant
Specific diagnosis XX
Code 1 = benign nevus, 2 = atypical lentigo, 3 = atypical junctional nevus,
4 = familial or congenital nevus, 5 = blue nevus, 6 = juvenile melanoma,
7 = borderline melanoma, 8 = lentigo maligna, 9 = lentigo malignant
melanoma, 10 = superficial spreading melanoma, 11 = nodular melanoma,
12 = acral melanoma, 13 = mucosal melanoma, 14 = metastatic
melanoma, 88 = other [specified], 99 = melanoma type unspecified, 99 =
unspecified pathology.
68
Mitosis X
Code 1 = low [1/5HPF], 2 = moderate [1/5HPF-1/HPF], 3 = high [1/HPF],
9 = unspec.
Pigmentation X
Code 0 = none, 1 = minimal, 2 = moderate, 3 = marked, 4 = pigmented,
degree unspec., 5 = unspec.
Additional configuration XXX
Code 0= no, 1 = yes for polypoid configuration, regression, ulceration
Invasion ;
Clark level X
Depth measurement [mms] XXX
Depth group X
Code 1 = T1, 2 = T2, 3 = T3, 4 = T4,
Invasion of epidermis X
Code 0 = no, 1 = yes
To stratum corneum X
Lymphatic invasion X
Venous invasion X
Dominant cell type X
Code 1 = epithelioid, 2 = spindle, 3 = mixed, 8 = other, 9 = unspec.
Differentiation X
Code 1 = poor, 2 = moderate, 3 = well, 9 = unspec.
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Associated changes X
Code 0 = none, 1 = dermal or compound nevus, 2 = blue nevus, 3 =
junctional nevus, 8 = other, 9 = unspec.
Inflammatory reaction X
Code 0 = none, 1 = slight, 2 = moderate, 3 = marked, 9 = unspec.
Infiltrate type X
Code 1= lymphocytic, 2 = histiocytic, 3 = plasma cell, 8 = other, 9 =
unspec.
Perilymphatic inflammation X
Code 0 = none, 1 = present
Removal X
Code 0 = not removed, 1 = completely removed, 2 = incompletely
removed, 9 = unspec.
Multiple primary tumors X
Site XXXXX
Site XXXXX
Spread at time of definitive treatment
Clinical evaluation of first station nodes X
Code 0 = not involved, 1 = involved, 2 = equivocal, 9 = unspec.
Pathological evaluation of first station nodes X
Code 0, 1 = not involved, 2 = involved, 3 = equivocal, 4 = examined,
status unknown, 9 = not examined
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If pathology positive, # nodes examined XX
# positive XX
Involvement of nodes other X
than first station nodes
Stage [MD Anderson] XX
Performance status [ECOG scale] X
Surgery ; X
Code 1 = shave biopsy, 2 = punch or incisional biopsy, 3 = excision biopsy,
4 = excision + 1-5 cm skin, 5 = excision + 5+ cm skin
Dissection of first station nodes X
Code 0, 2 = no, 1 = yes, 9 = unspec.
Date of definitive surgery XX XX XX
Date of dissection of first station nodes XX XX XX
Immunotherapy XX
Code 0 = none, 1 = BCG [NCIC Trial], 2 = BCG [BCCA], 3 = BCG
intralesional, 4 = levamisole, 5 = C Parvum, 6 = BCG + levamisole, 7 =
BCG + C parvum, 8 = other immunotherapy, 98 =unspecified
immunotherapy given, 99 = unspec.
Date of commencement of immunotherapy XX XX XX
Duration of immunotherapy [mo.] XX
Adjuvant chemotherapy XX
Code 1 = DTIC , 2 = DTIC 1 Gm x 3, 1 Gm q 4 wks, 3 = DTIC 850 mg/m2,
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4 = DTIC 250 mg/m2, q 4 wks, 5 = Cisplatin, 6 = VCR/PCZ/CCNU, 7 =
HD-MTX, 8 = other, 9 = unspec.
Date of commencement of chemotherapy XX XX XX
# courses of DTIC XX
Radiotherapy XX
Code 0 = none, 1 = to primary, 2 = to first station nodes, 3 = to tumor and
first station nodes,4 = to metastatic sites, 5 = to 1/2 body, 8 = other, 98 =
unspec. radiotherapy given, 99 = unspec.
Date of commencement of radiotherapy XX XX XX
RECURRENCE
Date of first recurrence XX XX
Sites of first recurrence XXXXXXXX
Code 0,1 = none, 01 = local, 02 = within 5 cm of primary, 03 = in transit,
04 = first station nodes, 05 = liver, 06 = lung, 07 = brain, 08 = Gl tract, 09
= skin, 10 = subcutaneous, 11 = bone, 12 = marrow, 13 = other nodes, 88
= other, 98 = metastases, site unspec., 99 = residual disease
Type ; single / multiple / unknown X
Subsequent primary melanoma XX XX
Date of diagnosis XXXXXX
Site XXXXX
Other subsequent primary tumor
Date of diagnosis XX XX
72
Site XXXX
Morphology XXXXX
Treatment of recurrence
1. Surgery X
Code 0, 1 = none, 2 = re-excision of primary, 3 = Regional node dissection,
4 = amputation, 5 = excision of single distant metastasis, 9 = unspec.
Surgical excision X
Code 1 = complete, 2 = gross residual, 3 = micro, residual, 9 = unspec.
Date of relapse after radical surgery XX XX XX
for first recurrence
2. Radiotherapy X
3. Chemotherapy X
# of chemotherapy cycles XX
Response to initial chemotherapy X
Code 1 = Complete response, 2 = partial, 3 = minor, 4 = stable, 5 =
progression, 9 = indeterminate
Duration of response [mo] XX
Subsequent chemotherapy X
# of chemotherapy cycles XX
Response to second chemotherapy X
Duration of response XX
Subsequent chemotherapy X
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# of chemotherapy cycles XX
Response to third chemotherapy agent X
Duration of response XX
Tamoxifen treatment X
Code 0, 2 = no, 1 = yes
Other hormone treatment X
Hormone receptor status of melanoma XX
fmol/mg
Duration of tamoxifen therapy [mo] XX
Response to hormone treatment X
Duration of response XX
BCG immunotherapy for recurrence X
Duration [mo] XX
Response to BCG X
Duration of response XX
Survival ;
Date of death XX XX XX
Date of last review alive XX XX XX
Status XX
00 = lost to follow-up
01 = alive, disease-free since primary treatment
02 = alive, disease-free due to regression since primary treatment
74
03 = alive, disease present continuously since diagnosis
04 = alive, disease present from recurrence after disease-free interval
05 = alive, current disease status unknown
06 = dead from disease
07 = dead from other causes, disease present
08 = dead from other causes, disease absent
09 = dead from other causes, disease status unknown
33 = alive, disease free since treatment for recurrence
Autopsy X
Date of abstract XX XX
2H. Age, Site, Stage Description.
Age refers to patient's age at pathologic diagnosis. Categorisation
of age was determined by partitioning melanoma mortality distribution.
Patients were divided into 3 categories : 0-39, 40-59 and 60-99. The
International Classification of Disease [ICD] 8th. version was used to
categorise primary sites [Table 3], Four principal categories were used :
head and neck [H & N], trunk [T], lower limb [LL] and upper limb [UL].
Stage was categorised [Table 4] using a modification of the MD Anderson
Hospital System [Haskell, 1980] as local [stage 1 and 2], regional [stage
3] and distant [stage 4], Survival times were calculated from date of
diagnosis to death, last written or physician contact. Mortality data was
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provided by the Division of Vital Statistics of the Provincial Ministry of
Health [Gallagher and McBride, 1987],
21. Statistical Methods.
Data was analysed with the Statistical Package for Social Science
[SPSS-X release 3.1]. Trends in incidence were analysed using simple
linear regression analysis. The model utility test was used to test statistical
significance. Time intervals between events during the course of disease
were compared for men and women by calculating mean and median
times in months. Mann-Whitney U-tests were used to test the differences
between sexes. Age standardised rates based on the number of tumors
were adapted to those of the BC population at the 1971 census by the
direct method of standardisation [Waterhouse, 1980], All population data
were obtained from Census Canada publications [Statistics Canada, 1988],
The age standardised rate calculates cancer risks by age group eliminating
the effects of different population sizes and changing proportion of older
people in later years [Gallagher and McBride, 1987],
Survival curves were generated using the product limit method
[Kaplan and Meier, 1958] with a biomedical computer program BMDP
[Dixon, 1981], version 1988. This method allowed the inclusion of patients
lost to follow-up. The Tarone-Ware chi-squared analysis was used to
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determine the relationships between the different variables. Cases with
missing data were excluded from the relevant analysis procedures. A level
of significance of 5% or less was considered significant an all statistical
tests used in this report. Means and standard deviations are all reported
in the standard notation : mean +/- standard deviation. The mean survival
times were calculated using survival times of cases with a response [a
death from melanoma]. All statements of percentage refer to percentage
of total cases in the study population [First or Final Analysis] unless
otherwise stated.
Table 3 over/
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Table 3.
Primary Site Codes
1730 Lip}
1731 Inner canthus}
1731 Palpebra}
1732 Ear}
1733 Face}
1734 Neck}
Head and Neck
1735 Trunk } Trunk
1736 Upper limb }
1737 Lower limb }
1841} Female external genitalia
1844}
1903 Conjunctiva
1963 Lymph nodes of axilla or arm
9999 Unspecified
Suffix; 1 :Right;2 : Left; 0,9 :Unknown
Upper limb
Lower limb
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Table 4. STAGING SYSTEM
Stage 0 Lentigo Maligna
Stage 1A Intact Primary
1B Primary locally excised
1C Multiple primaries
Stage 2 Local spread within 5cm from Primary
Stage 3 Regional Metastases >5cm from Primary
3A In Transit
3B1 Regional nodes clinically and pathologically +ve
3B2 Nodes clinically - but pathologically +ve
3B3 Primary unknown : nodal presentn. of met. melanoma
3B4 Previous primary : nodal recurrence
3AB Intradermal mets + regional nodes
Stage 4 Distant hematogenous metastases
4A Single
4B Multiple
4B1 Skin only
4B2 Visceral
4B3 Lymph nodes
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3. RESULTS
3A. Incidence and Mortality Rates.
Age-standardised incidence rates of CMM in BC have increased
significantly for both males and females [Figure 2], Rates for males and
females from 1971-88 increased 5-fold and 3-fold respectively. Linear
regression analysis gave a slope of 0.459 [r^O.942 ; p=<0.0001] for males
and a slope of 0.463 [r^O.816 ; p=<0.0001] for females. In 1988,
age-standardised incidences of melanoma in males and females were 11.5
and 12.8 per 100,000. In 1983, the age-standardised death rate per
100,000 in Canada and BC was 1.8 [Gallagher and McBride, 1987],
Mortality rates are also shown in Figure 2.
3B. Age and Sex Distribution.
Sex incidence according to age group and year of diagnosis is
summarised in Figures 3 and 4. In Figure 3, Age Group on the X axis
refers to the prior decade eg 30 = third decade. The sex incidence in each
age group was virtually equal with the exception of a striking dominance
of female melanoma in the 4th decade. The incidence for 1981 in Figure
4 is projected from the 6 month period of the study. The increasing
incidence from the Cancer Registry data in Figure 1 is paralleled in the
increasing incidence measured by BCCA referrals [Figure 4],
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Figure 2.
British Columbia Melanoma incidence and mortality
1971-1988.
+ Male Incidence ta Female Incidence -H~ Male Mortality Female Mortality
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Data was analysed to determine if there was any change in
melanoma incidence by age at diagnosis over the period of study. Analysis
of incidence by age group is presented in Figure 5. In 1978-80, there was
an increase in melanoma incidence in the 4th decade, rising from 10-22%
of melanomas each year from 1972-77 to between 25-27% of melanomas.
This occurred at a time when BCCA incidence increased quite markedly
[from 1977-78]. This is confirmed for females in the Cancer Registry data
but not for males. Changing referral patterns could also influence BCCA
incidence data.
In the Final Analysis, there were 419 males and 472 females with
an overall female : male ratio of 1.13 : 1. This was not a constant ratio
throughout the period of the study. From 1972-75 the ratio averaged 0.84
: 1 and from 1976-81, 1.25 : 1. Overall median age was 47 years, mean
48.2 +/-16.9. Median age for males was 49 years and 44.0 years for
females. For males, mean age was 49.7 +/- 17.4 and for females 46.9 +/-
16.3 years. The differences between the means was not statistically
significant. Median ages for primary tumors in major body sites are
presented in Table 5. Overall there was little difference between median
ages for all primary sites except head and neck where median ages were
higher. Females had lower median ages for primaries on the trunk and
upper limb. The range of median ages was narrower for males than for
females : 46-58 years for males and 39.5-56 years for females.
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Figure 4
SEX INCIDENCE AND YEAR OF DIAGNOSIS
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Figure 5
AGE GROUP AND YEAR OF DIAGNOSIS
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Table 5.
Median and mean [brackets] ages in years at diagnosis
among the 4 major primary sites.
SEX HEAD & NECK TRUNK UPPER LIMB LOWER
LIMB
M 58 [57.4], 46 [46.4], 48 [49.8], 48 [48.1]
F 56 [54.5], 39.5 [42.5], 43 [47.1], 47 [46.7]
3C. Clinical History.
Of 908 patients, 11 had a history of 1 previous melanoma and 2 had
2 previous melanomas. Basal cell carcinoma occurred in 50 [5.5%] and
squamous cell skin carcinoma in 11 [1.2%] of patients. Benign nevi were
previously removed in 179 [19.7%] patients, 97 with 1, 43 with 2, 21 with
3 and 18 with 4 or more.
Change in size of a mole was the commonest [43%] presenting
symptom. Other symptoms were development of a new mole [13%],
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change in color [9%], bleeding or ulceration [8%] and pain/tenderness/itch
[8%] in a mole. Melanoma was recognised incidentally by a physician in
7% of cases in patients who did not bring it to their physician's attention.
Clinical description of primary tumor diameter is summarised ; 0-5mm, 15%
: 6-10mm, 34% : 11-15mm, 21% : 16-20mm, 10% : 21-30mm, 7% :
31-40mm, 1% : 41+mm, 1% : unspecified, 12%.
Presenting symptoms according to primary site are summarised in
Figure 6. Change in size of a mole was the commonest symptom in all
sites [43-46%]. Incidental recognition by physicians varied from 5% for H
& N to 8% for trunk primaries. Bleeding or ulceration was the presenting
symptom in 4% of upper limb primaries, 8% of trunk and 9% for H & N and
lower limb. Development of a new mole varied from 8% for trunk, 14% for
upper limb, 16% for lower limb to 21% for head and neck primaries.
Figure 6, 7 over/
87
Figure 6
SYMPTOM CODES
-m- TRUNK -<a- UPPER LIMB LOWER LIMB --B- HEAD/NECK
SYMPTOM CODES 0 recognised by physician
1 change in size of mole
2 color change
3 pain/itch
4 bieeding/ulceration
5 new mole
6 irregular contour
7 nodal enlargement
8 nodal pain
9 other
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Figure 6 cont
SYMPTOM CODE
—■— TRUNK -a- UPPER LIMB LOWER LIMB --B- HEAD/NECK
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Figure 7
SYMPTOM CODE
-as- SSM •■•«••• NM ALM
-•Q- LMM X Metast. A. Unspec.
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First symptoms according to growth pattern are summarised in
Figure 7. Change in size of a mole was the presenting symptom with
virtually equal frequency in LMM [45%], SSM [43%] and NM [44%].
Pain/tenderness/itch occurred more frequently in NM than SSM [15% vs
6%]. Development of a new mole was reported by 11% of SSM patients
and 16% of NM patients.
Duration of presenting symptoms before diagnosis according to
primary growth pattern is summarised in Figure 8. Shortest symptom times
were associated with metastatic melanoma and ALM. Symptom times of
up to 1 year occurred in 74% of NM and 66% of SSM. Symptom times of
2+ years occurred in 41% of LMM, 21% of SSM and 14% of NM.
Time intervals in months for important events in the natural history
of melanoma are summarised in Table 6. Total refers to the number of
cases included in each analysis. The only interval of statistical significance
was survival time from diagnosis. Females had a longer time between
diagnosis and first recurrence with a corresponding increase in time to
death. The natural history of recurrent disease measured by time from
recurrence to death was similar between the sexes.
Disease-free intervals are defined as periods of time between
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diagnosis and events in the course of disease. There are 4 possible groups
of cases with respect to disease-free intervals : those who had no
recurrence or death, those who had recurrence but no death, those who
had no clinical recurrence but died from disease and those who had both
recurrence and death from melanoma. The only significant disease-free
intervals for males and females was in patients experiencing both
recurrence and death from melanoma [p = 0.047],
3D. Clinical Description of Primary Tumor.
Dominant primary colors were brown [42%], black [15%], grey [11 %],
red [4%], blue [3.5%], other/unspecified in 24%. Ulceration was described
in 21.7%. The primary was flat in 21%, raised in 51%, both raised and flat
in 8%, and 20% were unspecified/missing. Primary tumor diameters
according to year of diagnosis are presented in Figure 9. There did not
appear to be any trend towards decrease in primary tumor diameter over
the decade.
Figure 8 over/
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Figure 8
SYMPTOM DURATION AND GROWTH PATTERN
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Table 6.
Time intervals for events in the course of disease.
Time in months, except survival median, mean and SD
[years].
TIME # # Medn Mean StDev P
val.
M F M F M F M F
To
Diagn.
300 342 5.6 6.2 13.6 17.8 31.2 35.
0
0.13
To 1st
Recurr.
185 151 19.7 24.2 29.7 36.3 27.8 32.
9
0.07
1st-2nd
Recurr.
67 56 7.1 6.0 12.2 13.5 15.6 21.
1
0.63
Recurr.
to death
159 117 10.9 11.6 17.6 19.6 21.1 23.
9
0.6
Survival 417 466 749 892 7.03 8.42 4.26 3.9 <0.00
01
Footnotes : Only first recurrences treated surgically had 2nd recurrence
date recorded. "Recurr to death" = Time from first recurrence to death.
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3E. Biopsy and Excision.
Excision biopsies were performed in 774 [85%] patients, punch
biopsy in 123 [13.5%], shave biopsy in 1, no biopsy in 7, and 3 were
unspecified. After biopsy, excision of the primary lesion with 5+cm [total
width] of skin was performed in 576 [63.4%] of patients. Excision with 1-5
cm skin was performed in 234 [25.8%], excision alone in 70 [7.7%]. Punch
or incisional biopsy alone was performed in 15, shave biopsy alone in 1,
and 12 excisions were unspecified in size.
The extent of primary surgery in relation to diameter of primary is
summarised in Figure 10. Excision of the primary with at least 1 cm normal
skin was undertaken in 85-94% of patients in whom the excision specimen
was measured. Over the period 1972-81 the proportions of patients having
excisions with 5+ cm skin were 56, 55, 60, 55, 60, 70, 62, 76, 61 and 65%.
Extent of primary surgery in relation to primary tumor thickness is
shown in Figure 11. All but 3 patients with specified tumor depth had at
least an excision of the primary. Excision of 1 +cm skin was undertaken in
94, 96, 96 and 89% of T 1, 2, 3 and 4 primaries respectively. Excision of
5 + cm skin was undertaken in 57, 76, 74 and 68% of T 1,2, 3 and 4
primaries respectively.
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Figure 9
YEAR OF DIAGNOSIS
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Figure 10
PRIMARY SURGERY AND PRIMARY DIAMETER
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Figure 11
PRIMARY SURGERY AND PRIMARY DEPTH
SbaveBx IncisBx ExcBx Exc+l-5cm Exc+5+cm
EXTENT OF PRIMARY SURGERY
1 T1 WM T2 gST3
T4 ///^ Unspec
98
3F. Pathological Description,
a. General.
Histology was invasive in 863 [95%], in situ in 22 [2.4%], benign and
subsequently reviewed as malignant in 15 [1.7%], benign in 3 and
unspecified in 4 cases. Pigmentation was described in 98.9% of cases, to
minimal degree in 16%, moderate in 21%, marked in 16% and unspecified
degree in 41%. The following features and frequencies were present ;
regression, 7.4% : polypoid configuration, 8.8% : ulceration, 24.9% :
lymphatic invasion, 6.3% : venous invasion, 0.8%. Cell type was epithelioid
in 25.4%, spindle in 10.4%, mixed in 7.8% and unspecified in 56.2%.
Differentiation was poor in 3.9%, moderate in 7%, good in 4.2% and
unspecified in 84.8%. Mitotic rate was low in 24%, moderate in 23%, high
in 11.6% and unspecified in 42%. Associated dermal nevus, blue nevus
and junctional nevus were present in 8.7%, 0.6% and 4.6% of cases
respectively. Inflammatory reactions were absent in 5.8%, and present to
slight degree in 24%, moderate 27% and marked in 14.5% of cases ; 28%
were unspecified. Peri-lymphatic inflammation was present in 6.5%, absent
in 89.1% and unspecified in 4.3% of cases. Invasion to the stratum
corneum was reported in 48% of cases.
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b. Depth Assessment.
Depth assessments by Clark level and Micrometer [T 1 - 4
categories] are presented and correlated in Figure 12. Final Analysis
correlates are shown in Figure 13. Within Clark levels III and IV, there was
a wide variation in tumor thickness. Similarly, in all groups of tumor
thickness [T 1-4], there was considerable variation in Clark levels.
3G. Primary Site, Age, Growth Pattern and Stage.
Table 7 illustrates the Final Analysis of patients according to primary
site, sex, age, Clark level, growth patterns and stage. Predominant primary
sites were trunk for males [46% of total male population] and lower limb for
females [44% of total female population]. Trunk primaries occurred
predominantly under 60 years [81 % of all male and 86% of all female trunk
primaries] and were the commonest primaries in all decades through to
age 60. Lower limb and trunk primary sites were virtually equal in
frequency in the 7th decade and head and neck was the commonest [45%]
site in those patients over 70. 48% of all male and 44% of all female head
and neck primaries occurred over 60 years. Primaries distributed on the
lower limbs were similar to trunk primaries : 74% of all male and 80% of
all female lower limb primaries occurred under 60 years.
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Figure 12
CORRELATION OF CLARK LEVEL AND DEPTH
FIRST ANALYSIS
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Figure 13
DEPTH OF INVASION AND CLARK LEVEL
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Distribution of specified growth patterns was SSM [65%], NM [25%],
LMM [5%] and ALM [2%]. Growth pattern according to age is illustrated in
Figure 14. LMM incidence increased with age and occurred mainly on the
head and neck [80%]. Only 13% of all LMM occurred under age 50 years.
SSM declined in incidence over age 60 years.
3H. Depth of Invasion and Year of Diagnosis.
Clark level of invasion according to year of diagnosis is presented
in Figure 15. The proportion of level 1 and 2 primaries has increased over
the decade 1972-81. In the first 5 years, level 1 and 2 accounted for 13%
of all cases with specified depth and this increased to 24% in the second
5 years. The proportion of level V primaries decreased from 12% in the
first 5 years to 5% in the second. Values for 1981 were projected from the
6 month figures available for that year.
Table 7, Figure 14 and 15 over /
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Table 7.
Number of new cases of Cutaneous Malignant Melanoma categorised
by primary site and sex, age, Clark levels, growth pattern and stage.
Total H & N TR TR UL UL LL LL
M F M F M F M F
0-39yrs 307 22 15 67 56 18 34 20 75
40-59 342 28 18 89 40 20 32 26 89
60+ 223 46 26 37 16 19 21 16 42
Level 1 21 5 0 4 3 2 0 0 7
2 160 13 15 33 22 9 18 4 46
3 229 16 8 58 39 16 31 16 45
4 325 37 19 74 35 23 26 27 84
5 52 10 10 6 2 2 4 9 9
LMM 36 17 12 0 0 1 2 1 3
SSM 460 25 27 111 74 31 47 26 119
NM 177 30 7 40 20 7 17 19 37
ALM 16 1 0 0 0 4 4 5 2
NOS 157 21 11 35 18 13 14 10 35
Other 22 1 2 6 0 1 3 1 8
Local 784 81 53 176 104 55 80 46 189
Regionl 79 12 4 15 7 2 5 15 19
Distant 7 2 0 2 1 1 1 0 0
NOS = not otherwise specified
"Other" refers to borderline melanoma, atypical junctional nevus, blue
nevus and unspecified.
Figure 14 over/
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Figure 14
GROWTH PATTERNS AND AGE AT DIAGNOSIS
0-39yrs 40-59yrs 60+yrs
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31. Correlation of Pathology with Growth Pattern.
Several pathological correlates were assessed according to primary
growth pattern. Dermal or compound nevi were associated with 10% of
SSM and 13% of NM. Junctional nevus was associated with 6% of SSM
and 4% of NM. Cell type according to growth pattern is shown in Figure 16.
Most SSM and NM had epithelial cell type, and LMM had predominantly
spindle cell type. Analysis of cell type according to body site showed no
significant variations, epithelial cell type accounting for 53-63% and spindle
cell 22-26% at all sites.
Degree of differentiation according to growth pattern is summarised
in Figure 17. ALM an NM were most commonly poorly differentiated [66%
and 46% respectively]. In contrast, only 13% of SSM and 14% of LMM
were poorly differentiated.
Lymphatic invasion occurred in 10% of NM, 7% of LMM and 4% of
SSM. Venous invasion was reported in only 4 cases, 3 [1.7%] NM and 1
[0.2% SSM. Peri-lymphatic inflammation according to thickness is
presented in Figure 18. Overall, it was present in 3.5% of T1 and 2, and
10.5% of T3 and 4 primaries.
Figures 16, 17, 18 over/
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Figure 16
CELL TYPE AND GROWTH PATTERN
EPITHELIAL CELL■ SPINDLE CELL MIXED CELL
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Figure 17
DIFFERENTIATION AND GROWTH PATTERN
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Figure 18
PERILYMPHATIC INFLAMMATION AND DEPTH
250
T4 Unspec. Depth
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Presence of inflammatory reaction according to primary depth is
shown in Figure 19. For T1 primaries, moderate or marked inflammatory
reaction was present in 73% of cases whereas in T4 primaries 54% had
no or only slight inflammatory reaction.
3J. Depth of Invasion, Sex, Primary Site, Growth Pattern and Stage.
Final Analysis of depth of invasion by sex according to age, primary
site, growth pattern and stage is presented in Table 8. There were 223
cases missing from this analysis, mainly because of absence of depth
measurement. Overall median depth of invasion was 1.20mm, mean
1.73mm +/- 1.49. Median for females was 1,10mm and for males 1,45mm.
The respective means were 1.56mm +/- 1.39 and 1.93 +/- 1.57.
Depth distribution of primary tumors was 31% T1, 29% T2, 25% T3
and 15% T4. Females had 61% of T1, 55% of T2, 52% of T3 and 43% of
T4 primaries. Primary tumors T1 and T2 constituted 55% of all H&N, 57%
of all LL, 61% of all T and 69% of all UL lesions. By Clark's classification,
levels II and III constituted 39% of all H&N, 45% of all LL, 55% of all T
and 56% of all UL lesions. Males had 54% of T1 and T2, 56% of level II
and III, 69% of T3 and T4 and 62% of levels IV and V H & N primaries.
Males had 62% of T1 and T2, 60% levels II and III, and 70% of T3 and T4,
68% levels IV and V trunk primaries. Females had 65% of T1 and T2, 66%
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levels II and III, and 62% of T3 and T4, 45% levels IV and V upper limb
primaries. Females had 86% of T1 and T2, 85% levels II and III,and 73%
of T3 and T4, 72% levels IV and V lower limb primaries.
SSM and LMM tended towards thinner lesions : 42% of SSM and
62% of LMM were T1. NM presented with thicker lesions : 46% were T3
and 37% were T4. ALM had and infrequent growth pattern : 66% were T3
and T4.
3K. Tumor Depth, Diameter and Volume.
Tumor measurements of depth, diameter and volume in those cases
in whom both were available are presented in Table 9. There was a
significant difference in means between the sexes for all measured values.
Overall primary median diameter was 10.00mm, mean 13.15mm +/-10.11.
Median diameters were identical for both sexes but depth of invasion and
tumor volume were greater in males. Overall median tumor volume was
106 mm3, mean 401 mm3 +/- 1309.8.
Figure 19 over /
112
Figure 19
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Table 8.
Final Analysis of all new cases of Cutaneous Malignant Melanoma
categorised by Depth and sex, age, primary site, growth pattern and
stage. % is of total population of cases with a measured depth of
invasion [ 668 cases ].
T1 T1 T2 T2 T3 T3 T4 T4
M F M F M F M F
0-39 31 54 19 47 33 40 12 11
40-59 31 55 45 37 29 36 20 15
60+ 18 19 23 23 19 12 23 16
H&N 17 17 15 10 14 9 19 6
Trunk 45 32 46 24 47 14 19 14
UL 14 28 13 22 8 16 5 5
LL 4 51 13 51 12 49 12 17
LMM 8 8 2 2 1 1 3 1
SSM 65 110 63 75 30 45 12 11
NM 0 1 12 12 33 32 30 22
ALM 1 0 1 2 3 1 2 2
NOS 6 9 9 16 14 9 8 6
Local 80 128 84 105 72 78 44 36
Regnl. 0 0 3 2 9 10 11 6
Distant 0 0 0 0 0 0 0 0
LMM = lentigo maligna melanoma
SSM = superficial spreading melanoma
NM = nodular melanoma
ALM = acral-lentiginous melanoma
"Other" refers to borderline melanoma, atypical junctional nevus,
metastatic, and not otherwise specified.
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Table 9.
Measured Characteristics of Primary Tumor
# Medn Mean Std.
Dev.
M F M F M F M F
Depth 290 355 1.45 1.1 1.93 1.56 1.57 1.4
Diam. 374 415 10.0 10.0 14.2 12.2 11.2 8.9
Vol. 265 320 148.8 88.4 548.2 279.2 1581 1018
115
3L. Stage.
Staging information was complete in the Final Analysis in 870 cases
: 90% local, 9% regional and 1% distant disease. Regional lymph node
dissection was performed in 282 patients and 84 [29.8%] were positive
histologically. The incidence of regional or distant disease according to
primary site in the total staged population was 6.2% [UL], 7% [T], 11.8%
[H & N] and 12,6% [LL], and according to primary site in males and
females respectively was 14.7% and 7% [H & N], 8.8% and 7.1% [T], 5.2%
and 7% [UL], and 24.6% and 9.1% [LL]. No T1 primaries were spread
beyond the local area. Regional metastases occurred in 2.5% of total T2,
11.3% of total T3, and 17.2% of total T4 primaries at presentation.
3M. Recurrence.
Disease recurred in 38% of patients in the Final Analysis. There
were 5 cases in whom disease recurred 10 + years from diagnosis. Of all
females, 32% experienced recurrence and of males, 44%. Figure 20 shows
the distribution of sites of recurrence by primary site. Local recurrence is
within 5cm of the primary. "Organ" category includes lungs, liver and brain,
and "Other" includes bone, marrow, skin, non-regional nodes and
unspecified sites. Of all first recurrences 54% were in regional lymph
nodes. Primary sites responsible for all first recurrences were T [38%], LL
[25%], H&N [22%] and UL [13%]. First recurrence occurred in a single site
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in 46% of patients with recurrence, 27% in 2 sites, 16% in 3 sites and 11%
in 4+ sites.
3N. Survival.
Survival in males and females is illustrated in Figure 21. Five, 10
and 15 year survival proportions were 68.9%, 58.2% and 55.5% for males
and 82.9%, 74% and 70.3% for females. Overall mean survival times +
standard error of those who died from melanoma were 11.3 + 0.36 years
for males and 13.78 + 0.3 years for females. Female survival was
significantly longer [chi2 = 27.65; p = < 0.00001]. Detailed analysis of
prognostic factors is presented in Chapter 3. Melanoma was the cause of
death for 31% of patients and accounted for 82% of all deaths. Survival
analysis at last follow up is shown in Table 10. Of all patients who had a
recurrence, 16% were disease free at last follow up.
30. Other Cancers.
Other malignancies occurred in 115 [13%] patients following
melanoma diagnosis, mostly [66%] non-melanoma skin cancer.
Subsequent primary melanoma occurred in 21 [2.2%] patients.
Figures 20, 21 over /
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Figure 20
FIRST RECURRENCE AND PRIMARY SITE
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Figure 21
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Table 10.
Survival status at last follow-up
PATIENT STATUS # PTS. % STUDY
POPULATION
Alive, disease free since primary treatment 465 52.3
Dead from disease 280 31.4
Alive, disease free since treatment for
recurrence
54 6.1
Dead from other causes, disease absent 52 5.8
Lost to follow up 11 1.2
Dead from other causes, disease present 10 1.1
Dead from other causes, disease status
unknown
8 0.9
Alive, disease present from recurrence after
disease free interval
8 0.9
Alive, current disease status unknown 2 0.2
Alive, disease present continuously since
diagnosis
1 0.1
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4. DISCUSSION
4A. Epidemiology.
Cutaneous malignant melanoma has been studied extensively over
the past 20 years, seeking better understanding of demographic,
environmental, clinical and pathological factors. The increase in
age-standardised incidence in western developed countries has been well
documented [Roush, Holford, Schymura et al., 1987 : Muir and Nectoux,
1982 : Osterlind, Engholm, Jensen, 1988] and a similar pattern was seen
in this study. Melanoma incidence in several countries has increased by
5% per annum in the 1960's and 70's [Magnus, 1977], These increasing
rates suggest that the trends observed are the results of true changes in
risk.
Comparisons of the incidence of melanoma are difficult because of
different dates of reports and the known progressive increase in incidence
in many parts of the world [Balch and Milton, 1985], The 1988 incidence
rates in men [11.5] and women [12.8] in BC are certainly lower than
Australia [20.4 and 24.5 per 100,000 for men and women, in 1976] and
higher than Scotland [5.1 per 100,000 in 1979]. In Sweden the incidence
of melanoma has risen from 2.5 to 11.6 per 100,000 in 1980. Melanoma
incidence in BC is therefore intermediate in relative world terms but its
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progressive increase is cause for serious concern.
Although melanoma prognosis is improving, the rising incidence is
associated with an annual increase in death rate of 3% per year in North
America [Gallagher and McBride, 1987], Data from the Surveillance,
Epidemiology and End-Results program [Ries, Hankey, Edwards, 1990]
show that the incidence in males exceeds that in females and is increasing
at a faster rate [4.8% per year compared with 3.6%]; the death rates in
males and females are increasing at 2.5% and 1.3% a year respectively.
In this present study, the death rate in males has exceeded that in females
in 8 of the 9 years from 1977-85 and overall survival for males was shorter
for new patients registered from 1972-81.
Median age [47 years] of all patients in this study was virtually the
same as those reported from Sydney and Alabama [48 and 44 years
respectively] {Balch, Shaw, Soong et al., 1985}. The only age at which
there was a striking sex difference was in the 4th decade when females
had 66% of all melanomas. This was due to the 4.3 fold increase in female
lower limb melanoma incidence which was evident at all ages.
4B. Second Melanoma Risk.
Melanoma patients have an increased risk of subsequent melanoma.
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The magnitude of risk is 3-5% [Belief, Vaisman, Mastrangelo et al., 1977
: Lynch, Frichot, Lynch et al., 1975 : Moseley, Giuliano, Storm et al., 1979],
The observation of previous and subsequent melanoma rates of 1.4% and
2.8% in this series is consistent with these previous reports. The risk of
second melanoma is considerably higher than the risk of developing first
melanoma in the general population. In the USA, the lifetime risk of
developing one melanoma is about 0.15% [Roses, Harris, Ackerman,
1983]. Patients with previous melanoma require surveillance for new
primary disease as well as for recurrent disease.
4C. Nevi and Melanoma.
The association of cutaneous nevi and melanoma has been known
for many years. Firstly, the existence of above-average numbers of nevi
has been reported to be a significant risk factor [Lee, 1985 : Swerdlow,
English, Mackie et al., 1986]. Secondly, individuals with giant congenital
nevi have a risk of up to 8% [Kopf, Bart, Rodriguez-Sains, 1977], Thirdly,
histologic sections of melanomas often show associated pre-existing
intradermal nevi, occurring in up to 40% of melanomas [McGovern, 1972],
Finally, some individuals and family members have peculiar-looking nevi
which are dysplastic histologically and which have a significant likelihood
of becoming malignant [Greene, Clark, Tucker etal, 1985]. The relationship
between nevi and melanoma is discussed further in the Chapter 1.
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In the present series, almost 20% of patients had a previous benign
mole removed. The study period antedated the description of the dysplastic
nevus syndrome and it is not possible to relate the melanomas to these
abnormal nevi. The medical records were insufficient to determine the
incidence of moles, normal or abnormal, in the patients' immediate family.
However, co-existent nevi of any type were reported pathologically in only
13.9% of cases of established melanoma. This rate is less than in many
reports but slightly higher than previously described [Clark, Ainsworth,
Bernardino et al., 1969],
4D. Presenting Symptoms.
Growth and color change were the main presenting symptoms [total
65%] and this is in accordance with previous reports in which these
symptoms occurred in over 70% of new melanoma patients [Milton and
Lewis, 1963 : Wick, Sober, Fitzpatrick et al, 1980], Analysis of distribution
of presenting symptoms by primary site showed fewest bleeding/ulcerated
lesions on the upper limb and more head and neck lesions presenting with
development of a new mole. Fifteen percent of LMM, 8% of SSM and 3%
of NM were recognised incidentally by physicians. Alternatively stated,
patients complained of 97% of NM, 92% of SSM and 85% of LMM. There
did not appear to be undue delay in NM diagnosis with more NM being
diagnosed within a year of symptoms than SSM. Itching in a mole is a
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suspicious symptom [Milton, 1968 : Wick, Sober, Fitzpatrick et al., 1980 :
Mackie, 1990], In the present series , itching was more common in NM
[15%] than in SSM [6%].
4E. Symptom Duration.
A median symptom duration of 5.9 months was almost the same as
reported from the Sydney Melanoma Unit [5 months] where females had
a slightly longer symptom duration than males [6.2 vs. 4.5 months]. This
could be interpreted as an indicator of biologically less aggressive tumors
since longer symptomatic periods are associated with long natural history
in other tumors eg. gastric cancer [Rains and Capper, 1968], Observations
of longer intervals to recurrence in females and that a statistically
significant survival advantage was demonstrated only in those dying with
melanoma would be also be consistent with females having biologically
less aggressive tumors. In a study of melanomas of 3 depth groups
[<0.75mm, 0.75-3mm, >3mm], symptom duration was not longer in thick
compared to thin melanomas [Hersey, Sillar, Howe et al., 1991],
suggesting that thicker tumors have a more rapid growth rate. Thick tumors
were mainly nodular melanomas of the head and neck in older males.
4F. Primary Diameter.
At diagnosis, 49% of tumors were under 1 cm in diameter but over
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the decade there was no indication that the primary diagnosis was being
made earlier judging by primary diameter. In contrast however, the
proportion of Clark level 1 and 2 primaries has increased in that time. This
is more important because tumor depth is a much more significant
prognostic factor than diameter [Drzewiecki and Andersen, 1982],
4G. Biopsy and Definitive Primary Surgery.
Excision and incision biopsy techniques are usually recommended
for diagnostic purposes [Urist, Balch, Milton, 1985] and these accounted
for 98.5% of all biopsies in the present series. Specifically, shave biopsies
are not recommended and only one was performed in this series. The
optimum width of excision as definitive management of primary melanoma
remains debatable. The risk of local recurrence is determined more by the
depth of the primary than the width of normal skin excised around it [Urist,
Balch, Milton, 1985]. A trend towards recommending narrower excision
margins than the classical 5cm all round has occurred in the 1980's, and
a large co-operative group trial in North America is currently investigating
a 2 versus 4 cm excision margin [US Intergroup Melanoma Trial], During
the period of the present study, there was no decrease in the number of
>5cm excisions undertaken as primary treatment. An excision of >1cm skin
was undertaken in 89-94% of patients with measured tumor depth T1 -4 but
wider excisions [>5cm skin] were performed in a smaller proportion
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[57-74%]. Recurrence data have not been analysed according to width of
excision.
4H. Histopathology.
The principal histopathological features of primary melanoma are
growth pattern, tumor thickness and depth of invasion, ulceration, cell type,
mitotic activity, lymphocytic reaction, cell type, vascular invasion,
regression, pigmentation, associated pre-existing nevi and solar
degeneration [McGovern and Murad, 1985], Both the extent of definitive
surgery and assessment of individual prognosis are based upon
histopathology. However, agreement between pathologists about various
histologic parameters other than thickness is only about 70% [Larsen,
Little, Orell et al., 1980], Furthermore, the prognostic usefulness of specific
histopathologic features depends on the criteria used to test such variables
as ulceration, mitoses and lymphocyte response [Day, Harrist, Gorstein et
al., 1981 : Day, Sober, Lew et al., 1981 : Day, Lew, Mihm et al., 1982], In
the present study, over half of the pathology slides were reviewed centrally
and this could certainly influence conclusions about histopathological
features. For example, cell type, differentiation and mitotic rate were
frequently unspecified in type or degree.
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4Hi. Differentiation.
Differentiation in the primary was related to growth pattern, bad
prognosis growth pattern being associated with less well differentiated
tumors. Specifically, nodular and acral-lentiginous melanoma were virtually
never well-differentiated, and historically these types are more likely to
recur than SSM or LMM [Balch, Soong, Shaw et al., 1985],
4Hii. Lymphatic and Vascular Invasion.
Lymphatic and vascular invasion were infrequent, especially venous
invasion [4 cases]. Vascular invasion rates in previous reports varied from
0.7% [Little, 1972], 5.8% [Larsen and Grude, 1979] to 37% [Hornstein and
Weidner, 1973]. The wide variation in these reported rates suggests either
under-reporting or over-reporting. Many studies have reported however that
vascular invasion is an adverse prognostic factor [Ronan, Han, Das Gupta,
1988], but other studies have not [Sondergaard and Schou, 1985].
4Hiii. Inflammatory Reactions.
Inflammatory reactions were commoner in association with thinner
primary tumors but specific perilymphatic inflammation was commoner with
thicker primaries. There is no uniformity in reporting host response in terms
of inflammatory reaction in melanoma and this has led to difficulty in
evaluating its significance [Ronan, Han, Das Gupta, 1988]. Detailed
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analysis of histological features will be discussed in the context of
prognostic factor analysis [Chapter 3].
41. Comparison of Various World Series.
4Hi. Sex Ratio and Age.
Data on sex, age, primary site and growth patterns have been
compared with the findings of 12 other major series from the USA [Griffel,
1974 : Fisher, 1989 : Newell, Sider, Bergfelt et al., 1988 : Popescu, Beard,
Treacy et al., 1990 : Balch, Urist, Maddox et al, 1985], Canada [McGregor,
Birdell, Grace et al., 1983], New Zealand [Shaw, 1988], Scotland [Pondes,
Hunter, White et al., 1981 : Mackie and Hunter, 1982], Ireland [Gordon and
Lowry, 1986], Denmark [Osterlind, Hou-Jensen, Jensen, 1988] and
Australia [McCarthy, Shaw, Milton et al., 1985]. This study's sex ratio was
similar to all series except those of Ireland and two in Scotland where the
female : male ratios were 2.8, 1.9 and 2.17 : 1 respectively. All series
except two in the USA [Fisher, 1989 : Newell, Sider, Bergfelt et al., 1988]
showed a female preponderance. Median ages of patients in this study
were slightly lower than most others reported.
4lii. Primary Site.
The commonest primary site in females in all studies is the lower
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limb accounting for 33-67% of all cutaneous melanoma. For males, the
trunk was the commonest primary site [33-47%] in all studies except
Ireland, Scotland and Rochester where head and neck was the commonest
site. The findings in this study that 46% of all male melanomas were
located on the trunk and 44% of all female melanomas were on the lower
limb are consistent with most other series. A trend of increasing frequency
of trunk melanoma and decreasing frequency of head and neck melanoma
in males has been reported from Sydney and Alabama [Balch, Shaw,
Soong et al., 1985] in the period 1958-85. Unfortunately, at the time this
study was initiated, ICDO disease site codes did not distinguish distal from
proximal extremity, although BCCA has now incorporated sub-site
distinctions into its present melanoma staging diagram. Lesions on the
feet have previously been associated with poorer prognosis [Balch, Soong,
Shaw et al., 1985] : similarly, scalp lesions had poorer survival than face
or neck primaries.
4liii. Primary Growth Pattern.
In this study, the observed growth pattern distribution was consistent
with most previous reports. The most frequent [65%] growth pattern was
superficial spreading melanoma, with nodular melanoma and lentigo
malignant melanoma accounting for 25% and 5% respectively. SSM is
usually the most common growth pattern [51-73%] nodular melanoma next
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[14-35%] with lentigo malignant melanoma between 4-9%. In Ireland,
nodular melanoma was the most common type and lentigo malignant
melanoma caused 18% of all melanomas [Gordon and Lowry, 1986],
4liv. Depth of Invasion.
Depth measurement by micrometer is now accepted as the most
important indicator of prognosis [Balch, Soong, Shaw et al., 1985], The
observations that 61 % of the total population had primary tumors less than
1.5mm depth and that no T1 primaries were spread beyond the local area
at diagnosis provide both encouragement and incentive to increase
educational efforts towards earlier recognition and diagnosis. Depth
comparisons with other series are hindered by lack of standard reporting
practices. In the south-east Scotland series from 1971-76, only 30% of
patients had T1 and 2 tumors [Pondes, Hunter, White et al., 1981], In a
worldwide comparative study [Balch, Soong, Shaw, 1985], 12% of patients
had primary tumors >4mm thick whereas in this series 15% were >3.0mm.
In the combined experience of the Sydney Melanoma Group and the
University of Alabama, median tumor thickness for males and females has
decreased since the 1950's [Balch, Shaw, Soong et al., 1985] to 1.4 and
1.2mm during 1976-80. These are close to the median depths observed
from 1972-81 in the present series [1.45mm for males and 1.10mm for
females]. Poorer prognosis in nodular melanoma [Balch, Soong, Shaw et
131
al., 1985] is related to their depth. For example, 83% of NM but only 24%
of SSM were T3 or T4 in this series. ALM is also usually a deep lesion
[66% were T3 or T4],
4lv. Depth of Invasion and Clark Level.
Observed correlations between frequencies of micrometer depths
and Clark levels varied from excellent [in female lower limb primaries] to
fair [T1 and T2 primaries in all body sites in both sexes]. The distribution
of tumor thickness within each Clark level is similar to previous reports
[Balch, Murad, Soong et al., 1979], The prognostic separation which each
staging system permits will be studied further.
4J. Tumor Volume.
Estimation of tumor volume is potentially flawed by concomitant
non-invasive components in the primary contributing to greater diameter
and volume. However, in a large series such as this it may be valid.
Median tumor diameters were found to be identical for both males and
females. Tumor volume was greater than expected in males from depth
alone. This may have been due to the absence of either depth or diameter
measurements in some patients leading to a larger difference between the
sexes.
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4K. Stage.
Several staging systems have been utilised in malignant melanoma
[Ghussen, Kruger, Groth, 1990], The original 3 stage system of local [stage
1], regional [stage 2] and distant [stage 3], and the MD Anderson Hospital
system used here are purely anatomical, whereas the American Joint
Committee and the International Union Against Cancer systems incorporate
depth of the primary in the definition of different stages. The elective lymph
node dissection rate in various series obviously influences eventual stage
but this factor is not included in any of the staging systems except when
it is positive with consequent up-staging. Most series report that the
majority of patients have stage 1 disease at presentation, consistent with
this series. Correlating primary sites with potential metastatic disease at
diagnosis according to sex showed that males had about twice the
likelihood of regional or metastatic disease with head and neck primaries
compared with females and almost three times with lower limb primaries.
Elective and therapeutic lymph node dissection analyses will be reported
separately.
4L. Recurrence.
The pattern of recurrent disease in melanoma is now well known.
The disease free interval is directly related to the depth of the primary
[Balch and Milton, 1985]. Regional lymph nodes are the commonest site
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of first metastasis. In this series, 54% of first recurrences were in regional
nodes. In a recent series of 377 stage 1 patients, 100 of whom underwent
elective lymph node dissection [ELND], 43% of first recurrences were in
regional lymph nodes and 57% were in distant sites [Meyskens, Berdeaux,
Parks et al., 1988], ELND is known to be associated with a different pattern
of metastatic disease ie. fewer regional nodal metastases [down from
about 60% to 5%] and proportionate increase in other sites [McCarthy,
Shaw, Milton, 1985], The expected likelihood and pattern of metastases
influences follow-up recommendations with thinner lesions requiring less
vigorous attention than thick tumors [McCarthy, Shaw, Thompson et al.,
1988], The distribution of distant metastases in the present series is
consistent with previous reports. The prognostic significance of developing
recurrent disease is very clear from this series. Only 16% of patients
experiencing recurrence were free of disease at last follow-up. New
treatments are urgently required for this group of patients.
The phenomenon of late recurrence in melanoma is well known,
particularly in choroidal melanoma. In the present series, there were 5
recurrences 10+ years after diagnosis. In a series of 105 stage 1
cutaneous melanoma patients, there were 7 recurrences beyond 10 years
[Briele, Beattie, Ronan et al., 1983], and at that time there had been 7
other reports in the literature. In a series of 536 patients, 5 had late
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recurrence [Callaway and Briggs, 1989], and in a series of 769 patients,
there were 11 cases of late recurrence [McEwan, Smith, Matthews, 1990],
These events are important from the point of view of necessity for clinical
and statistical follow-up. The estimated late recurrence rate among those
patients who survive the first 10 years after diagnosis is 7% [McEwan,
Smith, Matthews et a!., 1990],
4M. Prognosis in Males.
Poorer prognosis of malignant melanoma in males is well
documented [Balch, Shaw, Soong etal., 1985 : O'Doherty, Prescott, White
et al., 1986] and confirmed here. Male sex has been shown to be an
independently poor prognostic factor. The sex difference in survival in the
present study could be due to several factors. Males had thicker and larger
volume tumors in general, predilection to trunk, head and neck primaries,
the majority of thick primaries in these sites, the majority of regional or
metastatic disease in all sites except upper limb at presentation and a
tendency to shorter disease-free intervals to recurrence.
The role of hormonal factors in the etiology and natural history of
malignant melanoma has been recognised and investigated for over 40
years. Early reports of a therapeutic effect of orchidectomy [Herbst, 1943
: Howes, 1943] stimulated interest in endocrine aspects of melanoma which
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was intensified with the demonstration of steroid hormone receptor proteins
in melanoma in the 1970's [Fisher, Neifeld, Lippman, 1976], Practically
however, the observed single agent response rates in metastatic
melanoma to estrogens, anti-estrogens, androgens, progestogens and
glucocorticoids have been disappointingly low [Walker, 1988 : Rose,
Pedersen, Mouridsen, 1985] and it remains to be shown that hormonal
mechanisms can be used to advantage in the treatment of melanoma.
There has been renewed interest recently in anti-estrogen therapy
in metastatic melanoma in conjunction with chemotherapy since a higher
than expected response rate was observed in patients treated with
tamoxifen, BCNU, Cisplatinum and DTIC [De Prete, Maurer, O'Donnell et
al., 1984]. The effect of tamoxifen may however be to increase the
sensitivity of melanoma cells to cisplatinum [McClay, Albright, Jones et al.,
1991], A randomised trial to determine the contribution of tamoxifen to
these chemotherapy agents is now underway in the USA.
4N. Comparison of Outcomes Between Series.
Several factors must be taken into account when comparing survival
of patients between series [Balch, Soong, Shaw, 1985]. Referral centre
results differ from population-based studies. Results from the last decade
may be superior due to earlier diagnosis. The distribution of tumor
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thickness must be considered. Patterns of surgical practice, especially the
elective lymph node dissection rate, will have a significant effect on staging
and possibly on ultimate survival. Relapse is less likely in pathological
compared to clinical stage 1 patients. In this series, overall 5-year survivals
of 68.9% and 82.9% for males and females [10% of whom had regional or
distant metastases at diagnosis] compare favorably with those from 11
series in which 5-year survivals for stage 1 melanoma ranged from 62-81%
and 70-100% in males and females respectively.
40. Future Prospects.
Early diagnosis is the best available method of improving survival in
cutaneous malignant melanoma. Since CMM can be found readily by self
inspection, there is an opportunity to shorten median times to diagnosis
with education. A public health education program in Queensland resulted
in more thin tumors registered recently compared to 10 years previously
[Little, Holt, Davis, 1980], An increased proportion of thin melanomas has
also been reported following public and physician education campaigns in
United Kingdom [O'Doherty and Mackie, 1988 ; Fairris, 1988 : Curley,
Marsden, Fallarfield et al., 1988 : Mackie, 1990 : Harris and Savin, 1990],
A physician checklist of major [changes in size, shape and color] and
minor [inflammation, bleeding/crusting, sensory change, diameter > 7mm]
features suspicious of melanoma formed the basis of the successful
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campaign for early diagnosis of melanoma in the west of Scotland [Mackie,
1990], It has been suggested that further campaigns be directed towards
high risk individuals identified by risk factor charts rather than whole
populations [Mackie, Freudenberger, Aitchison, 1989 : Harris and Savin,
1990], Warning signs in a mole, assymmetry, border irregularity, color
variation, and diameter [>6mm], known as the ABCD of melanoma
[Friedman and Rigel, 1985], have been emphasised along with assessment
and surveillance of individuals with dysplastic nevus syndrome and/or
family members with melanoma [Reynold and Austin, 1984], Public
campaigns and further research in early detection and treatment should be
capable of reducing melanoma mortality, especially in areas of higher
incidence such as British Columbia.
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1. INTRODUCTION
1A. General.
The clinical behaviour of malignant melanoma can be quite variable.
The phenomena of recurrence of melanoma thought likely curable and the
lack of further recurrence in some patients who have already experienced
recurrence are familiar to clinicians following melanoma patients. The
likelihood or risk of recurrence after surgery for stage 1 primary melanoma
can however be assessed with reasonable accuracy in most patients.
Several developments in contemporary understanding of malignant
melanoma now allow clinicians to offer patients a good estimate of the
chance of recurrence. This is not only helpful to patients but is of major
importance in undertaking studies of adjuvant therapy and in comparing
results of treatment in different centres.
The principal elements of the third and contemporary period of
melanoma history are the description of four primary growth patterns and
the recognition that depth of the invasive component is the major
determinant of survival [Clark, Ainsworth, Bernardino et al., 1969 : Breslow,
1970 : Reed, 1976], The first report of depth of invasion as a prognostic
factor was in 1953 [Allen and Spitz, 1953].
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1B. Methodological issues.
Three approaches have been used to study relations between single
factors in survival analysis after initial treatment. These include direct
numerical relations [graphics, cross-tabulations, chi-square tests],
stratification of variables, and multivariate analysis. The latter was chosen
to study significant factors from univariate analysis in the present report.
This permits accurate identification of the dominant risk factor(s). For
example, survival in female lower extremity melanoma is generally good
: whether this relates to patient sex, primary site, primary growth pattern
, primary depth or other factors can be assessed by multifactorial analysis.
The Cox proportional hazards model is currently the preferred
method of survival analysis throughout the world [Cox, 1972 : Lew, Day,
Harrist et al., 1983]. This analysis selects from a list of single factors the
"best" combination to predict survival. A stepwise procedure forcing single
factors and combinations to compete is undertaken. The best individual
prognostic factors are selected and complementary factors are added one
at a time to complete the model. The model selects factors associated with
earlier as opposed to late death. Data with dominance of short-term
follow-up may yield different conclusions from more mature data.
Alternative models should be routinely formed to examine other possible
contributing factors [Day, Lew, Mihm et al., 1982], Potentially important
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factors should be tested in different ways, such as Clark level being
examined as a dichotomous variable [ie level II v. other levels, levels II and
III v. levels IV and V, level V v others] and as a linear variable [ie level II
= 1, level III = 2 etc.]. Most programs undertaking the Cox model exclude
all patients in a series with even one piece of relevant data missing. If such
exclusions are > 10% of the patients there is a risk of selection bias. At
completion of the model, results should be confirmed by life-table survival
analysis.
The Cox proportional hazards model is ideal for assessing time to
recurrence or death. In contrast, logistic regression analysis is ideal for
binary events [events which have two possible outcomes], and can be
expanded to include more than two possible outcomes, such as categorical
variables [Vollmer, 1989],
1C. Literature review.
Prognostic factor analyses have been reported by many groups and
institutions. The Universities of Alabama and Sydney have reported the
largest collaborative study of prognostic factors for primary, regional and
metastatic melanoma [Balch, Soong, Shaw et al., 1985], In 3505 stage 1
patients, principal characteristics were as follows : median age 45 years,
53% female, 27% T1, 30% T2 primaries, 24% ulcerated. Single factor
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survival analysis showed female sex, extremity compared with axial
primary, increasing age, tumor thickness, level of invasion, ulceration,
regression, pigmentation [all p=<0.00001], growth pattern [LMM and
SSM>NM, p=<0.0004], lymphocytic infiltration [p=<0.0066], highly
significant. Further analysis of primary site showed scalp to be worse than
other head and neck primary sites [p=<0.05] and foot to be worse than
other lower extremity sites [p=<0.00001], The poorer prognosis of scalp
along with upper back, upper outer arm and neck [BANS] primaries had
been reported previously [Day, Mihm, Lew et al., 1982] but this study did
not confirm the BANS sites as high risk. Females had better survival in all
extremity sub-sites [p=<0.00001] but had similar survival with head, neck
and trunk primaries. Males had more frequent ulceration of the primary [29
vs 19%] and this could contribute to their poorer prognosis. Between the
sexes there was no difference in survival with ulcerated primaries. Elective
lymph node dissection [ELND] was of borderline significance [p=0.069].
Prognosis of acral-lentiginous melanoma [ALM] was not assessed because
of its relatively recent recognition and the importance of minimum 8-10
years follow-up.
The significant single factors which were still significant in
multifactorial analysis were thickness, ELND, pathological stage [1 vs 3],
ulceration and primary site [all p=<0.00001], while level of invasion, sex
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and regression were significant to a lesser degree. Thickness and
ulceration had the best correlation with survival in all subgroups examined.
Unlike the other significant prognostic factors, ELND was non-random in
distribution ie patients were selected to have this procedure. It is therefore
possible that the selection process identified a specific risk group rather
than the procedure having survival benefit.
Stage 3 and 4 [MD Anderson system] patients were also examined
for prognostic features. Stage 3 patients were grouped as 3B1 and 3B2,
and 3B3, 3B4. Single factor analysis showed primary ulceration to be most
significant [p=<0.00001] followed by number of nodes positive [p=<0.0002],
thickness [p=<0.004] and age [p=<0.0369]. Multifactorial analysis showed
only number of nodes [p=<0.0005], ulceration [p=<0.00001] and age
[p=<0.0478] to be significant: tumor thickness was of marginal significance
[p=0.0686]. Survival of the 3 groups within stage 3 was similar provided it
was calculated from time of lymph node metastases. For patients with
distant metastases, number of metastatic sites and location of metastases
were significant in both uni- and multivariate analysis and remission
duration was also significant in the multifactorial model.
Multivariate and discriminant analyses have been undertaken to
define 4 risk groups of patients with stage 1 melanoma [Schmoeckel,
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Bockelbrink, Bockelbrink et al, 1983 and 1983], In 585 cases, the most
significant factors were tumor depth and mitotic activity, particularly when
combined as a "prognostic index". Vascular invasion, ulceration in tumors
>3mm thick, severe cellular atypia, small lymphocyte-like cell type and
absence of inflammatory response were also associated with high risk of
metastases. Less relevant factors were level of invasion, sex, site, tumor
breadth, and clinical diameters. Growth pattern, age, symptom duration,
presence of co-existing nevus were not significant risk factors for
recurrence. Using the significant factors, a classification of melanoma into
4 risk groups was developed :
1. Low Risk : <8% recurrence rate.
Features : <0.75mm thick + mitotic index <10 mit/mm2 :
no signs of regression, ulceration, vascular invasion : cases with diameter
>3cm should be classified as medium risk.
2. Medium Risk : approximately 30% recurrence rate.
Features : cases other than low, high or very high risk.
3. High Risk : approximately 65% recurrence rate.
Features : prognostic index >13: or ulceration in tumors >3mm thick.
4. Very High Risk : approximately 95% recurrence rate.
Features : mitotic index >25mit/mm2 : or unequivocal vascular invasion : or
high risk melanoma in palmar, plantar or subungual location.
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1D. Prognostic factors and staging systems.
Because of their prognostic implications, depth and level of invasion
have been incorporated into the current melanoma staging systems of the
International Union Against Cancer [UICC] and the American Joint
Committee on Cancer [AJCC] {Ghussen, Kruger, Groth, 1990}.
UICC stages are summarised ;
Stage 1 ; local primary <or= 1.50mm, level <or= 3.
Stage 2; " " 1,51-4.00mm, level 4
Stage 3 ; " " >4.00mm, level 5 or satellites, or in transit metastases
or regional node metastases.
Stage 4 ; distant metastases.
AJCC stages are summarised ;
Stage 1A ; local primary <or= 0.75mm, level <or= 2
Stage 1B ; " " 0.76-1.50mm, level 3
Stage 2A ; " " 1.51-4.00mm, level 4
Stage 2B ; " " >4.00mm, level 5 or satellites
Stage 3 ; Regional nodes, mobile and <5cm diameter, or <5 in transit mets.
Stage 4 ; Regional nodes, >5cm diam, or >5 in transit mets. or distant
mets.
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In an analysis of 220 patients with extremity primary melanoma
treated by wide primary excision, regional node dissection and limb
perfusion these staging systems have been compared with the original 3
stage system and the MD Anderson system, which do not take account of
depth or level of invasion [Ghussen, Kruger, Groth, 1990], The AJCC
system provided best differentiation of prognosis. Differences in survival
between stages were stage 1 and 2 [p=0.078], stage 2 and 3 [p=<0.001],
stage 3 and 4 [p=<0.001], stage 2A and 2B [p=<0.001]. There were only
9 stage 1A patients and the difference in survival between stage 1A and
1B [31 patients] was not significant [p=0.4],
1E. Present study.
The present study is a retrospective review of cutaneous malignant
melanoma registered with the British Columbia Cancer Agency [BCCA]
between 1972 and 1981. Clinical and pathologic factors previously reported
to be of prognostic significance have been identified from the patients'
clinical records and analysed according to outcome with a minimum
follow-up of 7.9 years. For treatment purposes during this time, melanomas
were classified as low or high risk. Primary depth was used to distinguish
the two groups. Up to 1982, lesions less than 0.75 mm deep were
classified low risk. Since 1982, lesions more than 1.5 mm thick have been
classified high risk. The extent of primary surgery [width of excision and
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ELND] and inclusion in adjuvant trials depend on the low/high risk
classification. Stage was defined using the MD Anderson Hospital system.
The present study is the first analysis of outcome in these patients.
Clinical and pathological descriptions varied in completeness. For example,
primary tumor depth measurements were unavailable in 223 cases. Most
of the histologic sections were reviewed by 2 BCCA pathologists. Most of
the clinical descriptions of the primary tumor were obtained from medical
records prior to consultation at BCCA since most patients had the primary
removed prior to referral. These descriptions were from many family
physicians, dermatologists and general surgeons, with varying
completeness.
2. PATIENTS AND METHODS
2A. Patient population.
In 1983 a retrospective review of all patients registered in the BCCA
with malignant melanoma from June 1 1972 to May 31 1981 was
commenced. Full details of the patient population and reasons for
exclusion are described in Chapter 2 [Carmichael and Wilson, 1991]. In
summary, 1944 patients were registered with malignant melanoma in the
Provincial Cancer Registry, 1245 of whom were referred to the BCCA.
Final analysis was undertaken on 891 patients.
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2B. Data collection.
A Chart Abstract Form was completed from each patient's chart from
which the following clinical and pathological factors were analysed:
1. Clinical
Age at diagnosis, sex, primary site, diameter, color, surface elevation,
ulceration, regression, extent of initial surgery, stage.
2. Pathological
a. growth pattern : lentigo malignant melanoma [LMM], superficial
spreading melanoma [SSM], nodular melanoma [NM], acral-lentiginous
melanoma [ALM ], not otherwise specified [NOS]
b. mitotic rate : low [1/5 high power fields]
moderate [1/5 - 1/hpf]
high [> 1/hpf]
c. polypoid configuration : absent / present
d. regression : absent / present
e. ulceration : absent / present
f. degree of pigmentation : none/minimal/moderate/marked
unspecified degree / unspecified
g. Clark level of invasion : I, II, III, IV, V ; micrometer depth in mms.
h. lymphatic / vascular invasion : absent / present
i. dominant cell type : epithelioid/spindle/mixed/other/unspecified
j. degree of differentiation : poor/moderate/well/unspecified
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k. associated nevus : absent / present
I. presence and degree of inflammatory reaction :
absent / present : slight / moderate / marked / unspecified
m. presence of perilymphatic inflammation : absent / present
n. stage : MD Anderson system
A total of 796 patients were identified with stage 1 disease. Clark
level 1 patients and those with "borderline melanoma" were excluded from
analysis because of 100% survival. Follow-up data was missing in 7 cases
leaving a total of 753 cases for analysis.
2C. Definition of factors.
Age refers to age at pathological diagnosis. Age was treated as a
continuous variable for the multivariate analysis and as a categorical
variable for univariate analysis. Categorisation of age was determined by
partitioning melanoma mortality distribution.
Histopathology was performed in hospitals throughout the province,
most slides being reviewed by two pathologists in the BCCA. Tumor growth
patterns and depth were reported using standard criteria [Clark, Ainsworth,
Bernardino et al., 1969 : Clark, 1967 : Breslow, 1970], Depth categorisation
was determined from the T category of the TNM classification [American
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Cancer Society, 1983] : T1 <0.75mm, T2 0.76-1.50mm, T3 1.51-3.00mm,
and T4 >3.0mm. Depth was used as a categorical variable in univariate
analysis and as a continuous covariate in its logarithmic form for
multivariate analysis. Tumor volume was calculated from :
II * [diameter / 2]2 * depth.
Mitotic rate was assessed in 5 high power fields for each primary
tumor. Mitotic rate was treated as a categorical variable for both forms of
analysis since no actual counts of mitoses per square mm. were recorded.
BANS sites refer to primary tumor located on the following parts of
the body surface : upper back, posterior aspect of upper arms, posterior
neck and scalp. The posterior upper arm was not coded separately in the
Chart Abstract Form. This report utilises posterior upper extremity instead.
2D. Statistical methods.
The principal study objective was evaluation of survival from
melanoma in relation to various clinical and pathological factors. The
response variable was time from diagnosis to death from melanoma.
Observation times for patients leaving the study for reasons other than
death from melanoma, and for patients alive at last follow-up were
considered as censored observations. Survival times were calculated from
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date of diagnosis to date of death or last physician contact. Cases with
missing data were excluded from the relevant analysis procedure.
Univariate analysis was performed to assess the prognostic value
for survival of individual variables using the product limit method [Kaplan
and Meier, 1958] with a biomedical computer program BMDP [version
1988], The log rank test was used to determine significance of differences
between categories [Peto, Pike, Armitage et al., 1977],
Multivariate analysis was undertaken with the Cox regression model
[Cox, 1972] using Harrell's program PHGLM written for SAS. Significant
co-variates, determined through univariate analysis, were initially entered
into the model and a continuous stepwise analysis was performed.
Different combinations of covariates and alternative models were examined
to determine the best prognostic model.
The PHGLM program solves the non-linear equation with iterative
techniques. Analysis and computation are easier if there is one failure or
death from melanoma in each time period [Vollmer, 1989]. Coding of
factors in the regression model is critical [Vollmer, 1989], Linear
relationships implying a decrease in prognosis may not hold for certain
covariates, as each category within a covariate may have a distinct
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biological effect. The categories in Clark level, growth patterns,
inflammatory reaction, surface description and primary site have been
coded as separate binary factors. These covariates have been analysed
both in a binary and linear manner for multivariate analysis. The
proportional hazards assumption in the final model was checked
graphically [Andersen, 1982],
Three methods of calculation of survival proportions were used :
disease-specific, disease-free and overall. Disease-specific survival is
calculated using only those patients who died from melanoma. Overall
survival proportions are calculated using deaths from all causes.
Disease-free survival refers to time from diagnosis to first recurrence.
3. RESULTS
3A. Univariate analysis.
Univariate analysis results and log rank test p values are presented
in Table 1. Date of diagnosis, sex, primary site including BANS sites,
growth pattern, surface description, Clark level, depth of invasion, clinical
and pathological ulceration, tumor diameter and volume, lymphatic
invasion, mitotic rate, inflammatory reaction, invasion to stratum corneum,
pigmentation, polypoid configuration and type of surgery were significant.
There were insufficient cases of LMM with adequate data to assess its
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prognostic significance. Age, primary color, type of inflammatory infiltrate,
primary cell type, clinical and pathological regression, previous nevi were
not significant.
3B. Multivariate analysis.
Multivariate model building was applied to various groupings of
covariates in order to find a scoring of the variables that gave rise to a
satisfactory proportional hazards model. The full model shown in Table 2
had a total of 217 cases of which 54 were uncensored. A total of 543
cases were deleted due to absence of one or more covariate values. As
no more than 10% of the number of uncensored cases of covariates should
be examined in multivariate analysis [Harrell, 1983], different models were
examined excluding covariates with a large number of missing values. The
reduced model examined 15 covariates with 134 uncensored cases and
120 cases with missing values.
Depth of invasion was coded in logarithmic form to increase the
power of the model. Both pigmentation and surface description were found
significant in multivariate analysis but were excluded from the final model
due to their subjective determination.
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Table 1. Coding and univariate analysis of prognostic factors.
Factor # Pts Uncensd.
cases
Missing
values
Multivariate
Analysis scoring
X2, p values
from univariate
analysis
Clark Level 192 61
ii 147 1 if lev ii, 0 if not X = 106.7
iii 219 1 if lev iii, 0 if not p <0.0001
iv 294 1 if lev iv, 0 if not
V 32 1 if lev v, 0 if not
Depth of Invasion 160 142
T1 183 Continuous X = 97.5
T2 186 (log depth ) p <0.0001
T3 156
T4 86
Pathol Ulceration 209 16
_ 544 0 if absent X = 66.9
+ 193 1 if present p <0.0001
Growth Pattern 215 24
SSM 428 1 if SSM, 0 if not
NM 153 1 if NM, 0 if not X = 40.4
ALM 13 1 if ALM, 0 if not p <0.0001
NOS 135 0 if NOS
Tumor Volume 143 208
<300mm3 405 continuous X = 35.7
300-600mm3 67 p <0.0001
600-900mm3 22
>900mm3 51
Clinical ulceration 193 52
_ 529 0 if absent X = 33.6
+ 172 1 if present p <0.0001
Date of Diagnosis 218 0
<1978 420 0 if <1978 X = 27.8
1978 + 333 1 if 1978 + p <0.0001
Gender 218 0
Male 347 0 if male X = 24.5
Female 406 1 if female p <0.0001
Lymphatic Invasion 204 17
_ 702 0 if absent X = 22.2
+ 34 1 if present p <0.0001
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Table 1 cont.
Factor # Pts. Uncens.
cases
Missing
Values
Multivariate
anal, scoring
X!, p values
from univar.
analysis
Surface
descrpn.
183 135
Flat 159 1 if flat, 0 if not X = 23.3
Raised 396 1 if raised, 0 if
not
p <0.0001
Both 63 0 if both
Prim. Site 218 0
Head & Neck 123 1 if H&N, 0 if not X = 20.9
Trunk 274 1 if trunk, 0 if not p <0.0001
Upper Limb 133 1 if UL, 0 if not
Lower Limb 223 0 if LL
Inflam.
Reaction
150 183
Slight 192 1 if slight, 0 if not
Moderate 225 1 if moderate, 0
if not
Marked 117 1 if marked, 0 if
not
None 36 0 if none
Pigmentn. 203 32
Minimal 127 X = 18.4
Moderate 168 1 if moderate, 0
if not
p 0.0011
Marked 153 1 if marked, 0 if
not
Unspec. 273 0 if minimal
Tumor Diam. 199 75
<5mm 107 continuous X = 13.7
6-8mm 123 p 0.0052
9-1 Omm 141
11-15mm 157
16+mm 150
BANS Sites 218 0
Absent 548 0 if absent X = 12.5
Present 205 1 if present p 0.0004
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Table 1 cont.
Factor # Pts Uncens
pts
Missing
values
Multivar.
anal, score
X2, p values
(univ anal.)
Mitoses 133 303
Low 175 1 (low), 0 if not X = 12.8
Medium 185 1 (medium),0 if not p 0.0017
High 90 0 if high
Color 172 155
None 2 X = 13.7
Black 122 p 0.0565
Blue 26
Red 30
Brown 326
Grey 84
White 8
Surgery 217 33
Local Excision 192 1 if LE, 0 if not X = 11.2
LE + ELND 3 1 if LE + ELND, 0
if not
p 0.0472
Wide Excision 327 1 if WE, 0 if not
WE + ELND 198 0 if WE + ELND
Polypoid 213 6
Absent 686 0 if absent X = 9.4
Present 61 1 if present p 0.0022
Cell Type 110 418
Epithelioid 199 X = 5.2
Spindle 81 p 0.1595
Mixed 55
Age 218 0
0-39 272 X = 3.95
40-59 301 p 0.1391
60+ 180
Str Corn inv 211 15
_ 369 0 if absent LOCOIIX
+ 379 1 if present p 0.003
Previous nevi 218 0
_ 714 X = 0.21
+ 39 p 0.6436
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When the covariates coded in a binary manner in the reduced model
in Table 2 were assessed in the final model, several covariates became
significant. All the Clark level and growth pattern covariates became
significant with beta values of -1.98, -1.36 and -0.92 for Clark levels II, III
and IV respectively and beta values of 0.96, 0.80 and 1.44 for SSM, NM
and ALM respectively.
Alternate models coding primary site as head and neck, anterior
trunk, posterior trunk and extremities were examined. The final models
differed from the reported model in Table 2 in that BANS sites and sex
were significant and other primary sites were not. When the model was
adjusted for Clark level, significant factors were BANS sites, sex and
lymphatic invasion.
When the analysis was commenced, surface description and
pigmentation were both included in all the reduced models because they
were significant. The final model included the covariates for raised surfaces
and moderate pigmentation for all models with the exception of the model
adjusted for log depth. In this model, only raised surface was significant.
Because of the subjective determination of these covariates, they were
eliminated from the reported reduced model.
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Date of diagnosis is another covariate that was eliminated from the
reported reduced model even though it was significant in all reduced
models analysed. This was done because of possible effects of referral
patterns contributing to the increase in frequency of thin tumors in the
second 5 years of study.
The reduced model covariates were analysed with linear categorical
coding instead of binary coding and the results are shown in Table 3.
Lymphatic invasion, BANS sites, Clark level and growth pattern were
added to the final model as shown in Table 2.
Multivariate analysis was used to determine whether covariates were
significantly related to survival after adjusting for the effect of depth of
invasion and Clark level. The results are summarised in Table 4. Ulceration
and type of initial surgery were significant in all models. When depth
adjustment was made, sex, BANS sites and lymphatic invasion replaced
primary sites in the final model. When depth was removed, Clark level
became highly significant, indicating a high correlation between the two
variables.
Tables 2, 3, 4, 5, Figures 1-5 over /
162
Table 2. Summary ofmultivariate analyses with significant prognostic
factors.
Full model Reduced model Final model
217 cases 556 cases 556 cases
Clark level Beta P Value Beta p Value Beta p Value
ii -2.5219 0.0499 -1.985 0.0016
Hi -2.8475 0.0084 -1.356 0.0050
iv -2.3975 0.0145 -0.9206 0.0303
V
Log Depth 2.6561 0.0024 1.6753 <0.0001 2.0581 <0.0001
Path Ulcern 1.7931 0.007 0.5798 0.0025 0.5912 0.0018
Growth Pattern
SSM 2.3653 0.0029 0.9552 0.0060
NM 1.5043 0.0687 0.8006 0.0173
ALM 2.7067 0.0801 1.4423 0.0203
NOS
Tumor Volume -0.0006 0.282
Clin Ulcern -1.3358 0.036
Lymphatic Invasn 0.6029 0.4383 0.7459 0.0173
Type of Surgery
LE 0.9245 0.0515 0.7888 0.0017 0.561 0.0071
LE + ELND -1.6446 0.0466 0.2431 0.5578
WE 0.1538 0.7205 0.1635 0.4706
WE + ELND
Date of Diagnosis -0.6838 0.0981
Gender -0.500 0.1742
Age -0.0055 0.6263
Primary Site
Head & Neck 1.8611 0.0037 0.9516 0.0013 0.8782 0.0006
Trunk 1.5978 0.0177 1.1541 <0.0001 0.8985 <0.0001
Upper Limb 1.2882 0.0585 0.3211 0.3269
Lower Limb
Tumor Diameter 0.0516 0.2093
BANS Sites 0.4060 0.3842
Polypoid
configuration
0.7622 0.1724
Invasion to
stratum corneum
-0.7310 0.0867
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Table 3. Summary of multivariate analysis using linear coding for
categorical variates.
Covariate Beta X2 P value
Log Depth 1.71 22.58 <0.0001
Primary Site -0.297 10.67 0.0011
Path Ulceration 0.698 13.77 0.0002
Type of Surgery -0.196 10.13 0.0015
Growth Pattern -0.208 6.68 0.0097
Clark Level 0.468 7.83 0.0051
BANS Sites 0.471 5.85 0.0159
Lymphatic Invasion 0.632 4.26 0.0389
Survival proportions are presented in Table 5. There were 218
melanoma deaths and 56 deaths from other causes. Overall survival range
was 0.23-17.42 years, mean 8.69, median 8.08 years. Survival proportions
according to depth of invasion, Clark level, primary ulceration, age at
diagnosis and growth pattern are shown graphically in Figures 1-5.
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Table 4.
Multivariate analysis
adjusting for Log Depth and Clark Level.
Significant covariates after adjusting for:
Covariate Log Depth Clark Level Neither
645 cases 565 cases 565 cases
Log Depth <0.0001 <0.0001
Clark Level II
<0.0001
III
<0.0001
IV
<0.02
V
Ulceration <0.0001 0.001 0.002
H&N
Primary Site 0.0002 0.0006
Trunk
<0.0001 <0.0001
UpperL
Lower L
BANS sites 0.0002
Lymphatic invasn. 0.03
LE 0.002 0.003 0.007
Surgery
LE+LND
WE
WE+LND
Sex 0.01
Growth pattern was insignificant in all analyses
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Table 5. SURVIVAL PROPORTIONS
5 yr DFS Overall 5yr D/Spec 5yr D/S 10yr
Level 2 79% 86% 87% 78%
3 66% 81% 87% 78%
4 47% 68% 73% 58%
5 22% 34% 36% 26%
T1 82% 89% 95% 93%
T2 65% 82% 88% 75%
T3 46% 70% 74% 58%
T4 31% 49% 55% 42%
Path ulcern 36% 55% 61% 48%
P/ulcern neg 66% 80% 86% 78%
SSM 68% 80% 87% 78%
NM 44% 59% 66% 52%
ALM 23% 62% 69% 43%
NOS 46% 70% 74% 62%
Male 50% 66% 72% 60%
Female 64% 80% 86% 77%
Lymph lnv+ 26% 44% 49% 34%
Lymph Inv- 60% 76% 82% 72%
Surface flat 70% 78% 87% 84%
Raised 50% 69% 74% 62%
Flat+Raised 67% 84% 89% 77%
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Table 5 continued. SURVIVAL PROPORTIONS
5 yr DFS Overall 5yr D/Spec 5yr D/S 10yr
Head & Neck 52% 67% 74% 63%
Trunk 51% 68% 73% 62%
Upper Limb 66% 80% 85% 77%
Lower Limb 64% 80% 86% 77%
Min.Pigmtn. 47% 66% 73% 56%
Moderate P. 53% 71% 75% 62%
Marked P. 66% 79% 86% 75%
Unspec P. 63% 77% 83% 76%
Epithel. cells 53% 71% 75% 63%
Spindle cells 62% 77% 85% 73%
Mixed cells 58% 76% 78% 62%
BANS Sites- 61% 76% 82% 73%
BANS Sites+ 51% 67% 73% 60%
Mitoses low 66% 81% 88% 78%
Mitoses med. 58% 73% 72% 64%
Mit. frequent 57% 69% 73% 57%
Type of
surgery
LE 51% 68% 67% 38%
LE+ELND 33% 100% 50% 50%
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Table 5 contd. SURVIVAL PROPORTIONS
Type of
Surgery
5 yr DFS Overall 5yr D/Spec 5yr D/S 10yr
WE 59% 76% 78% 67%
WE+ELND 64% 76% 82% 67%
Polypoid
Absent 60% 75% 81% 71%
Present 41% 66% 68% 51%
Age Groups
0-39 yrs 63% 78% 83% 73%
40-59 yrs 58% 75% 79% 68%
60+ yrs 49% 66% 75% 64%
Regression
Absent 58% 75% 79% 69%
Present 62% 70% 81% 79%
Diagnosis
Date
<1978 49% 70% 74% 61%
>1978 69% 78% 87% 81%
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Figure 1
DISEASE-SPECIFIC SURVIVAL
According to Primary Depth
YEARS
■ T1 + - T2 T3 -a- T4
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Figure 2
DISEASE-SPECIFIC SURVIVAL
According to Clark Level
100
Level 2 —Level 3 —Level 4 —b— Level 5
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Figure 3
DISEASE-SPECIFIC SURVIVAL
According to Primary Ulceration
YEARS
ABSENT PRESENT
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Figure 4
DISEASE-SPECIFIC SURVIVAL
According to Age at Diagnosis
YEARS
*- 0-39 Yrs —»— 40-59 Yrs 60+ Yrs
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Figure 5
DISEASE-SPECIFIC SURVIVAL
According to Growth Pattern
YEARS
■ SSM + Unspec. * NM a ALM
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4. DISCUSSION
4A. Methodological issues.
Analysis of survival in patients with stage 1 malignant melanoma is
complex, requiring definitions of clinical and histologic features/covariates,
follow-up period and statistical methodologies to allow meaningful
comparisons of results between centres. The largest single report of
prognostic factor analysis in melanoma included a review of world
experience up to 1985 [Balch, Soong, Shaw et al., 1985], Since then, there
have been several other significant reports [Johnson, Emrich, Karakousis
et al., 1985 : Kopf, Gross, Rogers et al., 1987 : Rogers, Kopf, Rigel et al.,
1986 : Worth, Gallagher, Elwood etal., 1989 : Meyskens, Berdeaux, Parks
et al., 1988 : Vollmer, 1989 : Karjalainen and Hakulinen, 1988 :
Karakousis, Emrich, Rao, 1989 : Drzewiecki, Frydman, Andersen et al.,
1990 : Ronan, Han, Das Gupta, 1988].
Lack of uniformity in definition of covariates may lead to difficulties
in comparing results of prognostic factor analysis. The desirability of
labelling hands and feet as separate primary sites has been suggested
[Day, Lew, Mihm et al., 1982], The extent of lymphocytic infiltration may be
defined as 2 or 3 values [Day, Lew, Mihm et al., 1982 : Balch, Soong,
Murad et al., 1981 : Van der Esch, Cascinelli, Preda et al., 1981], The
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number of mitoses can be evaluated in random fields or only in areas of
most active tumor [Van der Esch, Cascinelli, Preda et al, 1981 : Day,
Mihm, Lew et al., 1982], and it can be given the range of values observed
or categorised into 2 or 3 groups [Day et al., 1982 : Van der Esch et al.,
1981 : Callery, Cochran, Roe et al., 1982], Inter-observer differences in
interpretation of Clark level and Breslow depth are well-known [Prade,
Sancho-Garnier, Cesarini et al., 1980]. In a study of consistency among
pathologists reporting melanoma, overall agreement was only 70% with
one in three disagreeing on each feature [Larsen, Little, Orell et al., 1980],
Growth pattern classification is not always possible and/or reproducible
[Larsen, Little, Orell et al., 1980]. Agreement amongst pathologists is least
for LMM [70.8%], but greater for SSM and NM. The elective lymph node
dissection [ELND] rate and the criteria for the procedure, both of which
may influence survival, vary between series. ELND is discussed further in
Chapter 4.
The present study had central pathology review in over half the
cases but was incomplete by some standards. In the W H O study of
prognostic factors in 1159 clinical stage 1 patients, histologic review was
absent in 35.5% [Veronesi, 1980]. Even in a large contemporary
co-operative review of primary melanoma, the pathology slides were
unavailable for review in almost 33% of cases [Western Canada Melanoma
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Study ; Worth, Gallagher, Elwood et al., 1989],
The basic distribution of covariates should be assessed when
comparing results [Johnson, Emrich, Karakousis et al., 1985], If a covariate
known to be associated with high failure rate were present in one study at
a high frequency, it would likely emerge as strongly related to treatment
failure, but if present at low frequency, the study may not have sufficient
power to detect its significance. The frequencies of clinical and pathological
covariates in the present study are discussed in Chapter 2.
End-points of analysis should also be consistent, most importance
being attached to disease- specific survival. Some studies have utilised
time to visceral recurrence [Day, Lew, Mihm et al., 1982] or metastasis-free
survival [Drzewiecki, Frydman, Andersen et al., 1990], Furthermore,
utilisation of different statistical tests to study the same end-point can affect
conclusions. Missing data may also affect statistical conclusions. Patient
selection in reported series is another factor potentially affecting survival
and conclusions about the biological risks of melanoma. Referral centre
results are likely to be different from population-based studies. The BCCA,
as the only provincial group offering multidisciplinary consultation for
melanoma patients and providing most treatments for recurrent melanoma,
is likely to have patients with poorer prognosis, with more melanoma
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"events" [which may precipitate referral] after diagnosis. Lower survival [5
- year survival of c50%] at referral centres such as Roswell Park Memorial
Institute has been attributed to selection bias [Johnson, Emrich, Karakousis
et al., 1985],
Guidelines for interpretation of the results of analyses of prognostic
factor significance in early breast cancer have recently been reported
[Levine, Browman, Gent et al., 1991] and these principles can also be
applied to studies of early melanoma. Critical points which should be
addressed in reports of prognostic factor analysis include :
1. description of an inception cohort of patients.
2. description of referral pattern.
3. blinded assessment of laboratory and clinical covariates.
4. completeness of follow-up.
5. adjustment for extraneous prognostic factors.
6. appropriate statistical methodology.
4B. Single factor analysis results.
In the present study, the significant single factors by log rank
analysis affecting prognosis were date of diagnosis, sex, primary site
including BANS sites, growth pattern, surface description, Clark level,
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depth of invasion, clinical and pathological ulceration, tumor diameter and
volume, lymphatic invasion, mitotic rate, inflammatory reaction, invasion to
stratum corneum, pigmentation, polypoid configuration and type of surgery.
Single factor prognostic factor analyses from several recent studies are
summarised in Table 6. The original descriptions of prognostic significance
of anatomic level of invasion and depth measured by micrometer [Clark,
Ainsworth, Bernardino et al., 1969 : Breslow, 1970] are confirmed by all
studies which assessed these factors. Other factors which were universally
associated with poorer survival were male sex, primary diameter, clinical
and pathological ulceration, mitotic rate, poor inflammatory response and
lymphatic invasion. Most studies also showed age, primary site, and growth
pattern to be significant. Certain factors were insignificant in several
studies yet highly significant in others. For example, regression was highly
significant [p=<0.0001] in the study from Sydney and Alabama, but
insignificant in 4 others listed in Table 6. Similarly, surgical treatment [ie
elective lymph node dissection] was significant in 2 studies [p=0.0006 and
<0.05], but insignificant in 2 others.
Table 6 over /
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Table 6. Single Prognostic Factor Analyses
1 2 3 4 5 6 7
Age + + - _ + + _
Sex + + + + + + +
Site + + + + - + +
Diameter NE NE NE + NE + +
Volume NE NE NE NE NE NE +
Surface NE NE NE NE NE NE +
Grth Patt + + - + + + +
Depth + + + + + + +
Level + + + + + NE +
Ulceration
Clin. NE + NE NE NE NE +
Path. + + + + + NE +
Cell type NE NE NE + - NE -
Inflamm. + NE + + + NE +
P/l infl. NE NE NE NE + NE NE
Pigmentn. + NE NE NE - NE +
Mit rate NE NE - + + + +
Lymph inv NE NE + + + NE +
Regression + NE - - - NE -
Polypoid NE NE NE NE + NE +
Differn NE NE NE NE + NE NE
LND + - + NE NE NE -
Stage + NA NA NA NA + NA
BANS - - NE NE - NE +
Legend for Table 6 :
1 : Balch, Soong, Shaw et al., 1985.
2 : Meyskens, Berdeaux, Parks et al., 1988.
3 : Johnson, Emrich, Karakousis et al., 1985.
4 : Drzewiecki, Frydman, Andersen et al., 1990.
5 : Worth, Gallagher, Elwood et al., 1989.
6 : Pondes, Flunter, White et al., 1981.
7 : Present Study
NE : not evaluated
NA : not applicable
+ = significant
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4C. Multivariate analysis results.
The results of multivariate analysis in the present series showed
depth, pathological ulceration, type of surgery and primary site to be
significant irrespective of the statitistical coding used. In addition, when
linear coding was used for categorical covariates, Clark level, growth
pattern, BANS sites and lymphatic invasion became significant. Sex was
not significant in either model unless adjusted for log depth, suggesting a
sex/depth interaction. The frequencies of tumor thickness and primary sites
between the sexes are discussed in Chapter 2. Briefly, females had 61%,
55%, 52% and 43% of T1, T2, T3 and T4 primaries. For lower extremity
primaries females had 86% of T1 and T2, and for upper extremity
primaries had 65% of T1 and T2. In addition, there was an overall
dominance of females under 40 years with T1 an T2 primaries.
The inter-relations between female sex, age, primary depth and site
have been examined in detail [Shaw, Milton, Farago et al., 1978 : Shaw,
McGovern, Milton et al., 1980 : O'Doherty, Prescott, White et al., 1986]. A
larger proportion of females had prognostically favorable age [young] and
primary sites. Younger females had significantly thinner primaries, but in
males and females matched by age, primary site and depth, females with
thick tumors still survived longer. Female sex was independently
prognostically favorable in 19 of 51 studies [Vollmer, 1989 : Table 7],
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In 54 studies utilising multivariate analysis, 42 showed that primary
depth is the most frequently significant prognostic factor in malignant
melanoma [Vollmer, 1989], These studies from 18 centres reported on
44-3445 patients [mean 529], mostly stage 1, and used 12 different
end-points. Mean and median follow-up times in these studies were 5 and
6 years respectively. Primary depth was also the most significant
prognostic factor in the present series and the follow-up time was
adequate. Only 5 patients had recurrence beyond 10 years [Chapter 2],
Five other studies of multivariate analysis of survival, not included in the
review [Vollmer, 1989], have been identified and are summarised in Table
7. The conclusions in one, however, are limited by the inclusion of only
sex, age, stage, year of diagnosis, follow-up year and primary site as
covariates : ulceration, depth and other histologic factors were not
considered [Karjalainen and Hakulinen, 1988], All other studies in Table 7
found depth to be consistently related to survival.
Primary depth is associated with several other covariates,
particularly ulceration, growth pattern, cell type, mitotic activity,
pigmentation, lymphocytic infiltration and primary diameter [Ronan, Han,
Das Gupta., 1988] and is largely responsible for the loss of significance of
many factors when subject to multifactorial analysis.
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4D. Prognostic index.
Incorporation of primary depth into a prognostic index has been
reported to allow accurate prediction of recurrence [Schmoeckel and
Braun-Falco, 1978]. The prognostic index is the product of depth and
number of mitoses per square millimetre on standard histological sections.
The mitotic rate, although significant in single factor analysis in the present
study, was not significant in multivariate analysis. In a review of 31 studies
of mitotic rate, 14 were positive in multivariate analysis as an independent
prognostic factor [Vollmer, 1989]. Of three other reports, one was positive
for mitotic rate as an independent prognostic factor [Pondes, Hunter, White
et al., 1981 : Worth, Gallagher, Elwood et al., 1989 : Drzewiecki, Frydman,
Andersen et al, 1990], A prognostic index [P I] value of <19 vs >19 has
been reported to be an independent prognostic variable for stage 1
melanoma, compared with 7 other predictive variables including depth
[Kopf, Gross, Rogers et al., 1987], For example, patients with melanoma
1.50 - 2.49mm thick had a 5 year survival of 84.1% determined by
thickness alone : however, among these patients a sub-group with PI >19
whose survival was only 58% was identified. The present study did not
include numeric quantitation of mitotic rate.
4E. Prognostic factors and staging systems.
The established association of increasing mortality with increasing
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depth of primary melanoma forms the basis for the AJCC and UICC
staging systems. Unfortunately, the melanoma literature over the past 20
years has not had uniform depth groupings for the purpose of reporting
results [Balch, Soong, Shaw, 1985 : Chapter 2], A method for accurate
prediction of survival in both sexes according to depth has been reported
[Karakousis, Emrich, Rao, 1989], In females, 5 year survival was 94% for
1mm thick melanomas and prognosis deteriorated by about 3% for each
one millimetre depth thereafter. In males the drop was 9% per millimetre
from a 5 year survival of 80% for 1.0mm thick melanomas.
Table 7 over/
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Table 7. Recent Multi-factorial Analyses.
1 2 3 4 5 6 7
Age + - - + + - -
Sex + + + + + - -
Prim,
site
- + - + + + +
BANS
sites
- - - - NE - +
Grth
pttrn
- - - - NE - +
Depth + + + + NE + +
Level - - - - NE - +
Clin
ulcer
+ NE NE NE NE - -
Path
ulcer
- + - NE NE + +
Mit
rate
NE - - + NE - -
Epth
cells
- + - - NE - -
Lymp
invsn
- - - - NE - +
ELND + NA NA NE NE - -
Wide/
local
excsn
NE NE NE NE NE + +
1 : Meyskens, Berdeaux, Parks et al., 1988.
2 : Drzewiecki, Frydman, Andersen et al., 1990.
3 : Worth, Gallagher, Elwood et al., 1989.
4 : Pondes, Hunter, White et al., 1981.
5 : Karlalainen and Hakulinen, 1988.
6 : Present Study ; binary coding.
7 : " " ; linear coding for categorical covariates.
184
There is not yet general agreement on the prognostic grouping of
primary melanoma according to depth. Analysis of melanoma survival
according to primary depth has produced differing results for the
appropriate "break-points" between groups. Three reports have reached 3
different conclusions. Reported depth groups are <0.75, 0.76-1.50,
1.51-3.99, >4.00mm [Balch, Murad, Soong et al., 1979] : <0.85, 0.85-1.69,
1.70-3.64, >3.65mm [Day, Lew, Mihm et al., 1981] : <0.85, 0.86-1.95,
1.96-4.00, >4.01 mm [Meyskens, Berdeaux, Parks et al., 1988], For the
purpose of stratification in the present U S Intergroup Study of Lymph
Node Dissection and Width of Excision in primary melanoma, 3 risk groups
are defined, namely <1, 1-4 and >4mm ; the study population is the
"intermediate" risk group. The UICC and AJCC staging systems utilise the
break-points of Balch, Murad, Soong et al, 1979.
4F. Level and depth of invasion.
Most studies [40/48] have not shown Clark level to have
independent prognostic significance after depth has been considered
[Vollmer, 1989]. Only the present study in Table 7 using linear coding for
Clark level showed independent significance for that covariate. Variations
in coding of Clark level in prognostic factor analysis has been suggested
as a contributing factor in the conflicting results of its significance [Vollmer,
1989]. In addition, within each Clark level there is a spectrum of tumor
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thickness [Balch, Murad, Soong et al., 1978 : Breslow, Cascinelli, van der
Esch et al., 1978 : Chapter 2], As a prognostic factor, Clark level has been
reported to be a better indicator of low risk than depth [Blois, Sagabiel,
Abarbanel et al., 1983]: in this review, there was an appreciable death rate
for thin tumors at deep Clark levels, and the death rate for level II tumors
was minimal [3/226] while there seemed to be no practical minimum
thickness which provided comparable predictive accuracy. It remains
possible that level of invasion as a biological observation has some
advantage over depth as a physical measurement in determining survival
in some patients.
4G. Primary site.
Primary site has been found significant in 25 of 53 multivariate
analyses of survival [Vollmer, 1989 : Table 7], Trunk, head and neck
primaries had poorer survival in the present series : BANS sites analysis
produced conflicting results according to the statistical coding used. After
adjusting for depth, however, BANS sites became significant. Few studies
have specifically addressed BANS sites as a potential prognostic factor.
Scalp primaries have been reported to have poorer survival than other
head and neck sites , even after accounting for sex and depth : as a group,
however, BANS sites were not significant [Balch, Soong, Shaw et al.,
1985]. Only the present study in Table 7 has shown BANS sites to be
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significant. Certain other anatomic sites have been reported to be
significant. Volar, subungual, head and neck primaries with subclinical
metastases in regional lymph nodes [ie clinical stage 1, pathological stage
3] are almost universally fatal [Day, Mihm, Lew et al., 1982], Nearly all
patients with melanoma of the hands and feet died if the primary was
thicker than 2.75mm [Day, Lew, Mihm et al., 1982],
4H. Age.
Although age is a powerful single prognostic factor, in most
multivariate analyses it ceased to be significant [Vollmer, 1989 : Table 7],
Age is associated with depth [Chapter 2 : Balch, Soong, Shaw et al., 1985],
the most important prognostic factor. Median primary tumor depth in the
third decade was 1.1mm, whereas it was 1.5mm in the fifth decade and
2.8mm in the seventh decade [Balch, Soong, Shaw et al., 1985], In the
University of Arizona experience, young women have the best prognosis,
young men and older women have an intermediate prognosis, and older
men have the worst prognosis [Meyskens, Berdeaux, Parks et al., 1988],
The Sydney Melanoma Clinic found that survival in women dropped sharply
>48 years, approaching that of males [Shaw, McGovern, Milton et al.,
1980], University of California found no difference in survival between
females <48 and >48 years, while males <48 years did significantly less
well than females of all ages, and significantly better than males >48 years
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[Blois, Sagabiel, Arbanel et al., 1982], Melanoma mortality rates in males
and females <50 years in Scotland were not significantly different, but
males >50 years had a relatively high risk of death [O'Doherty, Prescott,
White et al., 1986],
41. Primary growth pattern.
Growth pattern also failed to maintain its significance in most
nmultifactorial analyses. After adjusting for depth or Clark level, growth
pattern was insignificant [Table 4], It was insignificant in all studies in Table
7 and in 35 of 39 studies previously summarised [Vollmer, 1989], LMM has
been found to have a better prognosis, after matching for thickness, than
other growth patterns [McGovern, Shaw, Milton et al., 1980], There were
insufficient cases of LMM with complete data in the present series to
compare outcomes.
4J. Primary ulceration.
Primary ulceration is the remaining covariate which has frequently
[22/49] been positive in multifactorial analyses [Vollmer, 1989 : Table 7],
Most studies refer to pathologic ulceration. Ulceration width has also been
examined. Tumors with ulceration <3mm in width had the same survival as
tumors without ulceration [Day, Harrist, Gorstein et al., 1981]. Most
ulceration is found in thick tumors [median thickness 3.0mm compared to
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1.5mm for non-ulcerated tumors], but studies of ulceration in tumors of
equivalent thickness show lower survival in ulcerated tumors [Ronan, Han,
Das Gupta, 1988],
4K. Other factors.
Other less frequently significant prognostic factors in multifactorial
analyses include regression [3/29], vascular invasion [4/19], epithelioid cell
type [1/5], microscopic satellites [3/14] {Vollmer, 1989 : Table 7}. Degree
of cellular differentiation in the primary has been correlated with survival
[Allen and Spitz, 1953], but there are difficulties in grading differentiation
[Breslow, 1978] which limit its use for prognostic purposes. Poorly
pigmented tumors are usually less well differentiated and there are
conflicting results of the degree of pigmentation on survival [Ronan, Han,
Das Gupta, 1988], Similarly, for host response/inflammatory infiltrate, there
is no uniformity for histology reporting and prognostic factor analyses have
produced inconsistent results [Ronan, Han, Das Gupta, 1988]. The loss of
power of several of the above factors in multivariate analysis have
diminished their value in assessing prognosis.
The conclusion that the type of surgery was significant in
multifactorial analysis in the present study differs from most other studies.
Specifically, patients undergoing only local excision of the primary did less
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well : ELND did not result in better survival than patients not having ELND
but the comparability of the two patient groups is debatable [Chapter 4],
Even after adjusting for depth and/or level of invasion, patients having only
local excision did less well. Reasons for undertaking only local excision
were, however, not assessed during the chart review process. One
previous study reported that patients having a biopsy before definitive
surgery had a significantly better prognosis [Drzewiecki and Andersen,
1982], but in a further analysis of an expanded data base including the
same patients the significance of preliminary biopsy was lost [Drzewiecki,
Frydman, Andersen et al., 1990].
The present finding that wide excision is superior to local excision
is consistent with current melanoma surgical principles. However, the
patient groups [local and wide excision] may not be comparable.
4L. Conclusions.
In conclusion, the present univariate and multivariate analyses of
prognosis in clinical stage 1 malignant melanoma showed that micrometer
depth, pathological ulceration, primary site and type of initial surgery were
the principal prognostic factors. Alternate models coding primary sites
differently showed BANS sites and sex to be significant while primary site
ceased to be significant : adjusting this model for Clark level made BANS
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sites and sex again significant along with lymphatic invasion. Using linear
coding for categorical variables, depth, primary site, pathological ulceration,
type of surgery, growth pattern, Clark level, BANS sites and lymphatic
invasion were significant [in descending order]. After adjusting for depth,
significant factors [in descending order] were Clark level, ulceration, BANS
sites, type of surgery, sex and lymphatic invasion.
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ELECTIVE AND THERAPEUTIC
LYMPH NODE DISSECTION
IN
CUTANEOUS MALIGNANT MELANOMA
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1. INTRODUCTION
1A. Lymphatic spread of melanoma.
Malignant melanoma most frequently spreads via the lymphatic
system to the regional lymph nodes [McCarthy, Shaw, Thompson et al.,
1988] and may involve any distant organ. Whether the spread of melanoma
is always sequential ie. local/regional/distant or whether it may behave like
a systemic disease ab initio is debatable. The role of regional lymph nodes
in breast cancer has been reconsidered over the past 20 years with the
prevailing view that invasive breast cancer is potentially systemic soon
after the disease progresses beyond the in situ stage [Henderson, 1987],
The risk of spread of both melanoma and breast cancer is directly
related to the accessibility of tumor cells to draining lymphatic and venous
channels. Early dissemination by these routes depends upon tumor size
and proximity of vessels. In breast cancer, primary tumors are frequently
greater than 2 cm diameter whereas the invasive component of primary
melanomas fortunately is rarely as deep. Peritumoral lymphatic and
vascular invasion in breast cancer [Coppin, Atiba, Worth et al., 1989 : Lee,
DeLellis, Silverman et al., 1990] is significantly more frequent than in
melanoma, but is associated with a high risk of recurrence if present in the
latter [Ronan, Han, Das Gupta, 1988],
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Most patients with clinical stage 1 malignant melanoma are cured
surgically. For clinical stage 3 patients the prognosis is generally much
worse, usually being directly related to the extent of lymph node
involvement [Roses, 1985], For patients experiencing regional lymph node
relapse after previous primary melanoma the prognosis is similarly bad
[Veronesi, Adamus, Bandiera et al., 1982], Because surgery is presently
the only potentially curative treatment for melanoma and because the risk
of lymph node metastasis is known to be related to certain primary
characteristics, the concept of earlier surgical intervention in all patients
considered at significant risk of lymph node metastasis evolved. This was
supported by the observations of superior survival [p=0.004] in patients
with extremity melanoma with clinical stage 1, pathologic stage 3,
compared with clinical and pathologic stage 3 [Roses, Harris, Gumport et
al., 1981]. The origins of elective lymph node dissection are discussed
further in Chapter 1.
1B. Elective lymph node dissection.
Elective lymph node dissection [ELND] is defined as removal of the
regional lymph nodes in patients with clinically normal physical examination
of these nodes. This procedure is done en bloc with the primary excision
where technically feasible observing the same principles as those of
Halstead in his operation for breast cancer [Atkins and Hayward, 1967],
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However, since the predictability of lymph node involvement in melanoma
is considerably short of 100%, the procedure is frequently pathologically
negative, making patients and physicians question the therapeutic value of
the operation.
ELND protagonists argue that the removal of microscopic or
sub-microscopic metastatic disease in regional lymph nodes can prevent
the subsequent appearance of distant metastases in some of these
patients and that delaying the procedure until the development of clinically
positive disease will be associated with an extreme probability of
developing distant metastases even if a lymph node dissection is
performed at that time [Balch, 1988], Certainly ELND will not increase the
cure rate in patients who do not have metastatic disease in the lymph
nodes and this may be up to 60% of patients with primary melanoma. An
unnecessary radical operation such as ELND should be avoided if it cannot
be shown to be beneficial in reducing recurrence rates and increasing
melanoma-specific survival.
1C. Non-randomised trials of ELND.
Previous reports of ELND in stage 1 malignant melanoma have been
of 2 types. Firstly, non-randomised studies of large series of patients have
been undertaken by the University of Sydney and the University of
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Alabama. The Sidney series excluded patients with head and neck
primaries, acral-lentiginous melanoma and lentigo malignant melanoma
[McCarthy, Shaw, Milton, 1985], Survival in men with T3 primaries of the
extremities and trunk was 40% better with ELND, and lesser but significant
reductions in melanoma mortality were observed in women with T3 and T4
lesions of the extremities. The importance of follow-up for 5-10 years was
emphasised since the survival curves separated most strikingly during this
time. The Alabama series [Balch, Soong, Milton et al., 1982] reported
better survival at 10 years of follow-up in all patients with trunk and
extremity T1-3 primaries, and this was most marked in males with T2
lesions. ELND has also been reported to have survival benefit in
intermediate thickness [0.76-4.0 mm] melanoma of the trunk and
extremities in a study from North Carolina [Reintgen, Cox, McCarty et al.,
1983], This non-randomised study was analysed according to whether or
not patients had ELND compared with a concurrent control group, and also
by multifactorial analysis with other possible factors predictive of survival.
Death rate from melanoma was reduced from 12% to 5% in patients having
ELND [p=0.05] and by multivariate analysis the significant factors were
ulceration of the primary [p=0.0008], thickness [p=0.008] and ELND
[p=0.01], A smaller study of intermediate thickness melanoma
[1.51-3.99mm], however, failed to show a survival benefit from ELND
[Elder, Guerry, Van Horn et al., 1985], This study was analysed comparing
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survival curves, and prognostic factors were assessed by multi-factorial
analysis. Favorable prognosis was associated with low mitotic rate, age
between 40-59 years and lymphocyte response around the primary.
A retrospective review of 272 patients with melanoma of the trunk,
of whom 184 underwent ELND, reported 10 year survivals of 85 and 38%
for ELND negative and positive patients [Ariel, 1982], In this series, 62
patients had no ELND : in these patients, 10 year survival was 67% for
those who had no relapse in regional nodes and 23% for those who had.
1D. Randomised trials of ELND.
Two prospective randomised trials have been undertaken, one by
the World Health Organisation Melanoma Group [Veronesi, Adamus,
Bandiera et al., 1977] and another by The Mayo Clinic [Sim, Taylor,
Pritchard et al., 1986], The WHO Trial randomised 522 stage 1 and 31
stage 2 patients with extremity melanoma to wide excision with immediate
ELND or "delayed LND". Females predominated [81.4%] and lower limb
was the commonest primary site [82.8%]. Survival curves of the 2
treatment groups were superimposable and no subset of patients had
significant survival benefit from ELND.
The Mayo Clinic study had 3 treatment options drawn at random,
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namely no ELND, immediate ELND and "delayed ELND" [performed 2-3
months following primary surgery]. Of the 171 patients in the study, 103
had primary depth less than 1.5mm. Head and neck melanomas were not
included. There was no difference in survival between the 3 treatment
groups at median follow-up time of 4.5 years. Of 36 "melanoma events" in
the control group, 12 were regional lymph node metastasis and 11 were
distant metastasis ; 14 patients had therapeutic lymph node dissection for
recurrence [RTLND],
1E. Limitations of previous trials of ELND.
Both the randomised and non-randomised studies discussed above
have limitations [Balch, 1988], These most cited are ;
a) the large number of females with lower extremity lesions [with an
inherently better prognosis and hence a lesser likelihood of showing
a survival benefit with ELND] in the WHO Trial.
b) more patients with ulcerated primaries in the ELND arm of the WHO
Trial.
c) 66% of patients in the Mayo Clinic Trial with T1 or T2 primaries.
d) the exclusion of head and neck melanomas from both randomised
trials and the Sydney series.
e) problems of identification of an appropriate control group with whom
to compare results in the non-randomised studies.
200
IF. Therapeutic lymph node dissection.
Therapeutic lymph node dissection [TLND] is generally accepted as
the treatment of choice for patients with clinically positive lymph nodes in
the absence of evidence of systemic spread of melanoma ie clinical stage
3 at diagnosis [Balch, Urist, Maddox et al., 1985], TLND is also
recommended for patients with regional lymph node recurrence
[Recurrence {R} TLND] from previous melanoma.
IG. British Columbia Cancer Agency Experience of Lymph Node
Dissection in Malignant Melanoma.
The Melanoma Tumor Group of the British Columbia Cancer Agency
[BCCA] recommended in 1976 that ELND be undertaken in "high risk"
clinical stage 1 malignant melanoma defined as primary tumor of Clark
level 3 and >0.76mm depth of dermal invasion, Clark level 4 or 5, and in
whom one anatomic lymph node drainage site could be identified. This
recommendation was modified in 1983 to stage 1 patients with tumors
>1.5mm depth.
This study reports the BCCA experience of ELND and TLND [at
diagnosis and at recurrence] in malignant melanoma with a minimum
follow-up of 7.9 years. Factors influencing the ELND positivity rate are
presented. Survival in ELND patients is compared with other reported
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series of randomised and non-randomised patients and is compared with
a concurrent control group of clinical stage 1 patients treated in the same
decade without ELND [designated hereafter BCCA Control patients].
Reasons for omitting ELND included patient and referring surgeons'
decisions in the light of possible expected benefits.
The effect of ELND on survival of all patients with clinical stage 1
malignant melanoma registered at BCCA during the study period has been
analysed by multifactorial analysis according to whether or not they
underwent ELND. Survival after TLND and RTLND has been analysed and
compared with other reported series.
2. PATIENTS AND METHODS
2A. Study population.
In 1983 a retrospective review of all patients registered in the BCCA
with malignant melanoma from June 1 1972 to May 31 1981 was
commenced. Full details of the patient population and reasons for
exclusion are described in Chapter 2. In summary, 1944 patients were
registered with malignant melanoma in the Provincial Cancer Registry,
1245 of whom were referred to the BCCA. Final analysis was undertaken
on 891 patients. Reasons for exclusion are described in Chapter 2. All
patients who underwent ELND, TLND and RTLND were included. TLND
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was defined as lymph node dissection in patients with clinically positive or
equivocal regional lymph nodes. Lymph node dissection surgery with
curative intent was performed by referring surgeons throughout the
province usually after consultation with members of the Melanoma Tumor
Group. Surgical morbidity was not assessed retrospectively. Data on 147
demographic, histopathologic, treatment and outcome variables were
extracted from the medical records of the study population, computerised
and analysed according to the methods in Chapter 2. The data base was
updated in April 1990 to provide minimum follow-up of 7.9 years. Survival
times were calculated from date of diagnosis to date of death, last written
or physician contact.
Clinical stage 1 patients who did not have an elective lymph node
dissection for various reasons during the study period were identified
[BCCA Control patients]. Full clinical and pathological factor profiles were
obtained and follow-up recorded to permit comparison with the concurrent
ELND patients.
2B. Statistical methods.
Analysis of data was undertaken with the Statistical Package for
Social Science [SPSS-X release 3.1]. Survival curves were generated
using the product limit method [Kaplan and Meier, 1958] with a biomedical
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computer program BMDP [Dixon, 1981], Cases with missing data were
excluded from the relevant analysis procedure. Multifactorial analysis was
undertaken using the proportional hazards model [Cox, 1972], Differences
between survival curves were calculated using the log rank test [Peto,
Pike, Armitage et al., 1977],
3. RESULTS
3A. Elective Lymph Node Dissection.
Elective lymph node dissection was performed in 232 patients, 111
male and 121 female. In 9 cases, clinical evaluation of the regional lymph
nodes was unspecified and accounts for discrepancies in totals in Tables
1 and 2.
In patients with specified negative clinical evaluation of regional
nodes, ELND was pathologically positive in 20 [19%] males and 16 [14%]
females, for a combined positivity rate of 16%. ELND positive/negative
frequencies and overall % positivity according to primary site, primary
growth pattern, depth of invasion and Clark level are summarised in Table
1.
Depth measurements were available in 208 patients undergoing
ELND. Ranges and median depths of primary tumors in patients with
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positive and negative ELND were 0.85-8.Omm and 3.0mm, and
0.45-7.00mm and 1.6mm respectively. Median depth of primary tumors in
all ELND patients was 1.70mm, and 1.00mm in 530 BCCA Control patients
[p=<0.0001].
In patients with positive ELND, 18 had 1 node positive, 7 had 2
nodes positive and 8 had 3+ nodes positive ; 3 patients had an unspecified
number of nodes positive. Three patients with positive ELND had 1-5
nodes examined, 9 had 6-10, 6 had 11-15 and 11 had 16 + nodes
examined ; 7 patients had an unspecified number of nodes examined. Of
the ELND negative patients, 5 had 1-5 nodes examined, 4 had 6-10, 4 had
11-15, 14 had 15 + nodes examined ; 120 patients had an unspecified
number of nodes examined.
Disease recurred in 47 [25%] of ELND negative patients with
median survival 9.09 years from time of diagnosis for all ELND negative
patients. There were 23 [64%] recurrences in ELND positive patients with
median survival 4.16 years and 37% 10 year survival.
Levels of primary invasion and depth in stage 1 ELND patients and
BCCA Control patients are presented in Figures 1 and 2. Level IV
primaries dominated the ELND series [61% of all cases]. Primary depth
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was unspecified in 25% of BCCA Control patients and 4% of ELND
patients. In patients with depth measurements, more ELND patients had
T2-T4 primaries and, as noted above, the median depth of primaries of
ELND patients was significantly greater. Females accounted for 53% of the
ELND patients and 54% of the BCCA Control patients. Primary site
distribution in ELND and Control patients is shown in Figure 3.
Ten year disease-specific survivals according to level of invasion
and depth in BCCA ELND and Control patients are shown in Figures 4 and
5. Survival differences were significant in favor of ELND patients when
grouped according to either level of invasion or depth [p=<0.0001]. The
group [T2 primary] with the largest difference in survival [23%] had only 5
pathologically positive lymph node dissections [7%] out of a total of 73.
Univariate and multivariate analysis of survival was undertaken in
720 clinical stage 1 patients of whom 192 had local excision [L.E.], 3 had
L.E. + ELND, 327 had wide excision [W.E.], and 198 had W.E. + ELND
[Chapter 3]. Ten year disease-specific survivals for patients undergoing
different surgical procedures were 38% for L.E., 50% for L.E. + ELND, 67%
for W.E., and 67% for W.E. + ELND [Figure 6]. Multivariate analysis did not
show ELND to be a significant factor determining prognosis. By univariate
analysis, patients having only local excision had significantly poorer
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survival [p=0.0472], and this was still significant in multivariate analysis
[p=0.0015].
Table 1. Patient Characteristics.
ELND +ve ELND -ve
Sex Males 20 86
Females 16 102
Primary Site Upper Limb 3 42
Lower Limb 16 76
Head & Neck 5 24
Trunk 12 45
Growth Pattern SSM 16 103
NM 15 57
LMM 0 1
NOS 5 23
Primary Depth T1 0 15
T2 5 68
T3 12 66
T4 14 20
Unspecified 5 4
Clark Level 1 0 1
2 0 4
3 3 64
4 25 106
5 6 8
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Figure 5
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Figure 6
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Survival analysis was undertaken in the subset of patients with
extremity primary melanoma undergoing ELND to permit outcome
comparison with patients in the WHO series [Veronesi, Adamus, Bandiera
et al., 1982], Growth pattern and depth distributions for both series are
shown in Figures 7 and 8. The WHO series had more patients with
melanomas >3.5mm thick and fewer patients with melanomas <3.5mm
thick. Respective 10 year survival percentages in the present series and
the WHO series were 80 and 62%. Further survival comparisons for
patients in both series with superficial spreading melanoma [SSM], nodular
melanoma [NM], Clark level III and IV, and melanomas less than 3.5mm
thick are presented in Figure 9. All the BCCA survivals are in the range
11-25% better. Survival in the WHO series was calculated actuarially but
this is unlikely to explain the survival differences between the 2 series
[Veronesi, Adamus, Bandiera et al., 1977 : Veronesi, Adamus, Bandiera et
al., 1982], Median primary tumor depth was not reported in the WHO series
but was probably greater than in the BCCA series and could account for
the survival differences.
Three further sub-groups of patients were identified in the present
series to allow comparison of outcome in patients who appeared to benefit
most from ELND in the University of Sydney series ie males with T3 trunk
primaries, males and females with T3 extremity primaries [McCarthy,
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Shaw, Milton, 1985]. Acral-lentiginous melanomas were excluded. Ten year
survivals for 4 groups of patients are shown in Figure 7 : ELND patients
in Sydney and BCCA, and non-ELND Sydney and BCCA patients. Patient
numbers for each of these groups were 81, 19, 104 and 26 [T3, male,
trunk], 55, 11, 61 and 4 [T3, male, extremity], 71, 41, 135 and 18 [T3,
female, extremity]. Survival differences between the 2 cohorts of BCCA
patients, ELND and Control, for these specific sex and primary site groups
were not significant [p=0.1175]. The numbers of patients in the BCCA
ELND groups were, however, small, especially T3 male extremity primary
patients. Survivals for all BCCA patients in these categories were
intermediate between those of Sydney non-ELND and ELND patients.
Figure 7 over/
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3B. Therapeutic Lymph Node Dissection [TLND] at Primary Diagnosis.
Therapeutic lymph node dissection was performed in 50 patients at
primary diagnosis and 36 [72%] were positive pathologically. TLND was
positive in 24 [66%] males and 12 [33%] females. Of TLND positive
patients, 12 had 1 node positive, 3 had 2 positive, 12 had 3 + nodes
positive and 9 had an unspecified number of nodes positive.
Primary tumor depth measurements were available in 24 patients
with positive TLND. Range and median depth of primaries were
1.67-8.0mm and 2.0mm respectively. Disease recurred in 24 [67%] positive
TLND patients and median survival was 2.7 years.
3C. Therapeutic Lymph Node Dissection for Recurrence [RTLND].
Of the entire series of 891 patients, 537 had clinical stage 1 disease
without having ELND, and 125 of them developed regional lymph node
recurrence. TLND for recurrence [RTLND] was performed in 90 of these
patients. Range and median depth of responsible primaries in RTLND
patients were 1.0-7.0mm and 2.0mm respectively. Median time to regional
lymph node recurrence from primary treatment was 1.5 years. For all
patients who underwent RTLND, median survival was 1.8 years from the
date of recurrence and 4.4 years from date of primary diagnosis : 10 year
survival was 26%. Analysis of extent of lymph node positivity was not
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undertaken in these patients.
Survival comparisons were made between all 3 groups of BCCA
lymph node dissection positive patients ie ELND +ve, TLND +ve and
RTLND. Survival was defined from the date of LND positive surgery. No
statistically significant difference in survival was demonstrated [Figure 11],
Figures 10 and 11 over/
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4. DISCUSSION
The role of elective lymph node dissection [ELND] in surgical
management of cutaneous melanoma has been extensively studied in both
non-randomised [McCarthy, Shaw, Milton, 1985; Balch, Cascinelli, Milton,
1982; Reintgen, Cox, McCarty et al., 1983] and randomised [Veronesi,
Adamus, Bandiera et al., 1982; Sim, Taylor, Pritchard et al., 1986] clinical
trials. Results of randomised trials have not confirmed the results of the
non-randomised studies, although re-analysis of the World Health
Organisation Trial suggested that a subgroup of patients with intermediate
risk of recurrence did have a superior survival with ELND [Balch,
Cascinelli, Milton et al., 1985].
The results of ELND in melanoma have previously been reported in
terms of :
A. "yield" i.e. % probability of detecting lymph node metastases.
B. disease-free and overall survival.
C. its contribution as a prognostic factor in multifactorial analysis of
survival.
The importance of follow-up from 5-10 years has been emphasised
because of the observation that survival differences between patients
receiving wide excision + or - ELND do not become apparent until then
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[McCarthy, Shaw, Milton, 1985], Follow-up in the present study was 7.9 -
16.9 years and is therefore adequate to draw comparisons with other
series.
The yield of microscopically positive lymph nodes from ELND in this
study [16%] is within the range [4-25%] of previous reports [McCarthy,
Shaw, Milton, 1985; Veronesi, Adamus, Bandiera et al., 1982], Yields
according to primary tumor depth are also consistent with previous reports
of 5-10% for T2 , 17-20% for T3 and 39% for T4 tumors [Holmes, Mosely,
Morton et al., 1977; Wanebo, Woodruff, Fortner, 1975], Interestingly, the
series with the lowest reported overall yield [4%] showed the largest
treatment effect of ELND, suggesting that patients with a "negative" ELND
may in fact be those who are likely to benefit most from the procedure. The
difference between the yield [16%] in this study and the eventual lymph
node relapse rate of 23% in patients with clinical stage 1 disease not
undergoing ELND suggests that there are still patients with lymph node
metastases which may not be identified at ELND. A regional lymph node
relapse rate of 57% in patients with melanomas 1.5mm+ in thickness
treated by wide excision alone [Balch, Murad, Soong et al., 1979] is greater
than the expected yield of ELND and supports this conclusion. Similarly,
in the WHO Trial, 21% of patients with melanomas 1.5-4.9mm thick were
ELND positive but the RTLND rate in the control group was 56%.
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The extent of lymph node positivity in ELND positive patients [all
primary sites] in the present series is similar to the WHO experience in
extremity melanoma [Veronesi, Adamus, Bandiera et al., 1982], Proportions
of patients with 1, 2, 3+ and unspecified positive nodes were 50% and
46%, 19% and 22%, 22% and 20%, 8% and 11% between the present
series and the WHO series respectively.
The yield of microscopically positive lymph nodes from ELND
according to primary growth pattern has been compared with a previous
report which attempted to correlate histologic features of the primary with
the likelihood of occult regional lymph node metastases [Harrist, Rigel, Day
et al., 1984], The percentage positivities for SSM and NM were almost
identical [13 and 11% for SSM, and 21 and 23% for NM]. Multivariate
analysis showed that primary depth, presence of microscopic satellites, and
the time interval between diagnosis and ELND were most highly associated
with occult regional node metastases [Harrist, Rigel, Day et al., 1984],
The Australian series excluded patients with head and neck
primaries, acral-lentiginous [ALM] and lentigo malignant melanoma [LMM]
patients [McCarthy, Shaw, Milton, 1985], Excluding head and neck primary
patients in the present series reduces the yield to 15% and ALM and LMM
accounted for only 4 patients. The present series had more T2 [34%
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compared to 27%] and fewer T1 [7% compared to 15%] and this may partly
explain the difference in yield between the series.
In addition to the false negative rate in clinical assessment of
regional nodes, the problem of false positivity arises in patients with
palpable nodes. In the present series, 28% of patients with palpable nodes
were negative on pathological examination. A similar false positive rate
[27%] has been previously reported [Karakousis, Seddiq, Moore, 1980],
Survival of BCCA ELND patients has been compared with 3 different
series of patients :
1. BCCA Control clinical stage 1 patients concurrently treated without
ELND.
2. WHO series of extremity primary melanoma patients.
3. University of Sydney patients with melanoma of the trunk and
extremities.
Although the depth of invasion among BCCA ELND patients was
significantly greater than in concurrent BCCA Control patients, 10 year
survivals were significantly better, especially for T2 and level IV primaries.
However, Clark Level IV primaries accounted for 43% of T2, 73% of T3
and 65% of T4 primaries ; conversely, T2 primaries accounted for only
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29% of Level IV primaries, and T3 and T4 primaries accounted for 65%
[Chapter 2], These figures suggest that other factors besides ELND are
involved in the survival differences. BCCA ELND patients had more
favorable primary sites, more lower limb and fewer trunk, head and neck
primaries. Primary site was an independent prognostic factor for survival
[Chapter 3]. In addition, ELND was only performed when a single lymphatic
drainage area was present ; patients with midline or watershed primaries
did not have ELND. Multifactorial analysis of prognostic factors did not
show ELND to be significant [Chapter 3],
The results of survival analysis in BCCA extremity primary
melanoma patients undergoing ELND have been compared with those from
ELND patients in the WHO Trial [Veronesi, Adamus, Bandiera et al., 1982].
In all levels of invasion, depth groups and growth patterns examined,
BCCA patients had apparently better survival, likely related to other
prognostic factor differences between the 2 groups of patients. Depth of
invasion was greater in the WHO patients [36% primaries >3.5mm thick
compared with 11% in the BCCA series : 45% T4 primaries compared with
25% T4 primaries for all sites in the BCCA series].
The subgroups of patients reported to benefit most from ELND in the
University of Sydney experience were males with T3 primary melanomas
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of the trunk and extremities, and females with T3 extremity melanomas
[McCarthy, Shaw, Milton, 1985], BCCA ELND patients in these subgroups
did not have a significant survival advantage over patients in the same
subgroups from the BCCA Control group. Survival in BCCA ELND patients
in these subgroups was inferior to the Sydney ELND patients and survival
in the BCCA Control subgroups was superior to the Sydney non-ELND
patients. Overall, the results in BCCA patients would not support the
proceeding with a prospective randomised trial for T3 melanoma of the
trunk and extremities.
Median survivals for ELND and TLND positive patients were 3.3 and
1.7 years respectively in a series from University of Illinois [Das Gupta,
1988], Median survivals for ELND positive patients were reported in terms
of number of nodes positive [1 node : 4.8 years ; 2,3 nodes : 5.4 years ;
4+ nodes : 4 years ; p = NS] in a series from New York and median
survival for TLND positive patients was 2 years [Roses, Provet, Harris et
al., 1985]. For extremity primary melanoma patients having ELND, median
survival for ELND negative patients was in excess of 25 years, and 4.3
years for ELND positive patients [Roses, Harris, Ackerman, 1983], Median
survivals for ELND positive patients [2 years] and combined TLND and
RTLND patients [2.2 years] have been reported from Roswell Park
[Karakousis, Seddiq, Moore, 1980],
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Median survival of ELND positive patients in the present series [4.2
years] was superior to the University of Illinois and Roswell Park series and
consistent with the WHO and New York series. Median survival of ELND
negative patients [9.1 years] is comparable to a previous report of 8.1
years [Karakousis, Seddiq, Moore, 1980], Survival for TLND positive
patients in the present series [2.7 years] appears superior to the Illinois,
Roswell Park and New York series.
Survival in ELND positive patients has been analysed to identify
subgroups with better survival [Koh, Sober, Day et al., 1986]. A group with
primary tumor depth <3.5mm and <20% of lymph nodes positive had a
7-year survivorship of 66%. Within that subgroup, patients with primaries
on the trunk or extremities [excluding hands and feet] had a 7-year
survivorship of 76%. The group with tumors >3.5mm thick primaries and
>20% positive nodes had a 7 year survival of 29%. It was recommended
that this finding be considered in stratification in adjuvant trials of ELND
positive patients.
There are two current prospective randomised trials addressing the
role of elective lymph node dissection. An American Inter-Group Study
includes patients with intermediate thickness [1-4mm] clinical stage 1
melanoma of the trunk and extremities with randomisation to immediate
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ELND or not, and either a 2 or 4 cm diameter excision margin around the
primary. The accrual goal is 1500 patients. The WHO Melanoma Group is
studying trunk primary melanoma, clinical stage 1 and >2mm thick.
Randomisation is between wide excision +/- ELND. Therapeutic node
dissection would be offered to patients in the non-ELND group who
develop resectable regional node metastases. It is hoped that the benefits,
if any, will be shown by these trials. Results are not expected to be
available for several years.
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DISCUSSION
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The experience of a provincial cancer program, the British Columbia
Cancer Agency, over the decade 1972-1981 has been reviewed here in
relation to cutaneous malignant melanoma. Patient referral to the BCCA is
voluntary in contrast with provincial Cancer Registry notification which is
mandatory. Potential referral bias would likely be against the referred group
since treatments for advanced melanoma are almost exclusively available
through BCCA.
During the study period, 76 patients were entered on a National
Cancer Institute of Canada study of adjuvant immunotherapy. Ordinarily,
the only cohorts of patients on whom outcome analysis is undertaken are
those entered on clinical trials ; such patients have prospective data
collection and periodic follow-up reports sent to the responsible clinical trial
office. Assessment of clinical and pathological features, treatment and
outcome in the remaining majority of patients must be undertaken
retrospectively, as in this study.
The incidence of cutaneous malignant melanoma has risen
progressively : in 1988, incidence rates for males and females were 11.5
and 12.8 per 100,000 respectively. It has been estimated that the lifetime
risk of melanoma in the USA, where the current incidence is about the
same as in British Columbia, will rise from 1:135 [1987] to 1:90 [2000]
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{Balch, Houghton, Peters, 1985}. This alarming rise in incidence has been
offset in part by a trend towards thinner melanomas [Bagley, Cady, Lee et
al., 1981 : Balch, Shaw, Soong et al., 1985], confirmed in this study by
increasing frequency of Clark levels I and II, and decreasing frequency of
level V lesions. Depth comparisons by year of diagnosis were not possible
because depth measurements were not regularly recorded in the early
years of the present study. Interestingly, there was no observed decrease
in primary tumor diameters at diagnosis over the decade of study. The net
effect of increasing incidence and more frequent thin melanomas, however,
is a slowly increasing death rate in the USA [Ries, Hankey, Edwards,
1990]. In British Columbia, melanoma mortality rates have increased
minimally from 1974 to 1985.
The same investigative and reporting methodologies as have been
used in many centres world-wide have been applied in the present series.
Detailed discussion of the results has been presented in Chapters 2-4.
Principal clinical and pathological features of all patients in the present
study are consistent with most of the findings in clinical stage 1 melanoma
from 14 centres [Balch, Soong, Shaw, 1985], Specific characteristics of the
present series were median age 47 years, females 53%, extremity primary
47%, lentigo melanoma 5%, superficial spreading melanoma 65%, T1
primary 31%, and primary ulceration in 25%. Ethnic origin is known to
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affect melanoma risk, being lower in American blacks, and people of
African, Asian and Mediterranean descent [Matas, 1896 : Crombie, 1979
: Feibleman and Maize, 1981], but was not recorded in the review process
in the present series. The British Columbia population as a whole,
however, is mostly of Caledonian origin.
The incidence of melanoma compared to other cancers is relatively
low [BCCA, 1990]. In British Columbia, breast, prostate, lung and colorectal
cancer incidences are much higher [98, 80, 47 and 35 per 100,000 in
1988]. Provincial cancer screening services are available for cancer of the
cervix and, more recently, cancer of the breast. There are no plans for
mass melanoma screening. Public awareness of melanoma in Canada is,
however, increasing. The first week of June 1991 has been declared "Sun
awareness week" by the Canadian Dermatology Association, which offers
advice on sun exposure and protection and has called for closure of all
indoor suntan studios. The present premier of the province of Quebec had
a malignant melanoma of the trunk removed last year ; regular media
reports raised awareness of melanoma.
A program of national education for the prevention of deaths from
malignant melanoma has been proposed in the USA [Kopf, 1985 : Kopf,
1988] to include annual physical examination of the skin. The American
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Cancer Society draws a subtle distinction between cancer screening
[publicly funded] and early detection [individually funded] {Eddy, 1980} ;
presently, annual examinations are the individual's responsibility.
In order to reduce the denominator of individuals screened for
melanoma, the concept of a personal risk factor chart has been developed
[Mackie, Freudenberger, Aitchison, 1989]. By identifying persons with many
[>20] benign nevi, or with abnormal nevi, freckling tendency and history of
severe sunburn, those at increased risk of developing melanoma could
select themselves or be selected by their physicians for close surveillance
and counselling.
During the analysis of the present study, it became apparent that
more agreement is required among investigators in relation to reporting of
results. In the review of prognostic factor analyses [Chapter 3], definition
of variables and statistical methods were not consistent. It is quite possible
that methodological differences in multifactorial analyses have contributed
to the wide range of results and to some of the apparent geographic and
biological differences in melanoma.
The present study of lymph node dissection has not yet influenced
current treatment recommendations locally. From the National Cancer
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Institute of Canada Immunotherapy study, the national elective
lymphadenectomy rate for melanomas >0.75mm thick was about 20%
[unpublished observation]. Most Canadian centres do not recommend
ELND. Patterns of surgical practice change slowly and it appears that the
local practice is unlikely to change until the results of the 2 current
prospective randomised trials of ELND are available. On the positive side,
however, the practice of recommending adjuvant BCG immunotherapy has
been terminated as a result of the NCIC Trial.
The treatment of advanced unresectable melanoma continues to be
an area of active research. The Physicians Data Query [PDQ] Base
provided by computer link with the United States National Cancer Institute
currently lists 44 phase l/ll and 13 phase III studies of melanoma. The
phase l/ll studies range from investigation of "old" drugs [eg 6-thioguanine,
suramin, regional melphalan], new drugs [eg toremifene, gemcytabine,
lonidamine, merbarone, EDAM], combination chemotherapy [eg DTIC,
tamoxifen, cisplatinum], biological response modifier therapy [eg regional
interleukin 2 : alpha 2 interferon + interleukin : tumor-infiltrating
lymphocytes + interferon] and monoclonal antibody therapy [eg
anti-ganglioside R24 : anti-GD2 ganglioside : antibody MG-22 + interleukin
2], Phase III studies include 6 adjuvant therapy trials and 5 chemotherapy
+/- biological response modifier trials in metastatic disease. Such
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investigational enthusiasm is, however, not shared by all oncologists.
Observing that no disseminated neoplasm incurable in 1975 is curable
today and that metastatic melanoma is "negligibly responsive" to
chemotherapy, the practice of routine cytotoxic therapy or enrolment of all
patients on clinical trials in metastatic melanoma has been questioned
[Braverman, 1991], Further research is however needed in the areas of
tumor cell resistance, biological response modifiers and drugs with novel
modes of action. At present, the best method of treating metastatic
melanoma is to identify primary melanoma as early as possible and
prevent the development of metastatic disease [Rhodes, Sober, Mihm et
al., 1987 : Mackie, Freudenberger, Aitchison, 1989],
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Primary Cutaneous Malignant Melanoma:
Experience of the British Columbia Cancer
Agency From 1972 to 1981
Vicki E. Carmichael, BSc;* Kenneth S. Wilson, MB, ChB, FRCP(Edin}, FRCPC, FACPf
A retrospective review of 891 patients with newly diagnosed primary cutaneous
malignant melanoma (CMM) registered at the British Columbia Cancer Agency from
1972 to 1981 is presented. Age-standardized incidence rates in British Columbia
have increased markedly over that time. The female-to-male ratio was 1.13:1 and the
median age overall was 47 years. A change in the size of a mole was the most
common presenting sign (in 43% of patients) and the median duration of signs was
5.9 months. Predominant tumour sites were the trunk for males and the lower limbs
for females. Dominant growth patterns were superficial spreading melanoma (65%),
nodular melanoma (25%), lentigo maligna melanoma (5%) and acral lentiginous
melanoma (2%). On staging of the primary tumour, 90% of patients had local
disease, 9% of patients had regional disease and 1% of patients had distant disease at
presentation. Median depths of tumours were 1.45 mm for males and 1.10 mm for
females; no T1 tumours (tumours 0.75 mm or less in depth [TNM classification))
were staged beyond the local area. Disease recurred in 44% of males and 32% of
females. The 15-year survival rate was 55.5% for males and 70.3% for females.
These findings are compared with those of recent international series. It is apparent
that earlier diagnosis improves survival and that more education is needed in view of
the increasing incidence and death from CMM.
On pr&sente une etude retrospective de 891 patients souffrant d'un melanome
cutane malin (MCM) primaire nouvellement diagnostiquS, enregistr&s i l'Agence
pour le Cancer de Colombie Britannique entre 1972 et 1981. Dans cette province,
llnddence corrig£e pour l'Sge a augments sensiblement au cours de cette plriode.
Le rapport femmes / hommes a £ti de 1,13 pour 1 et l'Sge median de 47 annees. La
signe le plus ftiquemment observe etait une augmentation de la taille de la mile
(chez 43 % des patients) et la duree mediane des signes a ete de 5,9 mois. Les foyers
(Tapparition des tumeurs primitives etaient le tronc pour les hommes et les membres
inferieurs pour les femmes. Les caracteristiques tumorales dominantes ont ete les
meianomes malins I extension superficielle (65 %), les melanomes nodulaires
d'embiee (25 %), les melanomes sur melanose de Dubreuilh (5 %) et les melanomes
lentigineux des extremites (2 %). Lors du diagnostic, le stade evolutif des tumeurs
primitives etait le suivant: 90 % de tumeurs localisees, 9 % d'atteintes regionales et
1 % d'envahissements I distance. La profondeur mediane des tumeurs etait de 1,45
mm pour les hommes et de 1,10 mm pour les femmes; aucune tumeur de stade T1
(d'une profondeur inferieure i 0,75 mm [classification TNM]) n'a ete rehrouvde au
deli de la surface locale. La maladie est reapparue chez 44 % des hommes et chez
32 % des femmes. La survie i 15 ans a ete de 55,5 % pour les hommes et de 70,3 %
pour les femmes. Ces resultafs sont compares i ceux d'etudes internationales
recentes. II est evident qu'un diagnostic precoce ameiiore la survie et que, devant
I'augmentation de la frequence des MCM et de la mortalite qui lui est attribuable,
une meilleure education du public s'impose.
Malignant melanoma represent¬ed 1.41% of all canc rs in
British Columbia in 1974, but by
1987 the incidence had increased to
3.11% for men and 3.7% for wom¬
en.1 Similar increases in melanoma
incidence have been reported in the
United States, Scandinavia and Aus-
tralia.2"4 This alarming increase has
prompted many studies of risk and
prognostic factors. These studies
have suggested that the increase in
incidence is real and not due to
inadequate data,® artefacts of diag¬
nosis or notification, or changes in
"cosmetic factors."6-® Established
risk factors include the presence of
freckles® and benign nevi,10 a his-
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tory of severe sunburn resulting
in peeling,11 exposure to ultraviolet
light,11-13 occupation and socio¬
economic status.14*16
Many biologic factors influence
the natural history of malignant
melanoma,17 including stage, histo-
genic or growth pattern, anatomic
site of the tumour, age and sex.
This report is a retrospective de¬
scriptive review of these factors in
patients with primary cutaneous
malignant melanoma (CMM) regis¬
tered with the British Columbia
Cancer Agency (BCCA) from 1972
to 1981.
Patients and Methods
Patients
From 1971 to 1981 in British
Columbia the proportion of persons
of British origin decreased from
58% to 51%.' Those of European
ancestry increased from 18% to
27%, and the proportion of Asians
increased from 2.6% to 4.5%. The
higher proportion of inhabitants of
British origin is significant in that
persons of Celtic origin seem to
have a higher incidence of malig¬
nant melanoma.4
Registration of malignant disease
with the provincial cancer registry
is mandatory for pathologists, but
clinical referral to the BCCA is
voluntary. The present study in¬
cluded all new cases of primary
CMM diagnosed between June 1,
1972, and May 31, 1981, and regis¬
tered with the BCCA. Follow-up
extended to Apr. 30, 1990. In the
defined period of this study there
were 1944 persons in British Co¬
lumbia registered with melanoma in
the British Columbia Cancer Regis¬
try. Of these, 1245 (64%). patients
were also registered with the
BCCA. A list of cutaneous melano¬
ma patients registered during the
study period was generated manual¬
ly in 1983, and the 891 patients
thereon formed the basis of this
report. In 1990, an additional 198
patients were identified as having
been registered in the study period,
but these were not included.
A total of 27 patients had malig¬
nant melanoma in multiple sites at
diagnosis. Primary malignant mela¬
noma occurred on two separate oc¬
casions in 25 patients. These were
counted only once in the incidence
analysis.
Data Collection
Data on 147 demographic, his¬
topathologic, treatment and out¬
come variables were extracted from
the medical records of the study
population. Data were transcribed
on to an abstract form and later
computerized into a database
(dBase IV) to facilitate follow-up
and statistical analysis.
Histopathologic studies were per¬
formed at hospital laboratories
throughout the province. The ma¬
jority of the biopsies were reviewed
by two BCCA pathologists in Van¬
couver. Growth patterns of the mel¬
anoma were described pathological¬
ly by the classification system used
by Clark and associates.16 The five
main subdivisions of malignant mel¬
anoma used in this study were
lentigo maligna melanoma (LMM),
superficial spreading melanoma
(SSM), nodular melanoma (NM),
acral lentiginous melanoma (ALM)
and not otherwise specified (NOS).
Tumour depth was assessed by
Clark's histopathologic method19
and Breslow's micrometer measure¬
ment30 The study included cases
antedating the universal usage of
these methods. Depth measure¬
ments were not available for 223
(25%) patients and diameter mea¬
surements were unavailable for 102
(11%) patients. Depth categoriza¬
tion was determined from the "T"
category of the TNM classification
system:31 T1 (less than 0.75 mm),
T2 (0.76 to 1.50 mm), T3 (1.51 to
3.0 mm) and T4 (greater than 3.0
mm). The International Classifica¬
tion of Diseases, 8th revision, was
used to categorize primary sites.33
Four principal categories were used:
head and neck (H & N), trunk (T),
lower limb (LL) and upper limb
(UL). According to a modification of
the M.D. Anderson Hospital sys¬
tem,33 stage was categorized as
local (stages I and II), regional
(stage III) and distant (stage IV).
Statistical Methods
Data were analysed by the Statis¬
tical Package for Social Sciences
(SPSS-X release 3.1).34 All percent¬
ages refer to total cases in the study
population unless otherwise stated.
Trends in incidence were analysed
by simple linear regression analysis.
The "utility test" model was used
to test statistical significance of
incidences between males and fe¬
males. Means and standard devia¬
tions are all reported as mean =t
SD. Survival as a time interval was
calculated from date of diagnosis to
date of death, last written or physi¬
cian contact Statistical significance
of differences between the sexes
was tested by the Mann-Whitney
U-test.
Age-standardized rates based on
the number of tumours were adapt¬
ed to those of the British Columbi¬
an population at the 1971 census
by the direct method of standardiza¬
tion.35 Mortality data were provided
by the Division of Vital Statistics of
the provincial Ministry of Health.1
All population data were obtained
from Census Canada publications.36
Survival curves were generated
with the Kaplan-Meier product
limit method37 with the biomedical
computer program BMDP.36 The
Tarone-Ware x1 test® w*s used to
test the significance of gender on
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survival. Cases with missing data
were excluded from the relevant
analysis procedures. Overall mean
survival times were calculated using
only survival times of cases with a
response (death from melanoma).28
Results
Incidence andMortality
Age-standardized incidences of
malignant melanoma in British Co¬
lumbia have increased significantly
(p < 0.0001) for both females and
males (Fig. 1). In 1983, the age
standardized death rate per
100 000 in Canada and British Co¬
lumbia was I.8.1 The death rates
associated with malignant melano¬
ma in British Columbia did not
change substantially for either men
or women during the period 1974
to 1985 (Fig. 1).
Clinical History
A change in the size of a mole
was the commonest (43%) present¬
ing sign. Other signs and symptoms
were the development of a new
mole (13%), a change in colour
(9%), bleeding or ulceration (8%)
and pain, tenderness or itching (8%)
in a mole.
Bleeding or ulceration was a pre¬
senting sign in 4% of UL lesions,
8% of T lesions and 9% of H & N
and LL lesions.
Development of a new mole was a
presenting sign in 8% of T lesions,
14% of UL lesions, 16% of LL
lesions and 20% of H & N lesions.
Melanoma was recognized by a phy¬
sician in 7% of patients who did not
bring it to the physician's attention.
Age and Sex Distribution
There were 472 females and 419
males, an overall female-to-male
ratio of 1.13:1, but this was not
constant over the study period.
From 1972 to 1975 the ratio aver¬
aged 0.84:1 and from 1976 to
1981, 1.25:1. Patients' ages ranged
from 9 to 99 years for males and
from 3 to 93 years for females.
Overall, the median age was 47
years and the mean age 48.2 ±
16.9 years; for males, the mean age
was 49.7 ± 17.4 years, and for
females the mean age was 46.9 ±
16.3 years. The difference between
the means was not significant
Times From First Sign or Symptom
to Death
Median times from first sign or
symptom to diagnosis were 5.6 and
6.2 months in males and females
respectively. Females had longer
median time from diagnosis to first
recurrence (24.2 v. 19.7 months).
Median times from recurrence to
death were similar for females and
male (10.9 and 11.6 months).
Distribution by Age, Site, Growth
Pattern and Stage
Table I illustrates the distribution
of age, Clark's level, growth pattern
and stage according to site and sex.
Predominant sites were the trunk
for males (46% (193 of 419] of the
total male population) and lower
limb for females (44% (206 of 472]
of the total female population). T
lesions occurred predominantly in
patients under 60 years of age (81%
[156 of 193] of all male and 86%
[96 of 112] of all female T lesions).
In contrast 48% (46 of 96) of all
male and 44% (26 of 59) of all
female H & N lesions occurred in
patients over 60 years of age. The
distribution of LL lesions was simi¬
lar to that of T lesions: 74% (46 of
62) of LL lesions in males and 80%
(164 of 206) of LL lesions in fe¬
males occurred in patients under 60
years of age.
Overall there was little difference
in the ages of patients for lesions at
the major body sites except for the
H & N where median ages were
higher (Table II). Females had lower
median ages for T and UL lesions.
The recorded distribution of spec¬
ified growth patterns was SSM
FIG. 1. Melanoma incidence by sex (+ » male, B = female) and mortality by sex (X
— male, ▲ = female) in British Columbia 1971 to 1988.
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(65%), NM (25%). LMM (5%), and
ALM (2%). Fig. 2 illustrates growth
patterns by age. LMM proportions
increased with age and occurred
mainly on the H & N (80%). Only
13% of all LMMs occurred in pa¬
tients under age 50 years of age.
SSM proportions declined over age
60 years.
Staging information was com¬
plete in 870 cases: 90% had local
disease, 9% had regional disease
and 1% had distant disease. Region¬
al lymph node dissection was per¬
formed in 282 patients and in 84
(29.8%) patients the nodes were
found to contain malignant cells on
histologic examination. The inci¬
dence of regional or distant disease
according to the site of the primary
lesion in the total staged population
was 6.2% for UL lesions, 9% for T
lesions, 11.8% for H & N lesions
and 12.6% for LL lesions and ac¬
cording to the site in males and
females respectively was 14.7% and
7% for H & N lesions, 8.8% and
7.1% for T lesions, 5.2% and 7% for
UL lesions, and 24.6% and 9.1% for
LL lesions.
Distribution by Depth
Table III shows depth of invasion
by sex according to age, site,
growth pattern and stage. Overall
the median depth was 1.20 mm
(females 1.10 mm and males 1.45
mm).
The depth distribution of tu¬
mours was 31% for T1 tumours,
29% for T2 tumours, 25% for T3
tumours and 14% for T4 tumours.
Females made up 62% of patients
with T1 lesions, 55% of those with
T2 lesions, 52% of those with T3
lesions and 43% of those with T4
lesions. Males made up 69% of
patients with T3 and T4 H & N
lesions and 70% of patients with T3
and T4 T lesions. T1 and T2 tu¬
mours constituted 55% (59 of 107)
of all H & N lesions, 57% (119 of
209) of all LL lesions, 61% (147
of 241) of all T lesions and 69% (77
of 111) of all UL lesions. Clark's
Table II. Mean (and Median) Ages (Years) at Time of Diagnosis of New Patients With Primary
Cutaneous Malignant Melanoma According to Sex and Tumour Site
Site
Sex Head and neck Trunk Upper limb Lower Bmb
Male 58(57.4) 46 (46.4) 48(49.8) 48(48.1)
Female 56(54.5) 39.5(42.5) 43(47.1) 47(46.7)
Table L New Cases of Primary Cutaneous Malignant Melanoma According to Age. Clark's Level. Growth Pattern, Stage, Site and Sex
Site
Head and Upper Lower
neck Trunk Bmb Bmb
Groupings M F M F M F M F Tour
Age.yr
0-39 22 15 67 56 18 34 20 75 307
40-59 28 18 89 40 20 32 26 89 342
60-99 46 26 37 16 19 21 16 42 223
Total 96 59 193 112 57 87 62 206 872
Clark's level
1 5 0 4 3 2 0 0 7 21
1 13 15 33 22 9 18 4 46 160
■ 16 8 58 39 16 31 16 45 229
IV 37 19 74 35 23 26 27 84 325
V 10 10 6 2 2 4 9 9 52
Total 81 52 175 101 52 79 56 191 787
Growth pattern
LMM 17 12 0 0 1 2 1 3 36
SSM 25 27 111 74 31 47 26 119 460
NM 30 7 40 20 7 17 19 37 177
ALM 1 0 0 0 4 4 5 2 16
NOS 21 11 35 18 13 14 10 35 157
Other 1 2 6 0 1 3 1 8 22
Total 95 59 192 112 57 87 62 204 868
Stage
Local 61 53 176 104 55 80 46 189 784
Regional 12 4 15 7 2 5 15 19 79
Distant 2 0 2 1 1 1 0 0 7
Total 95 57 193 112 58 86 61 208 870
'Missing data account for differences between total study population (891) and totals in different categories above.
LMM - lentigo maligna melanoma, SSM - superficial spreading melanoma, NM - nodular melanoma, ALM - acral lentiginosis melanoma, NOS - not
otherwise specified
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ent in 2.5% of all T2, 11.3% of all
T3 and 17.2% of all T4 lesions at
the time of presentation.
Growth patterns indicate that
both SSM and LMM tend to be thin
lesions: 42% of SSMs and 62% of
LMMs were T1 tumours. NMs were
thicker lesions: 46% were T3 and
37% were T4. ALM was an infre¬
quent growth pattern: 66% of ALMs
were T3 and T4.
Recurrence
Disease recurred in 38% of the
total study population (32% of all
females and 44% of all males). Five
patients had recurrence 10 or more
years after the initial diagnosis.
Recurrences were predominantly
(54% of all first recurrences) in the
regional lymph nodes. The frequen¬
cies of primary sites responsible
for all first recurrences were as
follows: T, 38%; LL, 25%; H & N,
22%; and UL, 13%. Of patients
experiencing a first recurrence, 27%
had recurrence in two sites, 16% in
Table in. Age. Site, Growth Pattern and Stage of New Cases of Primary Cutaneous Malignant Melanoma According to Depth of Invasion and Sex
Depth of Iovasioo*
T1 T2 T3 T4 Totalt
Groupings M F M F M F M F No. %
Age.yr
0-39 31 54 19 47 33 40 12 11 247 37
40-59 31 55 45 37 29 36 20 15 268 40
60-99 18 19 23 23 19 12 23 16 153 23
Total,
No. 80 128 87 107 81 88 55 42 668 100
% 12 19 13 16 12 13 8 6 100
Site
Head and neck 17 17 15 10 14 9 19 6 107 16
Trunk 45 32 46 24 47 14 19 14 241 36
Upper limb 14 28 13 22 8 16 5 5 111 17
Lower fimb 4 51 13 51 12 49 12 17 209 31
Growth pattern
LMM 8 8 2 2 1 1 3 1 26 4
SSM 65 110 63 75 30 45 12 11 411 62
NM 0 1 12 12 33 32 30 22 142 21
ALM 1 0 1 2 3 1 2 2 12 2
NOS/other 6 9 9 16 14 9 8 6 77 12
Stage
Local 80 128 84 105 72 78 44 36 627 94
Regional 0 0 3 2 - 9 —10 11 6 41 6
Distant 0 0 0 0 0 0 0 0 0 0
* TNM classification
t Total study population
levels were assessed in 88% of
cases, and their distribution in rela¬
tion to depth is shown in Fig. 3.
No T1 lesions had spread beyond
the local area at the time of diagno¬
sis. Regional metastases were pres-
■i 1
I
*
i
Ok} 39
4010 59
o
5010 69
SSM MU ALM
Growth pattern of primary tumour
FIG. 2. Growth patterns of primary tumour by age (years). LMM = lentigo maligna
melanoma, SSM = superficial spreading melanoma, NM = nodular melanoma, ALM
= acral lentiginous melanoma.
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three sites and 10.5% in four or
more sites.
Survival
Five-, 10- and 15-year survival
rates were 68.9%, 58.2% and 55.5%
for males and 82.9%, 74% and
70.3% for females (p < 0.0001).
Overall mean survival of those who
died from CMM was 11.3 years for
males and 13.7 years for females.
Malignant melanoma was the
cause of death for 31% of the study
population and accounted for 82%
of all deaths. Of all patients who
had a recurrence, 16% were disease
free at last follow-up.
Other Cancers
Thirty (3%) of the 891 patients
had a previous basal cell cancer and
16 (2%) a squamous cell cancer.
Other malignant tumours occurred
in 48 patients (5%) before and 115
(13%) after the diagnosis of CMM.
Subsequent malignant tumours
were mainly nonmelanoma skin
cancers (66% of total subsequent
malignant tumours).
Discussion
CMM has been studied extensive¬
ly over the last 20 years, seeking a
better understanding of demograph¬
ic, environmental, clinical and
pathological factors. The increase
in age-standardized incidence in
Western developed countries has
been well documented,30-31 and a
similar pattern was seen in this
study. Melanoma incidence in sever¬
al countries increased by 5% per
annum in the 1960s and 1970s.32
These increasing rates suggest that
the trends observed are the results
of true changes in risk. Data from
the Surveillance Epidemiology and
End Results Program33 showed that
the incidence in males exceeds that
in females and is increasing at a
140
Depth of invasion
FIG. 3. Depth of invasion by Clark's level.
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faster rate (4.8% per year compared
with 3.6%); the death rates for
males and females are increasing at
2% and 1.3% per year respectively.
In our study the death rate for
males exceeded that for females in
8 of the 9 years from 1977 to 1985,
and overall survival for males was
shorter for new patients registered
from 1972 to 1981.
Data on sex, age, site and growth
patterns have been compared with
the findings of major series from
the United States,34"3® Canada,39
New Zealand,40 Scotland,4142 Den¬
mark,43 Australia44 and Ireland.45
This study's sex ratio was similar to
those in all series except the one in
Ireland and the two in Scotland,
where the female-to-male ratios
were 2.8:1, 1.9:1 and 2.17:1 respec¬
tively. All series except two in the
United States35^ showed a female
preponderance. The median age (47
years) of all patients in our study
was virtually the same as those
reported from Sydney and Alabama
(48 and 44 years respectively).3*
The commonest primary site in
females in all studies has been the
LL, accounting for 33% to 67% of
all cutaneous melanomas. For
males, the T was the commonest
primary site (33% to 47%) in all
studies except those in Ireland,
Scotland and Rochester where the
H & N was the commonest site.
The findings in this study that 46%
of all male melanomas were located
on the T and 44% of all female
melanomas were on the LL are
consistent with the findings in most
other series. A trend of increasing
frequency of T melanomas and de¬
creasing frequency of H & N mela¬
nomas in males has been reported
from Sydney and Alabama3* for the
period 1958 to 1985.
In_our study, the observed
growth-pattern distribution was
consistent with that of most previ¬
ous reports. The most frequent
(65%) growth pattern was SSM,
CUTANEOUS MALIGNANT MELANOMA
with NM and LMM accounting for
25% and 5% respectively. SSM is
usually the most common growth
pattern (51% to 73%), followed by
NM (14% to 35%) with LMM be¬
tween 4% and 9%. In Ireland, NM
was the most common type, and
LMM caused 18% of all melanomas
in that series.45
Depth measurement by microme¬
ter is now accepted as the most
important indicator of prognosis.44
The observations that 61% of the
total population had primary tu¬
mours less than 1.5 mm in depth
and that no T1 primary lesions were
spread beyond the local area at
diagnosis provide both encourage¬
ment and incentive to increase edu¬
cational efforts toward earlier rec¬
ognition and diagnosis of melano¬
ma. Depth comparisons with other
series are hindered by lack of stan¬
dard reporting practices. In the se¬
ries from Scotland for the period
1971 to 1976,41 only 30% of pa¬
tients had T1 and T2 tumours. In a
worldwide comparative study,47 12%
of patients had primary tumours
more than 4 mm thick, and in our
series 15% were more than 3 mm
thick. In the combined experience
of the Sydney melanoma group and
the University of Alabama, median
tumour thickness for males and
females has decreased since the
1950s38 to 1.4 and 1.2 mm, respec¬
tively, during the period 1976 to
1980. These median depths are
close to those depths observed from
1972 to 1981 in our series (1.45
mm for males and 1.10 mm for
females). Poorer prognoses in
NMs44 are related to their depth.
For example, 83% of NMs but only
24% of SSMs were T3 or T4 in our
series. ALM is also usually a deep
lesion, 66% being T3 or T4 in our
series.
The poorer prognosis of malig¬
nant melanoma in males is well
documented44 and has been con¬
firmed here. The sex difference in
survival in the present study could
be due to several factors: the gener¬
ally thicker and larger volume tu¬
mours in males, the predilection to
T and H & N lesions, the majority
of thick lesions at those sites, the
majority of regional or metastatic
disease in all sites except UL at
presentation and a tendency to
shorter disease-free intervals from
diagnosis to recurrence. The role of
hormonal factors in the etiology
and natural history of melanoma
has been recognized and investigat¬
ed for over 40 years,48 but this
association has yet to be successful¬
ly exploited therapeutically.
Most series report that the major¬
ity of patients have stage I disease
at presentation, consistent with the
findings in our series. Correlation of
primary sites with potential meta¬
static disease at diagnosis according
to sex showed that males had about
twice the likelihood of regional or
metastatic disease with H & N
primary lesions than females, and
almost three times the likelihood
with LL primary tumours. An analy¬
sis of the elective and therapeutic
lymph node dissections that were
performed in this series appears
elsewhere in this issue (pages 600
to 604).
The pattern of recurrent disease
in melanoma is now well known.
The disease-free interval is directly
related to the depth of the primary
lesion.45 Regional lymph nodes are
the commonest site of first metasta¬
ses. In this series, 54% of first
recurrences were in regional nodes.
Elective lymph node dissection is
known to be associated with a dif¬
ferent pattern of metastatic disease,
that is, fewer regional metastases
(down from about 60% to 5%) and a
proportional increase in other
sites.50 The prognostic importance
onihe ~ development of recurrent
disease is very clear from this se¬
ries. Only 16% of patients experi¬
encing recurrence were free of dis¬
ease at last follow-up. New treat¬
ments are urgently required for this
group of patients.
Several factors must be taken
into account when comparing sur¬
vival of patients between series.47
Referral-centre results differ from
population-based studies. Results
from the last decade may be superi¬
or due to earlier diagnosis. The
distribution of tumour thickness
must be considered. Patterns of
surgical practice, especially the rate
of elective lymph node dissection
will have a significant effect on
staging and possibly on ultimate
survival. Relapse is less likely in
patients with pathological than with
clinical stage I disease. In our se¬
ries, 5-year survival rates of 68.9%
and 82.9% for males and females
(10% of whom had regional or
distant metastases at diagnosis)
compare favourably with those from
other centres in which 5-year sur¬
vival rates for stage I melanoma
ranged from 62% to 81% and 70%
to 100% in males and females re¬
spectively.
Early diagnosis is the best avail¬
able method of improving survival
in CMM. Since CMM can be found
readily by self-inspection, the medi¬
an time to diagnosis can be short¬
ened with patient education. A pub¬
lic-health education program in
Queensland has resulted in an in¬
crease in the number of thin tu¬
mours registered.51 Awareness of
warning signs in a mole — asymme¬
try, border irregularity, colour var¬
iegation and diameter (over 6 mm)
or the ABCD of melanoma57 —
must be emphasized along with
assessment and surveillance of indi¬
viduals with dysplastic nevus syn¬
drome or family members with mel¬
anoma, or both.53-54 Public cam¬
paigns and further research aimed
at early detection and treatment
should reduce melanoma mortality,
especially in areas of higher inci¬
dence such as British Columbia.
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PRELIMINARY ANALYSIS OF A PHASE IB STUDY OF
INTRALYMPHATIC AND SUBCUTANEOUS IL-2 IN PATIENTS WITH
LOCAL AND REGIONAL METASTASIS IN MELANOMA. N.Yeilding,
J.Kirkwood. D.Vlock, A.Zajko, J.Bryant, A.Roih, M.Gempcricin-McQucen,
R-Herbermm, T.Whiteside. Depts of Medicine and Pathology, University of
Pittsburgh/Pittsburgh Cancer Institute, Pittsburgh, PA 15213.
We report the preliminary immunologic analysis and toxicity profile of
a Phase lb trial of low-dose intralymphatic and subcutaneous IL-2 for patients
(pts) with loco-regional metastatic melanoma Pts with in transit melanoma
of an extremity (alone or accompanied by N1-N2) received IL-2 at 13 x 10*.
13 x 105. 13 x 10*, or 13 x 10' Cetus U/M'/wk at 3 wk intervals by
intralymphatic (IL) infusion the first course, then intradermally TIW or TID
x 5 days for the second and third courses, respectively. In six pts who have
been treated in the first two dosage tiers, one complete response (CR) (7+
mos) was seen, two pts had stable disease (28+ and 19 mos), and 3 pts had
progressive disease. No dose-limiting toxicity was seen All pts experienced
mild to moderate pain and edema at the injection site; 4/5 pts experienced
mild to moderate fatigue; and one pt developed mild hypotension responding
to fluids. Immunologic parameters were analyzed x 3 prior to treatment and
serially thereafter. Overall, no consistent changes related to treatment have yet
been observed in the analysis of PBL phenotype, NK or LAK activity, or
mitogens or alloantigen response, or serum levels of IL-2. IFN, TNF, or the
soluble IL-2 receptor. The patient achieving a CR was noted to have increases
in PBL DR expression and DR/Leu 2a co-expression and an increase in serum
levels of TNF following IL-2 injection. Accrual to higher dosage tiers is
currently in progress. We conclude that loco-regional administration of IL-2
at low dosages produces minimal toxicity and is associated with clinical
responses. Accrual of additional patients may be needed to demonstrate
effects on systemic immune parameters. Regional assessment of immunologic
parameters may be more informative in the analysis of mechanisms of IL IL-2.
(Supported by the Pardee Foundation)
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SEQUENTIAL CHEMOIMMUNOTHERAPY FOR METASTATIC MELANOMA.
JM Richards. E Priest, V Hamasakl, P Skosey, K Ramming.
University of Chicago, Chicago, IL 60637
Since February 1990 we have evaluated a sequential
cheroolmmunotherapy (CITx) for the treatment of
metastatic melanoma. A cycle of therapy consisted of:
BCNU (150 mg/m ) on day 1, OTIC (220 mg/m*) and cDOP (25
mg/a*) on days 1-3 and 22-24, 1nterleukin-2 (IL-2) (1.5
mU/m* every 8 hrs) and alpha-interferon («IFN) (6mU/m
sc once dally) on days 4-8 and 17-21, and tamoxifen 10
mg po twice dally for 6 weeks. Patients were evaluated
for response 2-3 weeks after completing each cycle of
herapy. Thirty-nine patients have been entered Into
this trial as of Dec. 1, 1990, and 25 have completed at
least 1 cycle of therapy and have been evaluated for
response. The best response are as follows:
Response iiiu. Percent
Complete 6
Partial 9
Minor 1
Stable 8
Progressive 1
Median response duration has not been reached and 1s
greater than 5 mos. Immunologic alterations associated
with response will be presented.
24
36
4
32
4
60
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A PHASE IB TRIAL OF MURINE MONOCLONAL ANTIBODY RJ4
(ANTI-GD3) IN METASTATIC MELANOMA. J. Raymond. J.
Kirkwood, D. Vlock, M. Rabkin, R. Day, T. Whiteside, R. Herberman.
R. Mascari,and B.Simon. University of Pittsburgh/Pittsburgh Cancer
Institute, Pittsburgh, PA 15213
Rm reacts with the disialoganglioside GD3 found in a majority
of melanomas, and mediates antibody dependent as well as
complement dependent cytotoxicity against melanomas in vitro.
Initial clinical trials against melanoma have revealed clinical
responses at a range of doses of antibody. We have initiated a phase
lb trial of RM at dosages of 8-640 mg/M' to further evaluate
antitumor activity and the optimal immunomodulatory dosage in
subjects with metastatic melanoma. Five dose tiers of 6 pts each are
planned. To date, 12/30 pts (8 F/4 M; age 25-73) have completed
treatment on dose tiers I and II (8 and 80 mg/M*) given as a
continuous IV infusion x 8 d. 2 pts with response in tier I have
received maintenance therapy at half the initial dosage q 6 wk.
Toxicity has included gr I-II flu-like syndrome, anemia,
nausea/vomiting, and peritumoral pain, erythema, and edema. Two
pts have experienced gr II-III volume overload. 3/6 pts in tier I and
all above tier 1 have had urticaria. Chemical pancreatitis was noted
in I pt. There have been no gr 4 toxicities, or anaphylaxis. Tumor
response observed in 2 pts on tier I is notable: one developed 70%
response following the initial infusion, regrowth of tumor to near-
baseline and repeated response to maintenance at 6 and 12 weeks.
Another achieved partial response to initial treatment, and entered
complete response after maintenance x 2 cycles. Clinical evidence of
response to RM in this trial includes regression in 2/6 subjects at the
lowest dose tested, and tumor pain, edema, erythema and urticaria
that suggest an immune mechanism. It is too early to correlate
laboratory immune assessment and clinical responses in this study.
1047
CUTANEOUS MALIGNANT MELANOMA: BRITISH COLUMBIA
CANCER AGENCY EXPERIENCE FROM 1972 TO 1981. K. S.
Wilson ■ V. E. Canaichael. B.C. Cancer Agency
Victoria Clinic, Victoria, B.C. V8R 1J8, and
School of Health Information Science, University
of Victoria, Victoria, B.C. V8W 3P5.
A restrospective review of 891 patients with
newly diagnosed cutaneous malignant melanoma
(CMM) registered at the B.C. Cancer Agency from
1972 to 1981 is presented. Age standardized
incidence rates in B.C. have increased
significantly over that time. Sex ratio was
1.13:1 in favor of females and median age was 47
years. Change in size of a mole was the most
common presenting symptom and median duration of
symptoms was 5.9 months. Predominant primary
tumour sites were trunk for males and lower limb
for females. Dominant growth patterns were
superficial spreading melanoma (65k), nodular
melanoma (25%), lentigo maligna melanoma (5%) and
acral lentiginous melanoma (2%). Staging of the
primary tumour was 90% local, 9% regional and 1%
distant disease at presentation. Median depths
of primary tumours were 1.45 mm for males and
1.10 mm for females. No Ti tumours (tumours
<0.75 mm) were staged beyond the local area.
Disease recurred in 44% of males and 32% of
females. Fifteen year survival was 55.5% for
males and 70.3% for females. These findings have
been compared with other recent international
series. It is apparent that earlier diagnosis
improves survival and that more education is
needed in view of the increasing incidence and
mortality from CMM.
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ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA
Elective and Therapeutic Regional Lymph
Node Dissection for Cutaneous Malignant
Melanoma: Experience of the British
Columbia Cancer Agency, 1972 to 1981
Vicki E. Carmichael, BSc;* R. Edward Robins, MD, FRCSC;t
Kenneth S. Wilson, MB, ChB, FRCP (Edin), FRCPC, FACP*
The authors present a 10-year review of patients registered at the British Columbia
Cancer Agency (BCCA) who underwent lymph node dissection for malignant
melanoma. Pathological findings in the regional lymph nodes were correlated with
primary site, growth pattern, depth of invasion and Clark's level. Elective lymph
node dissection (ELND) was performed in 223 patients, and the overall positivity
rate (pathologically involved nodes) was 16%. Survival rates for patients who had
ELND were compared with those for BCCA patients not having had ELND and
patients from the University of Sydney, Sydney, Australia. Although patients who
underwent ELND had thicker and more frequently ulcerated primary tumours than
patients with stage I disease who did not undergo ELND, survival was better in the
group who had ELND. However, when all potential prognostic factors were analysed
by multivariate analysis, ELND was not a significant factor in prognosis.
Therapeutic lymph node dissection (TLND) was performed in 50 patients at the time
the primary tumour was diagnosed, and involvement of the lymph nodes was found
in 36. Of 525 patients with clinical stage I disease who did not have ELND, disease
recurred in the regional lymph nodes in 119; 86 of them had TLND for recurrence
(RTLND). Median survival rates from the time of diagnosis of the primary lesion for
ELND-positive, TLND-positive and RTLND patients were 4.2, 2.7 and 4.4 years
respectively; the differences were not significant New treatments are required for
patients with involved regional lymph nodes.
Les auteurs decrivent les r£sultats d'une etude d'une dur£e de 10 ans portant sur les
patients de I'Agence pour le Cancer de Colombie Britannique (ACCB) qui subirent
une dissection ganglionnaire pour un mdlanome malin. Les constatations des
examens pathologiques ont i\.i relives au foyer primaire, aux caractfristiques de
croissance, a la profondeur et au niveau selon la classification de Clark. Une
dissection ganglionnaire non urgente (DGNU) fut pratiqu£e chez 223 patients et le
taux (Texamens positifs fut de 16 %. Le taux de survie des patients qui subirent une
DGNU a iti compart i celui des patient de l'ACCB qui ne subirent pas de DGNU et
i celui des patients de l'Universit£ de Sydney, Sydney, Australie. Meme si les
patients qui subirent une DCNU avaient des tumeurs plus profondes et plus
fr£quemment ulc£r£es que les patients de stade I qui n'eurent pas de DGNU, la
turvie fut meilleure dans le groupe DGNU. Ndanmoins, 1'analyse multifactorielle de
tous les facteurs pronostiques possibles n'a pas fait ressortir la DGNU commme
facteur pronostique determinant Une dissection ganglionnaire therapeutique (DGT)
fut effectu£e chex 50 patients au moment du diagnostic primaire et une atteinte
ganglionnaire fut constat£e chez 36 d'entre-eux. Des 525 patients au stade dinique I
qui n'eurent pas de DCNU, une rfcidive ganglionnaire rfgionale survint chez 119;
de ce groupe, 86 subirent une DGT pour r4cidive (DGTR). Les survies medianes 1
partir du diagnostic de la lesion primaire pour les patients DCNU-positifs,
DGT-positifs et DGTR furent de 4,2, 2,7 et 4,4 ann6es, respectivement; la diff4rence
n'est pas statisb'quement significative. II existe un besoin de therapies nouveDes
pour les patients souffrant d'atteintes ganglionnaires r4gionales.
The role of surgery in removingclinically malignant or equiv¬
ocal regional lymph nodes (thera¬
peutic lymph node dissection
(TLND]) either when the diagnosis
of primary malignant melanoma is
made or subsequently for recur¬
rence (recurrent therapeutic lymph
node dissection [RTLND]) is firmly
established.1 However, the survival
benefit of removing clinically nor¬
mal regional lymph nodes as soon
as the primary lesion is diagnosed
(elective or prophylactic lymph node
dissection [ELND]) is controversial.1
Since 1976, the Melanoma Tu¬
mour Group of the British Colum¬
bia Cancer Agency (BCCA) has rec¬
ommended ELND for patients with
"high-risk" clinical stage I malig¬
nant melanoma, defined as those
with primary tumour of Clark's
level III and depth of dermal inva-
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sion greater than 0.76 mm, those
with Clark's level 4 or 5, and those
in whom one anatomic lymph node
drainage site could be identified.
This recommendation was modified
in 1983 to stage 1 patients with
tumours more than 1.5 mm deep.
In this study we report the BCCA
experience with ELND, TLND and
RTLND for malignant melanoma.
Factors influencing the ELND posi-
tivity rate are presented. Survival in
patients who had ELND is com¬
pared with that of a concurrent
control group of clinical stage I
patients who, in the same decade,
were treated without ELND (desig¬
nated BCCA control patients), and
with that of other series. Reasons
for omitting ELND included patient
and referring surgeon's decisions in
the light of possible expected bene¬
fits. The effect of ELND on survival
of all patients with clinical stage 1
malignant melanoma who were reg¬
istered at the BCCA during the
study period and were treated by
wide primary excision has been
analysed by multifactorial analysis
according to whether or not they
underwent ELND.
Patients and Methods
In 1983 we began a retrospective
review of all patients who had regis¬
tered at the BCCA with malignant
melanoma between June 1, 1972,
and May 31, 1981.2 The records of
891 patients were reviewed, and all
of those who underwent ELND,
TLND and RTLND and BCCA con¬
trol patients (vide supra) form the
basis of this report. Lymph node
dissection for cure was performed
by referring surgeons throughout
the province.
The data were analysed with the
Statistical Package for Social Sci¬
ences (SPSS-X, release 3.1).J Sur¬
vival was analysed by the product
limit method. Multifactorial analysis
was undertaken with the Cox pro¬
portional hazards model. Differ¬
ences between survival curves were
calculated with the log rank test.
Results
ELND
ELND was performed in 223 pa¬
tients, 104 male and 119 female. In
patients with specified negative clin¬
ical evaluation of regional nodes,
ELND was pathologically positive in
19 (18%) males and 16 (13%) fe¬
males for a combined positivity rate
of 16%. ELND positive and negative
frequencies and overall percent pos¬
itivity according to site and growth
pattern of the primary tumour,
depth of invasion and Clark's level
are summarized in Table I.
Depth measurements were avail¬
able in 202 patients who underwent
ELND. Median depths of primary
tumours in ELND-positive and
ELND-negative patients were 3.0
mm and 1.6 mm respectively. Med¬
ian depth of primary tumours was
greater in all patients who had
ELND (1.64 mm) than in 530
BCCA control patients (1.00 mm) (p
< 0.0001). Site distribution of the
primary tumour in patients who had
ELND and in BCCA control pa¬
tients was 20% and 17% (upper
limb), 41% and 25% (lower limb),
26% and 41% (trunk), and 13% and
18% (head and neck). Primary ul¬
ceration was present in 53% of
patients who had ELND and in 20%
of BCCA control patients. In pa¬
tients with positive ELND, 18 had
one positive node, 7 had two posi¬
tive nodes and 7 had three or more
positive nodes; 3 patients had an
unspecified number of positive
nodes. The number of positive
nodes made no significant differ¬
ence to the patient's survival. Dis¬
ease recurred in 27% (50 of 188) of
the ELND-negative patients. There
were 23 (66%) recurrences in the 35
Table L Characteristics of Patients With Pathologically Positive and Negative Nodes on Elective
Lymph-Node Dissection (ELND)
ELND ELND
Characteristics positive ■egathre
Sex
Male 19 85
Female 16 103
Site of primary
Upper fimb 3 41
Lower limb 16 77
Head and neck 4 24
Trunk 12 46
Growth pattern
SSM 16 102
NM 14 57
LMM 0 1
ALM 0 4
NOS 5 24
Depth of invasion of primary tumour*
T1 0 15
T2 5 67
T3 12 67
T4 13 24
Unspecified 5 15
Clark's level
N 0 4
II 3 65
IV 24 108
V 6 7
SSM « superficial spreading melanoma. NM - nodular melanoma, ALM - acral lentiginous
melanoma, LMM «* lentigo maligna melanoma, NOS « not otherwise specified
*TNM classification
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ELND-positive patients. In these pa¬
tients the median survival was 4.2
years, and 37% of them survived 10
years. Median survival of ELND-
negative patients has not been
reached (Fig. 1).
Ten-year disease-specific survival
rates according to depth and level
of invasion of the primary tumour
in BCCA control patients and those
who had ELND are shown in Figs.
2 and 3. Survival differences were
significant in favour of patients who
had ELND when grouped according
to either level or depth of invasion
(p < 0.0001). In patients with a T2
primary tumour, the group with the
largest difference in survival (23%),
only five (7%) had pathologically
positive lymph nodes out of a total
of 72 dissections.
Univariate and multivariate analy¬
sis of survival was undertaken in
720 clinical stage I patients. Of
these patients, 192 had local exci¬
sion (LE), 3 had LE and ELND, 327
had wide excision (WE) (more than
5 cm total width) and 198 had WE
and ELND. Ten-year disease-specif¬
ic survival rates for patients who
Year
FIC. 1. Ten-year disease-specific sur¬
vival rates in patients with nega¬
tive elective lymph node dissection
(ELND) (solid line), positive ELND
(short dashed line), positive therapeu¬
tic lymph node dissection (TLND) (dot¬
ted line) and therapeutic lymph node
dissection for recurrence (RTLND)
(long dashed line).
underwent the various types of sur¬
gical excision were 38% for those
with LE, 50% for those with LE and
ELND, 67% for those with WE and
67% for those with WE and ELND.
Multivariate analysis did not show
ELND to be a significant factor
determining prognosis. Univariate
analysis showed that patients hav¬
ing only LE had significantly poorer
FIG. 2. Ten-year disease-specific survival rates in patients with malignant
melanoma registered with British Columbia CanceT Agency (BCCA) according to
depth of primary tumour. Solid bars «= no ELND, dotted bars = ELND.
FIG. 3. Ten-year disease-specific survival rates according to level of invasion of
primary tumour. Solid bars - no ELND, dotted bars — ELND.
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survival, and multivariate analysis
showed this to be significant as well
(p = 0.0015).
Three subgroups of patients were
identified in the present series to
allow comparison of outcome in
patients who appeared to benefit
most from ELND in the University
of Sydney series, that is, males with
T3 trunk primaries and males and
females with T3 extremity prima¬
ries.4 Ten-year survival rates for
four groups of patients are shown
in Fig. 4. The groups were Univer¬
sity of Sydney patients and BCCA
patients who had ELND and Univer¬
sity of Sydney patients and BCCA
patients who did not have ELND.
Patient numbers for each of these
groups were 81, 19, 104 and 26
(T3, male, trunk); 55, 11, 61 and 4
(T3, male, extremity); 71, 41, 135
and 18 (T3, female, extremity). Sur¬
vival differences between the two
cohorts of BCCA patients — those
who had ELND and control — for
these specific sex and primary-site
groups were not significant (p «=
0.1175). The numbers of patients in
the BCCA ELND groups were
small, especially male patients with
T3 extremity primary tumours. Sur¬
vival rates for all BCCA patients in
these categories were intermediate
between the University of Sydney
patients who did not have ELND
and those who did.
TLND
TLND was performed in 50 pa¬
tients at the time the primary tu¬
mour was diagnosed, and 36 (24
males and 12 females) had patho¬
logically positive nodes. Of these 36
patients, 12 had one positive node,
3 had two positive nodes, 12 had
three or more positive nodes and 9
had an unspecified number of posi¬
tive nodes. The median depth of the
primary tumour was 2.0 mm. Dis¬
ease recurred in 24 (67%) patients
with positive nodes, and median
survival was 2.7 years. The 10-year
survival rate was 45%.
RTLND
Of 525 clinical stage I patients
who did not have ELND, 119 (70
male and 49 female) had regional
lymph node recurrence. RTLND
was performed in 86 of these pa¬
tients. The median depth of the
responsible primaries in these pa¬
tients was 2.3 mm. The site distri¬
bution of these primary tumours
was 47% in the trunk, 21% in the
lower limb, 18% in the head and
neck and 14% in the upper limb.
Median time to regional lymph node
recurrence from primary treatment
was 1.4 years. For all RTLND pa¬
tients the median survival was 1.8
years from the date of recurrence
and 4.4 years from the date of
primary-tumour diagnosis. Ten-year
survival was 26%. Survival curves
for ELND-positive, TLND and
RTLND patients (Fig. 1) were not
significantly different (p = 0.82).
Discussion
The role of ELND in the surgical
management of cutaneous malig¬
nant melanoma has been extensive¬
ly studied in both nonrandomized
and randomized clinical trials.1 Re¬
sults of two randomized trials did
not confirm the apparent benefits
seen in nonrandomized studies, but
reanalysis of the World Health Or¬
ganization (WHO) Trial suggested
that a subgroup of patients at inter¬
mediate risk of recurrence had a
superior survival with ELND.
The rationale for ELND is based
on the hypothesis that microscopic
metastases may disseminate sequen¬
tially from primary to regional
lymph nodes to distant sites and
that removal of nodal micrometas-
tases will prevent the development
of incurable distant metastases.5
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FIG. 4. Ten-year disease-specific survival rates in patients with T3 primary
malignant melanoma registered with BCCA and from University of Sydney, Sydney,
Australia, according to sex, site of primary tumour and whether or not ELND was
performed. Black bars = Sydney series, no ELND; dotted bars = BCCA series, no
ELND; cross-hatched bars = Sydney series, ELND; chequered bars — BCCA series,
ELND. M = male, F = female. UL = upper limb, LL = lower limb.
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The present study confirms the
high subsequent death rate in pa¬
tients with lymph node positive mel¬
anoma. We were unable to show,
however, that patients who had
pathologically positive nodes on
ELND had a better survival than
patients who underwent either
TLND or RTLND. We confirm the
finding of a previous report that the
number of positive nodes in patients
who had ELND is not significant
for survival.® However, if the num¬
ber of positive nodes is expressed as
a percentage, some patients with
ELND (those in whom the depth of
invasion of the primary tumour was
less than 3.5 mm and less than 20%
of the nodes were positive) have a
good prognosis (i.e., 66% 7-year
survival).7
The yield (percent probability of
detecting lymph node metastases)
of ELND in this study (16%) is
within the range (4% to 25%) of
previous reports." Yields according
to depth of the primary tumour are
also consistent with those of previ¬
ous reports: 5% to 10% for T2, 17%
to 20% for T3 and 39% for T4
tumours.® Interestingly, the series
with the lowest reported overall
yield (4%) showed the largest appar¬
ent treatment effect of ELND. Some
patients in the group with patho¬
logically negative nodes on ELND
may in fact be those who are likely
to benefit most from the procedure.
In the present series, the yield in
patients with the largest survival
difference (T2 primary tumours)
was only 7%. Most studies, includ¬
ing ours, have reported higher
lymph node relapse rates in patients
who did not have ELND than the
yield at ELND, suggesting that
some patients have lymph node me¬
tastases that are not identified at
ELND.*
Survival of BCCA patients who
had ELND has been compared with
BCCA control patients and patients
from the University of Sydney with
melanoma of the trunk and extremi¬
ties. Although depth of invasion
among BCCA patients who had
ELND was significantly greater and
primary ulceration was more fre¬
quent than in concurrent BCCA
control patients, 10-year survival
rates were significantly better, espe¬
cially for T2 and Clark's level IV
primary tumours. However, Clark's
level IV primary tumours accounted
for 43% of T2 primaries, and, con¬
versely, T2 primaries accounted for
only 29% of Clark's level IV prima¬
ry lesions.7 These figures suggest
that factors other than ELND con¬
tribute to the survival differences.
BCCA patients who had ELND had
more favourable primary sites, more
lower limb primaries and fewer
trunk and head-and-neck primaries.
In addition, ELND was performed
only when a single lymphatic drain¬
age area was present, not in pa¬
tients with midline or watershed
primary tumours.
The results of multifactorial anal¬
ysis in patients with clinical stage I
melanoma in our series showed that
ELND was not an independently
significant factor for survival. Nor
was there any significant benefit for
patients in the three groups of T3
primary melanomas who appeared
to benefit in the report from the
University of Sydney.4 The analysis
of survival after ELND according to
tumour depth showed the largest
difference in patients with T2 pri¬
mary tumours, a group for whom
we currently do not recommend
ELND.
The role of ELND in any sub¬
group of clinical stage I melanoma
remains uncertain. Ultimately, fur¬
ther prospective randomized trials
are required to define the therapeu¬
tic role of ELND. There are two
current prospective randomized"tri¬
als addressing the role of ELND. An
American intergroup study has in¬
cluded patients with intermediate-
thickness (1 to 4 mm) melanoma of
the trunk and extremities. The
WHO Melanoma Group is studying
trunk primary melanomas greater
than 2 mm thick.
Median survival rates for patients
with positive nodes on ELND and
TLND and patients who had
RTLND in the present series com¬
pare favourably with those of previ¬
ous reports.61011 However, all the
results confirm the need for new
treatments in patients with lymph
node positive melanoma.
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Clinical studies and case reports
Analysis of prognostic
factors in clinical stage 1
cutaneous melanoma
By Vicki Carmichael, BSc, Roger R, Davidson, PhD and Kenneth S. Wilson, BSc, MBChB, FRCPC
Clinical records of 753 patients with clinical stage 1 cutaneous malignant melanoma registered at
the British Columbia Cancer Agency (BCCA) between 1972-81 were reviewed. Multivariate analy¬
ses utilizing appropriate subsets of 28 clinical and pathological variables showed that logarithm of
micrometer depth, Clark level, pathological ulceration, primary site, type of initial surgery, growth
pattern, and lymphatic invasion were the principal prognostic factors. This retrospective study
compares the BCCA results with previous reports worldwide.
Introduction
The likelihood of recurrence after sur¬
gery for stage 1 primary melanoma can
be assessed with reasonable accuracy
in most patients. Of all clinical and
pathological variables in primary cuta-
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neous melanoma, depth of invasion
measured by micrometer has been found
to be most consistently and strongly
associated with risk of recurrence and
death from melanoma.1 The present
study is part of a retrospective review
ofcutaneous malignant melanoma reg¬
istered with the BCCA between 1972-
813 Survival analysis according to 28
clinical and pathologic factors was un¬
dertaken.
Patients and methods
Medical records of 796 patients with
clinical stage 1 cutaneous malignant
melanoma referred to the BCCA from
1972-81 were reviewed. Clark level 1
patients and those with "borderline
melanoma" were excluded from analy¬
sis because of 100% survival. Follow-
up data was missing in seven cases,
leaving a total of753 cases for analysis.
Definition of most variables has been
reported previously.3 BANS sites refer
to primary tumors on the upper back,
posterior aspect of upper arms, poste¬
rior neck and scalp. The posterior up¬
per arm and upper back were not coded
separately in the present series. This
report utilizesposteriorupperextremity
and posterior trunk instead ("modified"
ormBANS sites). Wide excision (WE)
was defined as >5 cm skin in the
re-excision specimen; all excisions of
lesserdimensions were designated local
(LE).
The principal study objective was to
evaluate survival from melanoma in
relation to 28 clinical and pathological
factors. Observation times for patients
leaving the study for reasons other than
death from melanoma, and for patients
alive at last follow-up were considered
as censored observations. Cases with
missing data were excluded from the
relevant analysis procedure. Minimum
follow-up was 7.9 years.
Univariate analysis was performed
to assess single factors using the Kaplan-
Meier product limit method. The log
rank test was used to determine signifi¬
cance of survival differences.
Multivariate analyses were undertaken
with the Cox proportional hazards re¬
gression model. Different combina-
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tions of covariates were examined to
determine the best prognostic model.
Categories in Clark level, growth pat¬
tern, type of surgery, inflammatory re¬
action, surface description and primary
site were coded as separate binary vari¬
ables. These covariates were analyzed
both as linear variables and using coded
dichotomous variables.
Results
Univariate analysis (Table 1) showed
that the following factors were signifi¬
cant: date of diagnosis, sex, primary
site including mBANS sites, growth
pattern, surface description, Clark level,
depth of invasion, clinical and patho¬
logical ulceration, tumor diameter and
volume, lymphatic invasion, mitotic
rate, inflammatory reaction, invasion
to stratum corneum, pigmentation,
polypoid configuration, and type of
surgery. There were seven covariates
in the model adopted for the basis of
multivariate analysis which used coded
dichotomous variables: 134 cases were
uncensored. Using the logarithm of
depth of invasion resulted in substan¬
tial improvement to the fit of the model.
When categorical covariates were
analyzed as linear variables, significant
factors were: log depth, Clark level,
pathologic ulceration, primary site, type
of surgery, (all P< 0.005 ), growth pat¬
tern, mBANS sites, and lymphatic in¬
vasion. After adjusting for the effect of
depth of invasion or Clark level, all the
factors mentioned above remained sig¬
nificant. Table 2 shows the results of
multivariate analyses in the present
study when covariates were examined
in linear fashion or as coded dichoto¬
mous variables.
There were 218 melanoma deaths
and 56 deaths from other causes. Ten-
Table 1:
Single factor analyses in clinical stage 1
malignant melanoma
14 2* 3s 4* 55 610 T
Age + + - - + + -
Sex + + +
'
+ + + +
Site + + + + - + +
BANS sites - - NE NE - NE +
Diameter NE NE NE + NE + +
Growth Pattern + + - + + + +
Depth + + + + + + +
Level + + + + + NE +
Ulceration
clinical NE + NE NE NE NE +
pathologic + + + + + NE +
Inflammatory reaction + NE + + + NE +
Pigmentation + NE NE NE - NE +
Mitotic rate NE NE - + + + +
Lymphatic invasion NE NE + + + NE +
Polypoid NE NE NE NE + NE +
*
present study
NE: not evaluated
NA: not applicable
+: significant (P=< 0.05)
-: not significant
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Table 2:
Recent multifactorial analyses in clinical stage 1
malignant melanoma
1* 2* 35 410 57 6* 7"
Age + - - + + - -
Sex + + + + + - -
Primary site - + - + + + +
BANS sites - - - - NE - +
Growth pattern - - - - NE + +
Depth + + + + NE + +
Clark level - - - - NE + +
Ulceration
clinical + NE NE NE NE - -
pathologic - + - NE NE + +
Mitotic rate NE - - + NE - -
Epithelial cell type - + - - NE - -
Lymphatic invasion - - - - NE + +
ELND + NA NA NE NE - -
Wide vs local
excision NE NE NE NE NE + +
*
present study; dichotomous variables
**
present study; linear variables
NE: not evaluated
NA: not applicable
+: significant (P=< 0.05 )
not significant
year disease-specific survivals for se¬
lected covariates were: 93% Tl, 75%
T2,58% T3,42% T4 primaries; Levels
II 92%, III 78%. IV 58%, V 26%;
primary ulceration - present 48%, ab¬
sent 78%; superficial spreading 78%,
nodular 52%, acral-lentiginous
melanoma 43%; males 60%, females
77%; either extremity primary 77%,
head and neck 63%, trunk 62%; lym¬
phatic invasion - present 34%, absent
72%; mBANS sites - present 60%, ab¬
sent 73%; local excision alone 38%,
wide excision 67%, wide excision +
elective lymph node dissection (ELND)
67%.
Discussion
Analysis of survival in patients with
stage l malignant melanoma is com¬
plex, requiring definitions of clinical
and histologic features/covariates, fol¬
low-up period, and statistical method¬
ologies. Lack of uniformity in defini¬
tion of covariates may lead to difficul¬
ties in comparing results of prognostic
factor analyses. For example, hands
and feet may be separately coded; cen¬
tral pathology review rates vary;
lymphocytic infiltrationmay be defined
as two or three values; mitotic rate can
be evaluated histologically and coded
differently; inter-observer differences
in interpretation of Clark level and
Breslow depth are well known, with
only 70% overall agreement among
pathologists; growth pattern classifica¬
tion is not always possible and/or re¬
producible; and ELND rates and indi¬
cations vary between series.
Patient selection is another factor
potentially affecting survival and con¬
clusions about the biological risks of
melanoma. Referral center results are
likely to be different from population-
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based studies.' The BCCA, as the only
provincial group offering
multidisciplinary consultation for
melanoma patients and providing most
treatments for recurrent melanoma, is
likely to have patients with poorer
prognoses, and with more melanoma
"events" (which may precipitate refer¬
ral) after diagnosis.
Single prognostic factor results from
the present study and several recent
studies are summarized in Table l.'-vl°
The prognostic significanceofanatomic
level of invasion and depth measured
by micrometer has been confirmed by
all studies which assessed these factors.
Other factors which were universally
associated with poorer survival were:
male sex, primary diameter, clinical
and pathological ulceration, mitotic rate,
poor inflammatory response, and lym¬
phatic invasion. Most studies also
showed age, primary site, and growth
pattern to be significant.
The results of multivariate analyses
in the present series showed log depth.
Clark level, pathological ulceration,
primary site, type of surgery, growth
pattern, and lymphatic invasion to be
significant irrespective of the statistical
coding used. In addition, when the
covariates were treated as linear vari¬
ables, mBANS sites became signifi¬
cant. Age and sex were not significant
in either model. Most previous studies
have found female sex to be insignifi¬
cant prognostically (Table 2).'
In 54 studies utilizing multivariate
analysis, 42 showed that primary depth
is the most frequently significant prog¬
nostic factor in malignant melanoma.1
Five other studies of multivariate
analysis of survival, not included in the
review,' are summarized in Table 2.
All studies, including the present, which
examined depth found it to be consist¬
ently related to survival. Primary depth
is associated with several other
covariates, particularly ulceration,
growth pattern, cell type, mitotic activ¬
ity, pigmentation, lymphocytic infil¬
tration and primary diameter." Depth is
also largely responsible for the loss of
significance ofmany factors when sub¬
ject to multifactorial analysis.
Primary site was significant in 25 of
53 multivariate analyses of survival
(Table 2).' Trunk, head and neck pri¬
maries had poorer survival in the present
series; mBANS sites were significant
using linear variables but not when
using dichotomous variables.
Age was not a significant prognostic
factor in the present and most previous
multivariate analyses (Table 2).' Age
is associated with depth,' the most im¬
portant prognostic factor.
Superficial spreading melanomawas
the most favorable growth pattern in
the present study. Lentigo maligna
melanoma has been reported to have a
better prognosis after matching for
thickness." There were insufficient
cases of lentigo maligna in the present
series for survival comparison.
Primary ulceration is the remaining
covariate which has frequently been
positive in multifactorial analyses (Ta¬
ble 2).' Ulceration is mostly found in
thick tumors (median thickness: 3.0
mm, compared to 1.5 mm for non-
ulcerated tumors ), but studies of ul¬
ceration in tumors of equivalent thick¬
ness show lower survival in ulcerated
tumors."
Patients having primary excisions
<5 cm diameter had poorer prognoses
in the present study. Reasons for un¬
dertaking only local excision were,
however, not assessed during the chart
review process. The present finding
that wide excision is superior to local
excision is consistent with current
melanoma surgical principles.
Conclusion
The present study of clinical stage 1
malignant melanoma showed that loga¬
rithm of micrometer depth, Clark level,
pathological ulceration, primary site, type
of surgery, growth pattern, and lym¬
phatic invasion were the principal
prognostic factors. ModifiedBANS sites
were only significant when linear coding
was used in the multivariate analysis.D
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A PHASE 18 TRIAL OF OM-CSF WITH MURINE MONOCLONAL
ANTIBODY R24 IN PATIENTS WITH METASTATIC MELANOMA
AIFF1ICF ACHACHOUA RORAT7. 0CAftON. D PEACE. LF UEBES.
HS HOCHSTER, J VH.CEK, F LAFLEUR, AND RH BLUM. KAPLAN
COMPREHENSIVE CANCER CENTER NYU MEDICAL CENTER NY, NY 10016
W« hav* Initiated a phata 1b trial to test the hypothesis that GM-
CSF treatment (tx) wll uprejutate monocyte and granulocyte antbody
dependent cellular cytotoxicity (ADCC), and that the combination of
GMCSF with an antibody (R24), which mediates ADCC, leads to enhanced
antitumor activity In pts with melanoma. Pt eligibility included biopsy
proven melanoma, i 2 prior chemotherapies. ECOG PS i 2, and adequate
organ function. Clinical response and toxicity were graded using
standard ECOG criteria. Monocyte and granulocyte ADCC were measured
using standard chromium release assays against the SK MEL 28 melanoma
cell Una. Effector/target (E/T) ratios were 32:1, 16:1, 8:1. 8 4:1.
GMCSF eras administered daily by sq injection for 21 days at a dose of
150 ughn2/day. R24 was administered by continuous IV infusion days
8-15 at 3 dose levels: 0, 10 and 50 mg/m2/day. Each pt received only
1 tx. A total of 17 pts have been treated to date, (8rrV7f: ages 37-71).
R24 dose: 0 • 5 pts, 10 • 8 pts, 50-6 pts. A1 pts were evaluabie tor
toxicity. GM-CSF toxicity Included local erythema, and pruritus at the
Injection site. 1 pt on GMCSF developed atrial fibrillation after 1 week of
tx. Toxicity from the R24 has included gr HI nausea/ vomiting and
urticaria in all pts. 2 pts on R24 Q 10mg/m2 developed gr 3
hypertension. One of these pts developed gr 3 CHF. 1 pt on R24 & 50
mg/m2 developed grade 3 hypotension. 1 pt who had melanoma Involving
the Gl tract developed UGI bleeding on Day 20 of tx. No objective tumor
responses have been observed. 12 pts were evaluabie tor Immunologic
response. A an E/T ratio of 32:1, there was a stat sig. enhancement of
monocyte ADCC after 3 weeks of tx. compared to baseline (p < OS,
paired t test). There was also a modest but stal sig. enhancement of
granulocyte ADCC after 3 weeks of tx as wel (p <.05). We conclude bat
GM-CSF given daily sq @ 150 ug/m2 X 21 days car enhance effector eel
ADCC. Although there have been no clinical responses to date, this study
la ongoing. Supported by NCI contract N01-CM-67895-01.
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PHASE I TRIAL OP MURINE MONOCLONAL ART I BOO! MO-22 AND IL-2
1* PATIENTS WITH DISSEMINATED MELANOMA. C.I. Goodman.
I. Helletrora, 0. Stevenson, K. Steen, K.S. Hellstroa.
Swedish Hospital Tumor Institute, Seattle, Washington 98104
and Erletol Myera-Squibb, Seattla, Washington 96121.
(Air previous trials here documented tumor regreeeione
in petiente with disseminated melanoma after treatment
with murine MAb's MG-21 and MO-22 which activate ADCC and
CSC. In an attempt to augment the antitumor activity we
conducted a phase I trial of MO-22 in combination with
interleukin-2. Seven patients were treated with MAb MO-22
as e 7-day continuous intravenous infusion (days 8-15), at
two doae leveia, 75 mg/n'/day (patient 1,2) and 150
mg/a'/day (patiant 3-7). The IL-2 vti given ea a con¬
tinuous infusion on daya 1-5, 6-12, 36-40, and 43-47.
IL-2 doae on day 1-5 end 36-40 wee fixed at 6 a 10*
lU/n'/day ami on day 49-54 at 18 x 10* IO/m'/dey. The dose
of IL-2 on days 8-12 was sscalated in aerial patients
(6 x 10* IO/m'/day petiente 1,2,3,4, 12 x 10* IC/m>
patisnts 5,6 and 18 z 10® IU/b' patient 7). PeaX sarua
concentrations of KAb were 19 Bcg/al at 75/m*/day and
24 mcg/ml at 150/e'/day. In Tiro localization of antibody
to tumor was documented in sll patients. All patients
developed HAMA, a median of 21 days sfter treatment. Mean
MX and ADCC activity of peripheral blood mononuclear cells
was augmented by IL-2 Increasing from pretreatment levels
of 15% and 51% to 44% and 77%, respectively. The side
effects of the two agents appeared to be additive and
consisted of fever, chills, nsusea, vomiting, urticaria,
weight gain, and azotemia. Mo acute antitumor activity was
seen, although one patient has remained stable for >6
months.
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SEQUENTIAL CHEMOTHERAPY/IMMUNOTHERAPY FOR METASTATIC
MELANOMA. J. Richards. N. MehU, L. Schroeder, A.
Dordal, Section of Hematology/Oncology, University of
Chicago, Chicago, IL 60637
Seventy-four consecutive patients (pts) with
Metastatic melanoma have been treated with a sequence of
cheaotherapy and biologic agents as follows: BCNU 150
■g/m1 d 1, DTIC 220 mg/m* d 1-3 and 22-25, clsplatln 25
■g/m1 d 1-3 and 22-25, tamoxifen 10 eg po bid x 6 wfcs,
IL-2 1.5 M/tf q 8hr d 4-8 and 17-21, and alfa-2a-
Interferon 6 wU/w? sq qd d 4-8 and 17-21. Median age of
patients was 47 yrs (range: 24-73), male: female
proportion was <6:28, and the Median KamofsKy
Performance Status was 90 (range: 70-100). Five patients
had primary ocular Melanoma. Sites of Metastatic disease
Included brain (15), liver (32), lung (40), lymph nodes
(39), subcutaneous sites (28) and soft tissue metastases
(25). The median number of metastatic sites was 2
(range: 1-7). The three most cooroon sites of progression
were lung, brain, and liver. Forty-one of our patients
were previously untreated. The response rate with this
regimen was 57* with a CR - 15X, PR - 40*. MR - 3%,
stable disease • 22%, and P0 - 20*. Median follow-up on
the study Is 12.06 months. Thirty-four of sixty-eight
patients have developed v1t1l1go-lIke depigmentation.
Overall response rates 1n this group of thirty-four
patients was 74*. Median time to progression on the
study was 9.1 months and median survival was 14 months.
Patients with no prior treatment (41) had a survival of
15.8 months compared with patients with prior treataent
(33) who had survival of 10.6 months.
1191
ANALYSIS OF PROGNOSTIC FACTORS IN CLINICAL STAGE I
CUTANEOUS MALIGNANT MELANOMA (CMM); BRITISH
COLUMBIA CANCER AGENCY (BCCA) EXPERIENCE 1972 •
1981. V. Carmlchael. R.R. Davidson, K.S. Wilson. Univ. of
Victoria and BCCA Melanoma Tumour Group, Victoria, B.C.,
Canada.
Medical records of 796 with clinical stage 1 CMM
patients referred to BCCA from 1972-1981 were reviewed.
Clark level 1, "borderline" melanoma pts and those lost to
follow-up were excluded leaving 7S3 cases for analysis. The
principal objective was to evaluate survival hi relation to 28
clinical and pathological variables. Minimum follow-up was 7.9
yrs. BANS sites were modified (mBANS) to post, upper limb,
post trunk, neck and scalp, because of limitations of site
coding. Wide primary excision was defined as > 5cm skin In
re-exclslon specimen. Multivariate analyses were performed
using Cox's proportional hazards regression model. Different
combinations of covadates were examined to find the best
prognostic model. When categorical covarfates were analyzed
as linear variables, significant factors were logarithm of
primary depth, Clark level, pathological ulceration, primary site,
type of Initial surgery (wide vs lesser excision), growth pattern,
mBANS sites and lymphatic Invasion In the primary. After
adjusting for effects of depth or Clark level, all the above
factors remained significant Elective regional node dissection,
undertaken In 223 pts, was not a significant prognostic factor.
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HEAD & NECK, SARCOMA, MELANOMA & OTHER SOLID TUMORS
*505
IANDOHIZED TRIAL OF RADIATION THERAPY (RT) PLUS
DIBROHODULCITOL (DBD) VS RT PLUS BCXU IN HICH GRADE
ASTROCYTOMA. A North Central Cancer Treatment Group
Study. T. Elliott, R. Dinapoli, J. O'Fallon, B. Rogera,
J. Earle, R. Morton, ?. Etzell, R. Marachke,
I. Scheithauer. Duluth MN 55805, Rochester KN 55905,
Peoria IL 61603, Des Moines 1A 50265, Fargo ND 58123,
Sioux Falls SD 57105.
DBO has activity in the aurine ependyaoblastoaa model
and, in huaxat, ia converted to dianhydrogalactitol (DAG).
DAC vas the aost active drug of 177 studied in this systea
(Cancer Chemother Rep 4:53) and has shown activity in
patients with gliomas vhen used vith RT initially or alone
at recurrence (JAMA 241:2046). In this study 238 pts vith
newly diagnosed supratentorial gr. 3 or 4 astrocytoma were
stratified by age, extent of resection and tumor grade.
All pts received RT consisting of 4500 rad vhole brain plus
1000-1500 rad to tumor volume plus 2 cm margin. By random
assignment they received either concomitant DBD (200 ag/a2
po xlOd q5vks) or BCNU (200 ag/m2IV q7vks). Six pts (2.5Z)
were ineligible. Of the 232 eligible pts, 56Z were male,
the median age vas 60, 83Z had performance scores of 0-2
(ECOC), 95Z had biopsy or subtotal resection, 34X were grade
3 and 60Z were grade 4 (6Z unknown grade). At present 71Z
of pts are dead, 14Z are alive but off treatment, and 15Z
remain on treatment. Times to progression are siailar for
both treatment arms vith medians of 22 vks. Survival curves
essentially overlap vith aedians of 41 vks. 78Z of all pts
experienced leukopenia but vith no meaningful difference in
incidence or severity between arms. BCNU, however, produced
more frequent vomiting (45Z vs 15Z) and also more frequent
severe thrombocytopenia « 50,000/ra2, 231 »• 141). In
comparison to the more established BCNU therapy, DBD is
more favorable vith regard to toxicity but currently shows
no evidence of improved survival in patients vith malignant
glioma.
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ALTERNATION VS SEQUENTIAL POL ICHEMOTHERAPY (VBM) AND RADIO¬
THERAPY IN THE TREATMENT OF ADVANCED HEAD AND NECK CANCER.
M. Merlano,M.R. Sertoli^M. Benasso,A. Grimaldi,L. Bonelli, G.
Margarino,R. Corvo7E. Pallestrini*A. Barbieri*R. Rosso.
Istituto Nazionale per la Ricerca sul Cancro,Genova;~Istituto
di Oncologia e di~Radiologia,University di Genova;*Divisione
O.R.L. ,0spedale S.Martino,Genova; *Servizio di Audiovestibolo-
gia,0spedale S.Martino,Genova.
A cooperative randomized study vas started in August '83
to compare in advanced Head and Neck cancer patients (pts) a
sequential program of induction chemotherapy (CT) followed by
locoregional treatment (radiation+surgery), Arm A, vs an al¬
ternation of 4 cycles of CT vith 3 courses of radiotherapy(RT)
(20 Gy in 10 days up to a total of 60 Gy) , eventually follo-
ved by surgery, Arm B. The same CT vas used in both Arms:
Vinblastine 6 mg/m2 h 0; Bleomycin 30 mg h6; Methotrexate 200
mg h24-26; Citrovorum Factor 45 mg h48. The aim pursued in
the first Arm is to obtain a neo-adjuvant treatment, vhile in
the second Arm is to enhance the activity of both CT and RT
through a kinetic recruitment. 69 pts entered the study, 35
in Arm A, 34 in Arm B. Median age of the vhole group is 62
years, 23 pts are stage III, 46 pts are stage IV, 13 pts are
female, 56 pts are male. No pts vas pre-treated, median P.S. ,
ECOG scale, is 0. The tvo Arms are comparable in terms of pts
characteristics. The main toxicity in both Arms is represen¬
ted by mucositis (14.3Z vs 44Z). The trial is ongoing. 46/69
pts are evaluable (20 in Arm A, 26 in Arm B). 40Z CR ♦ 15Z PR
and 53.8Z CR ♦ 23.1Z PR have been achieved, in Arm A and B rji
spectively. Actuarial survival is 14Z in Arm A and 28Z in Arm
B at 26 months. No significant difference by log-rank test is
yet detected in both response and survival .Crant CNR 8400803.4Q
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ADJUVANT LEVAMISOLE IMPROVES SURVIVAL AND DISEASE-FREE
SURVIVAL IN PATIENTS WITH POOR PROGNOSIS MALIGNANT MELANOMA.
I. Quirt, W. Shelley, A. Bodurtha, P. McCulloch, A.
HcPherson, A. Paterson, R. Prentice, H. Silver, A. Willan,
and K. Wilson. A Co-operative Study of the National Cancer
Institute of Canada, Kingston, Ontario.
5*8 patients with completely resected primary melanoma,
level 4, level 5, level 3 > .75 mm, satellite lesions, in-
transit metastases or regional lymph node metastases were
evaluated to exclude metastatic disease and randomized to 1
of * treatment options:
BCG (Connaught) by the multiple tine puncture disc *0 mg
weekly x 5 then q * weeks x 3 years.
Levamisole 2.5 mg/kg p.o. on two consecutive days
weekly x 3 years.
Combination - BCG alternating with Levamisole x 3 years.
Control - follow-up as in the other arms.
Median follow-up is 5.1 years.
Total
Patients
Control 138
BCG 138
Levamisole 135
Combination 137
The 5 year results are:
Disease-Free
Survival Survival
"735"
.53
.68
.57
T3T
.61
.74
.64
Cox's proportional hazards model was used to examine the
influence of treatment on outcome adjusting for stage, site,
age and sex. Because 3 treatment options were compared to
a single control a significance level of .0394 1s required
to limit the type 1 error to .05. With this model
Levamisole was associated with a statistically significant
improvement in survival (P*.036) and disease-free survival
(P*.027). The values for BCG vs. control and combination vs.
control were not significant.
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CELLULAR LOCALIZATION OF HEPATITIS B VIRUS ANTIGENS AND
IRON IN PRIMARY LIVER CANCER PATIENTS FROM SHANGHAI,
CHINA. X. D. Zhou,' L. DeTolle, R. P. Custer and W. T.
London. Fox Chase Cancer Center, Philadelphia, PA 19111,
Surgically resected specimens were obtained from 40
patients with primary liver cancer (PLC) at Zhoog Zhan
Hospital, Shanghai Medical University, the People's
Republic of China, between March 1983 and July 1984,
consisting of tumor and adjacent unlnvolved liver tissue.
Localization of hepatitis B surface and core antigens
(HBsAg, HBcAg) and Iron In hepatic parenchymal and tumor
cells was determined by peroxldase-antlperoxldase and
Perl's Prussian blue methods. Of the 40 tumors, 39
(97.5X) were primary hepatocellular carcinomas (PHC) and
one PHC mixed with cholanglocarclnoma. The serum HBsAg
positive rate was 80.01 (32/40). Cirrhosis was observed
In 90.01 (36/40). HBsAg was identified in unlnvolved
liver In 82.5Z (33/40), In tumors 35.OX (14/40). HBcAg
was detected in liver In 25.OX (10/40), but In only 7.5X
(3/40) of the tumors. Stalnable Iron was found in 65.OX
(26/40) of livers and 10.OX (4/40) of tumors. Twenty-two
of 33 PLC patients (66.7X) with HBsAg positive cells In
their livers also showed stalnable Iron, compared with 4
of 8 HBsAg negative cases, suggesting that hepatocytes
with higher Intracellular Iron are more likely to be
Infected with hepatitis B virus (HBV). The high preva¬
lence of HBsAg and cirrhosis in PHC Indicates that HBV
plays an Important etiologlc role of hepatocarcinogenesls
in China. However, there were 8 serum HB6Ag negative
(20.OX) and 5 nonclrrhotlc (12.5X) PHC cases In our
series, the etiology of which remains questionable.
(Supported by the Cancer Research Institute, Inc.,
New York, NY.)
PROCEEDINGS OF ASCO VOL 5 MARCH 1986
130
310
Improved Survival in Patients With Poor-Prognosis Malignant
Melanoma Treated With Adjuvant Levamisole: A Phase III
Study by the National Cancer Institute of Canada
Clinical Trials Group
By Ion C. Quirt, Wendy E. Shelley, Joseph L. Pater, Audley J. Bodurtho, Peter B. McCulloch,
Thomas A. McPherson, Alexander H.G. Paterson, Robert Prentice, Hulbert K.B. Silver,
Andrew R. Willan, Kenneth Wilson, and Benny Zee
Five hundred forty-three patients with completely re¬
sected malignant melanoma who were considered to
have a significant risk of developing recurrent disease
were randomized to one of four study groups. One
group received levamisole 2.5 mgAg on 2 consecutive
days weekly for 3 years, a second group received
bocillus Calmette-Gu^rin (BCG) for 3 years. A third
group alternated 8-week courses of BCG and levomi-
sole for 3 years and a fourth group underwent clinical
assessment at the same frequency as the three treat¬
ment groups. The median duration of follow-up is 8.5
years. The percentage of reduction in the death rate
and the recurrence rate in the treatment groups com¬
pared with the control group was calculated using the
Cox proportional hazards model and odjusted for age,
sex, and stage as covarionts. The patients treated with
levamisole were estimated to have o 29% reduction in
LEVAMISOLE was synthesized in 1966 andI became available a an anthelmintic for hu¬
man use in 1968. In 1971, Renoux and Renoux1
observed an increased immunity against Brucella
infection in Brucellaraccinated mice after levami¬
sole medication. Additional studies indicated that
levamisole could restore several T-cell functions
and restore the phagocyte function of polymorpho¬
nuclear cells, monocytes, and macrophages. The
most pronounced effects were to restore subnor¬
mal T-lymphocyte or phagocyte functions. Normal
immune functions usually could not be aug¬
mented.2
In 1973, Tripodi et al3 demonstrated that levami¬
sole could restore skin test reactivity to dinitro-
chlorbenzene in anergic patients with underlying
cancer. In 1980, Spitler and Sagebiel4 reported the
results of a randomized trial of adjuvant levami¬
sole in a fixed dose of 150 mg orally on 3 consecu¬
tive days every 2 weeks in patients with completely
resected poor-prognosis melanoma. In their pa¬
tients with primary melanoma, they observed a
both the death rate (P = .08) and the recurrence rate
(P = .09) compared with patients receiving no further
treatment. Fifty-five patients discontinued levamisole
earty because of gastrointestinal intolerance or arthral¬
gia, myalgia, fever, and immune leukopenia. The
patients treated with BCG alternating with levamisole
experienced a 10% reduction in the death rate and a
6% reduction in the recurrence rate, and the patients
treated with BCG alone experienced a 4% reduction in
the death rale and a 3% increase in the recurrence rate
compared with the control group. The degree of im¬
provement experienced by the patients that were
treated by levamisole is of sufficient magnitude to
warrant further investigation of this dose of levamisole
as adjuvant treatment in patients with melanoma.
J Clin Oncol 9:729-735. C 1991 by American Society of
Clinical Oncology.
trend to improved overall survival with a two-sided
P value of .07 and concluded that an additional
study was warranted.
In Canada in the mid-1970s, bacillus Calmette-
Guerin (BCG) was in wide use as an immunostim-
ulant in patients with melanoma, but no random¬
ized study had proved its value.
It was concluded that a large prospectively
randomized study of adjuvant BCG and adjuvant
levamisole was warranted.
From The Princess Margaret Hospital, Toronto; National
Cancer Institute of Cancer Clinical Trials Group, Kingston;
and Queen's University, Kingston; Ontario Cancer Foundation-
Hamilton Regional Centre, Hamilton; Dalhousie University,
Halifax; Cancer ControlAgency ofBritish Columbia, Vancou¬
ver, and Cross Cancer Institute, Edmonton, Canada.
SubmittedApril 5, 1989; accepted October 18, 1990.
Supported by the National Cancer Institute ofCanada.
Address reprint requests to Ian C. Quirt, MD, The Princess
Margaret Hospital, 500 Sherboume St, Toronto M4X 1K9
Canada.
C 1991 byAmerican Society ofClinical Oncology.
0732-183X/9110904-002053.00/0
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730 QUIRT ET AL
METHODS
Eligible Patients
To be eligible for this study patients must have had either
a primary melanoma that was level 4, level 5, or level 3
greater than 0.75 mm in vertical height; or any level with
satellite lesions within 3 cm of the primary melanoma; or
any level with in-transit metastases or regional lymph node
involvement with melanoma. Patients with completely ex¬
cised lymph node involvement from melanoma but no
known primary lesion and patients with completely excised
recurrent melanoma that was isolated to the regional lymph
node area draining the previous primary were also eligible
for the study. Pathology review was conducted by a local
reference pathologist in each participating center to deter¬
mine initial eligibility, and then the slides of all patients with
primary melanoma were reviewed by one central patholo¬
gist. After complete surgical excision, staging procedures
were performed to ensure that patients were free of
detectable residual disease. Patients had to be between 16
and 70 years of age, could not have a previous history of
another malignancy or rheumatoid arthritis, could not be on
continuous corticosteroid therapy, and had to be entered on
the study within 12 weeks of surgical excision.
Randomization and Treatment Schedules
After eligibility had been established, the patients were
approached about entry into the study. The complete
structure of the study, including the toxicities of the pro¬
posed treatments, was explained to the patients, and written
informed consent was obtained. The patients were then
randomized to one of four groups. One group received 40
mg of the Connaught strain of BCG by the multiple-tine
puncture disk weekly for 4 weeks then once every 4 weeks to
complete 3 years of treatment. The BCG was administered
on the upper outer aspect of each extremity in rotation. A
second group of patients received levamisole 2_5 mg/kg
orally on 2 consecutive nights weekly for 3 years. A third
group received the same schedule of BCG as the BCG
group for an 8-week period of time, then received levami¬
sole for an 8-week period of time, and finally, alternated
8-week courses of BCG given twice in the 8-week period,
with levamisole weekly for an 8-week period to complete 3
years of treatment. Because of this alternating sequence,
the overall dose of either BCG or levamisole per unit time
would be 50% when compared with the BCG-alone arm or
the levamisole-alone arm. A fourth group of patients
underwent careful observation at the same frequency as the
three treatment groups.
At entry onto the study, a full history was taken, a full
physical examination was performed, and a complete blood
count, BUN, creatinine, bilirubin, alkaline phosphatase,
SGOT (AST), protein electrophoresis, urinalysis, chest
x-ray, and 10 tuberculin unit (TU) purified protein deriva¬
tive (PPD) skin test were obtained. For the first 3 years after
a patient was enrolled on the study, a history, physical
examination, complete blood count, liver function profile,
protein electrophoresis, and PPD skin test was obtained
every 3 months and a creatinine, urinalysis, and chest x-ray
was obtained every 6 months. After 3 years from entry on
the study, the clinical assessment and laboratory tests were
obtained every 6 months, and after 5 years from enrollment
on the study, these evaluations were performed at yearly
intervals.
Patients were free to withdraw from treatment at any
time after enrollment on the study.
Any investigational treatment was discontinued if the
patient experienced a recurrence of their melanoma.
StatisticalAnalysis
In advance of the study, it was determined that to detect a
20% improvement in 5-year survival with a significance level
of .05 and a power of .9, we would require 130 patients in
each treatment arm.
The study was analyzed by the intention to treat. There¬
fore, all patients allocated to a treatment group were
analyzed as part of that group even if they discontinued
treatment early because of side effects or refused to take the
treatment after having given informed consent. The relapse-
free survival and overall survival curves, calculated using the
Kaplan-Meier method, are plotted from the date of entry on
to the study. For relapse-free survival curves, patients who
died of other causes were censored at the time of death;
however, on the overall survival curves, all deaths were
counted as failures.
The percentage of reduction in death rates and recur¬
rence rates were calculated through the Cox proportional
hazards model. We estimated the parameters in the Cox
proportional hazards model by maximization of the partial-
likelihood function. The death rates and recurrence rates
for each treatment were then calculated by substituting the
corresponding mean covariate vectors into the Cox propor¬
tional hazards model. Using these estimates, we obtained
the percentage of reduction in death rate and recurrence
rates for each study treatment relative to that of the control.
The results for unadjusted analyses were calculated from
the simplest Cox model, which include only the treatment
effect. The results for the adjusted analyses include age. sex.
and stage as covariates.
The proportional hazards model was also used to deter¬
mine the statistical significance of the effect of treatment
and prognostic factors on disease-free survival and overall
survival. For the analysis, stage was divided into (1) primary
only, (2) primary with regional (satellite, in transit, or nodal
spread), and (3) nodal presentation or recurrence. Primary-
only cases were further subdivided according to depth of
invasion into three categories (.76 to 1.49 mm; 13 to 4 mm;
and > 4 mm). Level was examined as a categoric variable
and age as a continuous variable. Each of the three
treatment arms was compared with the single control arm.
Since there was no prespecified hypothesis as to which arm
would be superior, the conventionally calculated P values
presented in the following sections underestimate the prob¬
ability that the observed results are due to chance. Two-
sided P values adjusted for the other factors in the model
are quoted for all treatment comparisons and prognostic
factors.
The product-limit estimate of the proportion of patients
free of relapse or alive at 5 years for each of the three
treatment arms was compared with that of the control using
Greenwood's formula.'
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RESULTS
Between February 1978 and December 1982,
577 patients were randomized. Of these, 34 were
subsequently found to be ineligible. On central
pathology review, 12 patients did not have mela¬
noma; 16 patients had melanoma that was too
superficial to meet the eligibility requirements;
one patient had received previous chemotherapy;
one patient had a conjunctival rather than cutane¬
ous melanoma, and the depth of invasion could
not be assessed; one patient was not under the
care of a participating physician; one patient had
metastatic disease at initial assessment; one pa¬
tient had a concurrent lymphoma; and one patient
was older than 70 years of age. Fortunately, the
number of ineligible patients was the same in all
four groups. Therefore, 543 eligible patients are
available for evaluation. The median duration of
follow-up on the study is 8.5 years. The pretreat-
ment characteristics of the patients are summa¬
rized in Table 1.
The relapse-free survival experienced by the
four groups of patients is shown in Fig 1. Com¬
pared with the control group, the group of patients
who received adjuvant levamisole experienced a
29% reduction in the adjusted risk of recurrence,
the group receiving BCG alternating with levami-
TobU 1. Pretreatment Charocleristics
Control BCG Lavomisole Combination
No. No. No. No.
S«x
Femole 63 54 68 55
Male 74 82 67 80
Stoge
Primory 103 94 99 98
SatellHosis 3 2 2 4
In-transit 1 2 0 4
Node-positive 30 38 34 29
Mean oge (years) 47.7 48.7 44.8 46.1
Site of primary
(primary patients only)
Head and neck 12 12 9 9
Lower limb 28 22 26 23
Trunk 47 43 43 44
Upper limb 16 17 21 22
Depth of primary
(primary patients only)
Unknown 1 0 1 0
0.76-1.5 39 32 38 43
1.51-2.5 31 28 33 22
2.51-4.0 17 19 15 18
> 4.0 15 15 12 15
Total patient 137 136 135 135
731
Time (years)
fig 1. Relapse-fro* survival curves for patients receiving
( ) levamisole, ( ) BCG, ( ) a combination of BCG
alternating with levamisole, and ( ) the control group.
sole had a 6% reduction in the adjusted risk of
recurrence, and the group receiving BCG alone
experienced a 3% increase in the adjusted risk of
recurrence.
The overall survival curves for the four treat¬
ment arms are shown in Fig 2. Compared with the
control group, the levamisole group experienced a
29% reduction in the adjusted risk of death, the
group receiving BCG alternating with levamisole
had a 10% reduction in the adjusted risk of death,
and the group receiving BCG alone experienced a
4% reduction in the adjusted risk of dying.
The product-limit estimates of 5-year relapse-
free survival and overall survival percentages are
summarized in Table 2.
The assessment of the statistical significance of
our results depends on the end point chosen. The
original sample-size calculation was based on the
assumption that the major point of interest was
the long-term (5-year) proportion of patients alive
and free of disease. Two-sided P values using
Greenwood's formula to assess the statistical signif¬
icance of the differences in the proportions ob¬
served in this trial are presented in Table 3.
An alternative approach to the analysis of such
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Time (years)
fig 2. Overall survival curves for patients receiving ( )
levamisole, ( ) BCG, ( J o combination of BCG alternat¬
ing with levamisole, and ( ) the control group.
data is to consider prolongation of survival or
disease-free survival rather than point in time
"cure" rates as the end point of interest and to use
time-to-event methods in the analysis. The two-
sided lvalues generated by applying Cox's model
to our data are summarized in Table 4.
To determine if ievamisole was particularly
effective or ineffective in any subgroup of patients,
a separate multifactor analysis of overall survival
with prognostic factor/treatment interaction terms
in the model was performed only on the patients in
the control and levamisole arms. The interactions
examined were treatment/age, treatment/stage,
and treatment/sex. The P values for these interac¬
tions in the multifactor model were: .17 for treat-
Toble 2. Product-Limit Estimates of 5-Year Relapse-Free
Survival and Overall Survival Percentages
5-Yeor 5-Year
Itelopse-Free Overall
Survival Survival
55 62
66 74
58 65
50 59
Table 3. P Values for 5-Yeor Proportions
Relapse-Free Overall
Survival Survival
Levamisole v control .0672 .0268
Levamisole alternating with BCG v control .7493 .6329
BCG v control .3987 .6226
ment/age, .45 for treatment/stage, and .43 for
treatment/sex.
Because the time interval from definitive treat¬
ment to entry on the study was quite long, a
separate analysis was performed to determine if
patients entered on the study within 6 weeks of
surgery had different survival experiences from
those entered after 6 weeks. No such difference
was observed.
The study included a broad base of patients
ranging from low-risk primary melanoma to high-
risk patients with regional lymph node metatases
from melanoma. The same degree of proportional
improvement in relapse-free survival and overall
survival was observed in patients with primary
melanomas less than 1 mm in vertical height,
patients with intermediate-thickness melanomas
(1 mm to 4 mm), and patients with high-risk
melanoma (primary melanoma > 4 mm, in-transit
metastases from melanoma, and lymph node me¬
tastases from melanoma).
No treatment-related deaths were observed in
this study. Eighteen deaths that were not related
to melanoma were documented; six in the control
arm, six in the BCG arm, three in the levamisole
arm, and three in the BCG alternating with
levamisole arm.
The analysis of prognostic factors by the propor¬
tional hazards model confirmed that stage, sex,
and age were significant prognostic factors.
The group that received BCG experienced local
inflammatory reactions at the vaccination sites and
occasional mild fever the day following the injec¬
tion but otherwise had no ill effect. The toxicity
from levamisole is summarized in Table 5. In the
arm that alternated BCG with levamisole, it was
not possible to attribute side effects specifically to
Table 4. Cox Proportional Hazards Model Adjusted for Sex,
Age, and Stoge
IUIops«-Free Overall
Survival Survival
levamisole v control .0800 .0964
Levamisole oftemating with BCG v control .7280 .5926
BCG v control .8707
. .8053
Control
levamisole
levamisole alternating with BCG
BCG
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Table 5. Levamisole Toxicity
Sid* Effect No.
Nausea 33
Vomiting 8
Anorexia 2
Bitter taste 14
Leukopenia 14
Fever 11
Arthralgia/myalgia 11
Skin rash S
Mouth ulcers 2
None 64
Total patients 135
either the BCG or the levamisole; therefore, the
levamisole toxicity is presented for the 135 pa¬
tients who received levamisole alone. Two constel¬
lations of side effects were seen. One group of
patients experienced a bitter metallic taste that led
to anorexia, nauseousness, and, in some patients,
vomiting. A second group of patients experienced
fever, arthralgia, and myalgia. Skin rash and mouth
ulcers were less frequent. Fourteen patients devel¬
oped an absolute neutrophil count below 2,000/
mm3. In all cases the WBC count normalized
rapidly when levamisole was discontinued, and no
evidence of infection was seen in any patient while
the blood count was reduced. Fifty-five patients
discontinued levamisole early because of toxicity.
Nineteen patients received levamisole for 1 to 3
months, 18 patients received it for 4 to 12 months,
11 patients received it for 13 to 24 months, and
seven patients received it for 25 to 35 months.
Forty-seven patients were able to complete a full 3
years of treatment. The other patients had levami¬
sole discontinued early because of relapse.
DISCUSSION
The concept of attempting to improve the prog¬
nosis of patients with melanoma by stimulating the
immune system is not new. It has long been
recognized that patients with primary melanoma
can experience immune destruction of portions of
their primary melanoma and that patients with
widely metastatic melanoma can experience com¬
plete disappearance of all metastatic disease with¬
out specific treatment. Over the last 2 decades,
many attempts have been made to treat me¬
tastases from melanoma and to prevent recur¬
rence of melanoma by using either specific killed-
melanoma-cell vaccines or nonspecific bacterial
and viral vaccines. Unfortunately, none of these
treatment modalities has proved effective.
Spitler and Sagebiel4 reported the results of
their randomized trial of levamisole versus pla¬
cebo in patients with poor-prognosis malignant
melanoma. They used a standard dose of 150 mg
for 3 consecutive days every 2 weeks. They did
observe a trend to improved overall survival in
patients with primary melanoma with a two-sided
lvalue of .07.
Loutfi et al6 published the results of another
trial of levamisole versus placebo in 156 patients
with level 3, 4, and 5 melanoma. The dose of
levamisole was 150 mg twice a week for 3 years.
Both the disease-free survival and overall survival
were slightly better in the placebo group. The
authors state that with 73 patients in the levami¬
sole group and 64 patients in the placebo group,
their numbers were too small to state definitively
that no difference existed. They did conclude that
levamisole is unlikely to reduce the risk of dying
below 60% of what it would be with no treatment.
In our study we observed a 29% reduction in the
risk of dying in the levamisole group compared
with the no treatment group.
Lejeune et al' issued the first report of an
ongoing study that randomized patients who had
primary melanoma, with level 3 with a thickness
equal or exceeding 1.5 mm, level 4, and level 5 to
dacarbazine, levamisole, or placebo. The levami¬
sole was taken on 2 consecutive days every week
for 2 years. The daily dose of levamisole was 150
mg for patients up to and including 70 kg, 200 mg
for patients 71 to 90 kg, and 250 mg for patients
above 90 kg. All patients with extremity melanoma
underwent lymph node dissection, and patients
with lymph node metastases were not eligible for
the study. The mean follow-up time was 3 years.
No reduction in either disease-free survival or
overall survival was observed in the 101 patients in
the levamisole arm compared with the 96 patients
in the control arm. Patients with extremity mela¬
noma underwent prophylactic lymph node dissec¬
tions. Because the patients with extremity mela¬
noma and occult lymph node metastases were
eliminated from the trial, it is likely that patients
on this study had a significantly reduced chance of
experiencing recurrence than did the patients on
our study.
Amery* published the results of a placebo-
controlled trial of levamisole in resectable bron-
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chogenic carcinoma. A standard dose of levami-
sole 150 mg/d for 3 days every 2 weeks was
administered. A subsequent analysis of these re¬
sults pointed out that most of the benefit had been
achieved in patients less than 70 kg in weight and it
was recommended that a minimum dose of 2.5
mg/kg of levamisole should be used in future
studies.'This same conclusion was reached by Van
Eygen et al10 in the treatment of upper respiratory
tract infections in children. Because of these
observations, we used a levamisole dose of 2.5
mg/kg on 2 consecutive nights each week.
The dose intensity of levamisole was apprecia¬
bly higher in our study than in those reported by
Spitler and Sagebiel4 or Loutfi et al.4 Over a
2-week period of time, an 80 kg patient received
800 mg of levamisole in our study compared with
450 mg in the study by Spitler and Sagebiel and
600 mg in the study reported by Loutfi et al.
Our patients who received levamisole experi¬
enced an improvement in both relapse-free sur¬
vival and overall survival. The degree of improve¬
ment is of sufficient magnitude to warrant further
investigation of levamisole in patients with mela¬
noma. However, these results highlight the impor¬
tance of the choice of end point in interpreting the
results of clinical trials. If one's interpretation is
based on the originally chosen end point for the
study, 5-year survival, the results observed in favor
of levamisole reach conventional levels of signifi¬
cance. On the other hand, comparisons based on
the entire disease-free or overall survival experi¬
ences of the groups indicate a moderate, but not
quite statistically significant, benefit for levami¬
sole. Which of these end points is more appropri¬
ate in these circumstances is debatable, but a case
can be made for considering the status of the
patients at a later point in time most relevant. A
treatment that has the ability to kill a small
number of residual tumor cells would only be
anticipated to be of benefit to individuals with a
very small burden of residual disease. One would
not anticipate that these patients would experi¬
ence a relapse in the first several months after they
had entered a clinical trial. Therefore, it is not
surprising that the relapse-free survival and over¬
all survival curves separate only after a 2- to 3-year
interval. The fact that the survival curves stay
together for this period of time when large num-.
bers of patients are represented on the curves
tends to minimize differences when the Cox pro¬
portional hazards model is used.
It is difficult to draw conclusions from the
relapse-free survival and overall survival curves
experienced by the group that received BCG
alternating with levamisole. When the study was
formulated we were concerned that excessive tox¬
icity might be seen if the two treatments were
administered concurrently. Therefore, patients
were treated with BCG initially for an 8-week
period of time and then were given levamisole for
an 8-week period of time, followed by alternating
8-week courses of BCG and levamisole. Hence,
the patients in the combination group all had an
8-week delay before receiving levamisole and only
received 50% of the dose of levamisole that
patients in the group that received levamisole
alone were treated with. Some patients relapsed
during the initial 8 weeks that they received BCG
without ever receiving levamisole.
Other investigators have reported that adjuvant
levamisole or adjuvant levamisole combined with
chemotherapy could reduce recurrence rates and
improve survival in other solid tumors. The Study
Group for Bronchogenic Carcinoma' performed a
double-blind control trial of levamisole in patients
with completely resected bronchogenic carci¬
noma. They observed 20 recurrences and 12 deaths
in the 60 patients who were treated with placebo
and 10 recurrences and seven deaths in the 51
patients who were treated with levamisole 150 mg
orally on 3 consecutive days every 2 weeks. Laurie
et al" compared both levamisole alone and levami¬
sole combined with fiuorouracil (5FU) to an obser¬
vation alone in patients with Dukes' B and Dukes'
C colorectal cancer. In this study, a significant
reduction in recurrence rates and improvement in
survival was observed in the group of patients that
received the combination of 5FU and levamisole.
The group of patients that received levamisole
without 5FU also experienced a reduced recur¬
rence rate and improved survival but the differ¬
ence was less statistically significant than observed
with a combination of 5FU and levamisole. The
major benefit was experienced by patients with
Dukes' C rather than Dukes' B colon cancer.
Moertel et al" then conducted a larger confirma¬
tory study of 5FU combined with levamisole and
levamisole alone compared with observation in
patients with Dukes' B and Dukes' C colorectal
cancer. The preliminary analysis of their results
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indicates a highly statistically significant improve¬
ment in relapse-free survival and an improvement
in overall survival in the patients who were treated
with 5FU combined with levamisole. At the time
of reporting, no improvement had been observed
in patients treated with levamisole alone. This
raises the possibility that the levamisole may be
acting by modifying the metabolism of 5FU and
making it more effective as an adjuvant treatment
rather than having any immune modulating effect.
We did observe significant gastrointestinal toxic¬
ity, arthralgia, myalgia, fever, and immune neutro¬
penia. Levamisole has produced fatal immune
neutropenia in patients with rheumatoid arthritis;
therefore, patients with rheumatoid arthritis should
not be treated with levamisole, and patients who
receive levamisole should have their WBC count
followed frequently.
The degree of improvement is of sufficient
magnitude to warrant further investigation of
levamisole in patients with melanoma, particularly
in view of the recent reports that the use of this
medication contributes to prolongation of survival
in the adjuvant therapy of patients with colorectal
carcinoma.I1I: Our results are only marginally
significant but are of a sufficient magnitude to be
clinically relevant if they are confirmed in future
clinical trials. Future studies should concentrate
on defining more accurately the mechanism by
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CLINICAL TRIALS SUMMARIES
Phase II Study of Mitolactol In Advanced Malignant Melanoma1-2
Nevln Murray,♦ Hulbert Silver, Amil Shah, and Kenneth Wilson3,4
Metastatic malignant melanoma is notoriously resist¬
ant to chemotherapy, particularly after previous drug
treatment. Mitolactol has been reported to produce re¬
sponse rates up to 30% (1,2). One of these studies re¬
ported responses to mitolactol in patients previously
treated with dacarbazine and a nitrosourea (2). Subse¬
quent trials of either mitolactol alone, using slightly dif¬
fering doses and schedules (3,4), or mitolactol and
semustine (5) did not achieve such encouraging results.
We report our experience with an intermittent oral regi¬
men for previously treated patients with advanced malig¬
nant melanoma.
All patients had biopsy-proven metastatic melanoma
with measurable disease in an unirradiated area. Mito¬
lactol was offered as a second-line chemotherapy when
dacarbazine or a nitrosourea had failed. Mitolactol, at a
dose of 180/mg/m2/day * 10 days, was given orally at 28-
day intervals. The dose was escalated by 10% in subse¬
quent cycles in the absence of significant side effects.
The characteristics of 21 patients with metastatic
melanoma treated on this study are shown in table 1.
Nineteen patients developed progressive disease within 2
months. Two patients, one with lung metastasis and an¬
other with subcutaneous lesions, had stable disease. How¬
ever, a careful review of the pretreatment growth rate of
these indolent melanomas indicated no change in the
doubling time related to drug treatment.
The median survival time of the entire group was 5
months. The median survival time for patients with pro¬
gressive disease was 4 months; for stable disease pa¬
tients, it was 14 months. The long survival of the two sta¬
ble disease patients was probably due to their slow-grow¬
ing tumor rather than a treatment benefit.
In conclusion, although mitolactol can be given safely
with this dose schedule, we found the response rate of the
drug in patients with previously treated metastatic mela¬
noma to be < 15% (rejection error < 5%). This may be
due to cross-resistance with other alkylating agents or it
TABLE 1 —Patient characteristics
No. of
Characteristic Patients (%)
Evaluable 21
Median age in yrs (range): 57(34-70)
Sea
Male g
Female J3
Performance status*
0-1 15(71)
2-3 6(29)
Sites of disease
Soft tissue 8(38)
Lung 7(34)
Liver 3(14)
Abdomen (excluding liver) 3(14)
Prior chemotherapy
Dacarbazine 18(85)
Lomustine 2(10)
None 1 (5)
Prior radiotherapy 5
No. of cycles ofmitolactol
1-2 19
4-10 2
Toxicity
Nausea and vomiting 3 (14)
Leukopenia (wbc count < 3000/mm') 7 (33)
TTirombocytopenia (platelet count 4 (19)
< 100,000/mm')
Infection 0
Bleeding 0
Response rates
Partial response (> 50% tumor area reduction) 0
Stable disease (< 50% tumor area reduction) 2
Disease progression f> 25% tumor area increase) 19
*
Eastern Cooperative Oncology Group criteria.
may merely indicate lack of activity of this drug. Further
studies of this schedule of mitolactol for patients previ-
1 Received Aug 21,1984, revised Dec 10,1984; accepted Dec 17,1984.
'Mitolactol was supplied by the National Cancer Institute. Bethesda,
MD.
'Melanoma Tumour Group, Cancer Control Agency of British Colum¬
bia, and Department of Medicine, University of British Columbia, Van¬
couver, Canada.
'We thank Lorraine Cbo for secretarial assistance and Linda Garant for
chart reviews.
*
Reprint requests to: Dr. N. Murray, Cancer Control Agency of British
Columbia. 600 W 10th Ave, Vancouver, British Columbia, V5Z 4E6,
Canada.
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ously treated with chemotherapy for advanced malignant
melanoma are not recommended.
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